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ABSTRACT 
 
Cardiac myosin binding protein-C (cMyBP-C) is a thick filament-
associated protein that has been suggested to regulate cardiac contraction via its 
amino terminal (N’) region. Following ischemic injury to the heart, cMyBP-C is 
cleaved into a predominant N’ fragment consisting of the first 271 N’ residues of 
cMyBP-C (domains C0 through C1 and the first 17 residues of the M-domain) 
that is referred to as C0-C1f. In vitro studies have suggested the importance of 
the C0-C1f region of cMyBP-C in regulating actin filament sliding over the thick 
filament to control cross-bridge cycling kinetics within the cardiac sarcomere. 
However, the necessity of the N’-C0-C1f region of cMyBP-C in regulating cardiac 
function in vivo has not been elucidated. I hypothesized that the N’-C0-C1f region 
of cMyBP-C is critical for normal cardiac function in vivo. To test this hypothesis, 
transgenic (TG) mice with 81 ± 2.2% expression of a truncated cMyBP-C missing 
the N’-C0-C1f region and 19 ± 2.2% expression of endogenous full-length (FL) 
cMyBP-C (cMyBP-C110kDa TG mouse line) were generated and characterized in 
comparison to their non-transgenic (NTG) littermates between 3- and 8-months 
of age. Short-axis M-mode echocardiography at 3- and 6-months of age showed 
a significant elevation (p < 0.05) in left ventricular (LV) internal diameter (LVID) 
and LV systolic volume at end systole in cMyBP-C110kDa hearts compared to NTG 
hearts at 6-months of age. Importantly, percent ejection fraction (EF) and 
fractional shortening (FS) were significantly reduced in cMyBP-C110kDa hearts 
 
 
xviii 
 
compared to NTG hearts at 3-months of age (p < 0.05), which were even further 
reduced in the hearts from 6-month old cMyBP-C110kDa mice compared to hearts 
from both 6-month old NTG mice (p < 0.0001) and 3-month old cMyBP-C110kDa 
mice (p < 0.05), indicating progressive cardiac dysfunction in cMyBP-C110kDa 
animals. Accordingly, global longitudinal strain (GLS) analysis revealed abnormal 
wall motion in cMyBP-C110kDa hearts compared to NTG hearts. I further observed 
cardiac enlargement, determined by whole-heart confocal imaging, and an 
elevation in cardiac pathological hypertrophy markers, determined by quantitative 
real-time PCR (qPCR) and RNA-Seq, in cMyBP-C110kDa compared to NTG 
animals. Histopathological and second harmonic generation (SHG) analyses on 
myocardial sections indicated increased cardiac fibrosis (p < 0.0001) and 
increased sarcomere area (p < 0.01) in cMyBP-C110kDa hearts compared to NTG 
hearts. Crucially, using immunofluorescence analysis coupled with SHG imaging 
of isolated cardiac myocytes from cMyBP-C110kDa and NTG hearts, I determined 
that the cMyBP-C110kDa TG protein localized properly at the C-zone within the 
cardiac sarcomere in the classic doublet pattern of cMyBP-C localization 
between α-actinin. This suggested that the contractile dysfunction observed in 
the hearts of cMyBP-C110kDa animals was due to the absence of the N’-C0-C1f 
region of cMyBP-C in the cMyBP-C110kDa TG protein and not aberrant 
mislocalization of this protein. Intriguingly, increased phosphorylation of the 
cMyBP-C110kDa TG protein at serines 282 and 302, and endogenous FL-cMyBP-C 
at serines 273 and 302, sites important for cMyBP-C’s regulation of actomyosin 
interactions, was observed in cMyBP-C110kDa myofilament fractions compared to 
 
 
xix 
 
those from NTG controls. Finally, using isolated, permeabilized papillary muscle 
fibers from cMyBP-C110kDa and NTG hearts on a steady-state force-ATPase 
experiment, I determined that a significant elevation in maximum force (p < 0.01) 
and rate of tension redevelopment (ktr) (p < 0.05) were produced from cMyBP-
C110kDa fibers compared NTG fibers. Based upon this data, I have determined 
that the N’-C0-C1f region of cMyBP-C is a critical regulator of actomyosin 
interactions and controls aberrant contraction kinetics within the cardiac 
sarcomere. I conclude that the N’-C0-C1f region of cMyBP-C regulates cardiac 
contractility and is necessary for maintaining normal cardiac function in vivo. 
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CHAPTER ONE 
 
INTRODUCTION 
 
Heart failure (HF) remains a leading cause of morbidity and mortality 
worldwide and affects 5.7 million people in the United States (Go et al., 2013) 
with a significant economic burden at a cost of approximately $32 billion annually 
(Heidenreich et al., 2011). HF is defined as the inability of the heart to maintain a 
cardiac output to distal organs that is sufficient to meet metabolic demand 
(Gordin & Fonarow, 2016). Left ventricular (LV) remodeling is the principal cause 
of many forms of HF (Cohn, Ferrari, & Sharpe, 2000). Systolic HF or HF with 
reduced ejection fraction (HFrEF) includes ventricular dilation and a reduction in 
cardiac contractility and ejection fraction (EF) (Burchfield, Xie, & Hill, 2013; 
Chatterjee & Rame, 2008). In contrast, diastolic HF or HF with preserved EF 
(HFpEF) is characterized by impaired cardiac relaxation and/or an increase in 
ventricular stiffness leading to abnormal ventricular filling with preservation in EF 
(Burchfield et al., 2013; Gutierrez & Blanchard, 2004; Zile & Brutsaert, 2002). 
Diastolic heart failure can occur alone or in combination with systolic heart failure 
(Zile & Brutsaert, 2002). LV systolic dysfunction is primarily caused by end-stage 
coronary artery disease (CAD), with patients having a history of myocardial 
infarction (MI) or reduced myocardial perfusion (Dargie, 2005). Similarly, diastolic 
LV dysfunction is related to ischemic heart disease as well as chronic 
hypertension, but may arise from restrictive, infiltrative, and hypertrophic 
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cardiomyopathies (Andersen et al., 2013; Moller, Pellikka, Hillis, & Oh, 2006). 
Myocardial remodeling leading to ventricular hypertrophy is central to the 
development of HF and likely occurs to maintain cardiac pump function (de 
Tombe, 1998). Indeed, this pathology is observed in most cases of HF in humans 
and in animal models (de Tombe, 1998). Cardiac myocytes and other cardiac 
cells are thought to be fundamentally involved in the process of myocardial 
remodeling (Cohn et al., 2000). In addition to LV chamber remodeling, end-stage 
HF involves such processes as loss of functional myocytes, hyperplasia of the 
extracellular matrix, and decreased myocyte function (de Tombe, 1998). The 
current study focuses on the latter aspect of HF, which includes the mechanisms 
by which decreased myocyte contractile function leads to HF. These 
mechanisms include alterations in (i) calcium handling, (ii) myofilament function, 
and the (iii) cytoskeleton (de Tombe, 1998). In particular, the work presented 
here directly focuses on providing a better understanding of myofilament function 
in health and disease through the direct study of a critical contractile regulatory 
protein known as cardiac myosin binding protein-C (cMyBP-C). 
Since its discovery in 1973 by Offer, Moos, and Starr (Offer, Moos, & 
Starr, 1973), cMyBP-C’s role in modulating cardiac contraction has been the 
topic of fervent investigation (Barefield & Sadayappan, 2010) and controversy 
(Pfuhl & Gautel, 2012). It has been well established that the C’ region of cMyBP-
C interacts with light meromyosin (LMM) and titin to position and intricately 
incorporate cMyBP-C into the thick filament and to anchor the thick filament 
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(Freiburg & Gautel, 1996; Gilbert, Cohen, Pardo, Basu, & Fischman, 1999; 
Miyamoto, Fischman, & Reinach, 1999; Okagaki et al., 1993; Pfuhl & Gautel, 
2012). This interaction may stabilize and organize the thick filament, however, 
this has yet to be confirmed (Nyland et al., 2009). In stark contrast to cMyBP-C’s 
C’ region, the interactions, role, and necessity of the N-terminal (N’) region of 
cMyBP-C remain incompletely understood (Pfuhl & Gautel, 2012). While the N’ 
region of cMyBP-C has been shown to interact with the subfragment 2 (S2) 
region of myosin heavy chain (MHC) (Gruen & Gautel, 1999), the same 
interacting region of cMyBP-C was suggested to bind to F-actin (Razumova et 
al., 2006; Squire, Luther, & Knupp, 2003). 
 cMyBP-C is thought to be a critical contractile regulatory protein that, 
through its binding to actin, myosin, or both, regulates the probability of cross-
bridge interaction with actin and rates of force development and relaxation 
(Moss, Fitzsimons, & Ralphe, 2015). Furthermore, phosphorylation of cMyBP-C 
within its N’ region is considered to be the predominant mechanism controlling 
cMyBP-C’s interactions and its ability to regulate contraction at the level of the 
sarcomere (Barefield & Sadayappan, 2010). Animal models of total cMyBP-C 
ablation develop hypertrophic cardiomyopathy (HCM) demonstrating the 
necessity of cMyBP-C in maintaining normal cardiac function (Harris et al., 2002). 
Intriguingly, MYBPC3, the gene encoding cMyBP-C, is the most highly mutated 
gene in human HCM accounting for approximately 40% of the identified 
mutations (Barefield et al., 2015), further suggesting the importance of cMyBP-C 
4 
 
 
 
in regulating cardiac function within the myofilament. Given that the N’ region of 
cMyBP-C is the most critical region controlling actomyosin interactions and the 
kinetics of cross-bridge cycling, elucidating the necessity of the N’ region of 
cMyBP-C in vivo is of critical importance to understanding the mechanisms by 
which cMyBP-C functions in both health and disease.  
The focus of my dissertation work has been on determining the necessity 
of the N’ region of cMyBP-C, particularly, a region referred to as C0-C1f, in 
maintaining normal cardiac contractile function in vivo. The N’-C0-C1f region of 
cMyBP-C is a 40 kilodalton (kDa) peptide consisting of the first 271 amino acid 
residues of cMyBP-C and incorporates domains C0 through C1 and the first 17 
residues of the M-domain (Govindan, McElligott, et al., 2012; Govindan, Sarkey, 
et al., 2012; T. L. Lynch & Sadayappan, 2014; Previs, Beck Previs, Gulick, 
Robbins, & Warshaw, 2012; Razzaque et al., 2013; Witayavanitkul et al., 2014). 
The importance of the N’-C0-C1f region of cMyBP-C is several-fold. Initially, our 
group identified this region as a predominant N’ cleavage fragment of cMyBP-C 
following cMyBP-C’s dephosphorylation during conditions of hypoxia or ischemic 
injury (Govindan, McElligott, et al., 2012). In two subsequent reports, we 
discovered that C0-C1f was sufficient to cause contractile dysfunction in isolated 
rat ventricular myocytes (Govindan, Sarkey, et al., 2012) and could impair 
myofilament function in human cardiac myofilaments (Witayavanitkul et al., 
2014). Intriguingly, a later study by Razzaque et al. demonstrated that 
endogenous expression of C0-C1f was sufficient to cause HCM and HF in mice 
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(Razzaque et al., 2013). Importantly, others have reported the ability of C0-C1f to 
inhibit actin filament sliding over myosin (Previs et al., 2012) and that the first 17 
residues of the M-domain (the “f” region of C0-C1f) are crucial to this process (A. 
Weith et al., 2012). Together, these studies suggest the importance of the N’-C0-
C1f region of cMyBP-C in regulating myofilament function both in vitro and in 
vivo. Therefore, we proposed that the N’-C0-C1f fragment may be the vital 
portion of cMyBP-C’s N’ region that allows this protein to control actomyosin 
interactions and cardiac contraction.  
My central hypothesis stemming from these previous findings and that 
forms the cornerstone of my dissertation work is that the N’-C0-C1f region of 
cMyBP-C is necessary for maintaining normal cardiac function in vivo. I tested 
this hypothesis using a novel transgenic (TG) mouse model developed in our lab 
that is missing the N’-C0-C1f region but that still expresses the remaining 110 
kDa more distal C’ fragment of cMyBP-C (cMyBP-C110kDa mouse model) within 
the cardiac sarcomere.  
The experiments that I performed during my dissertation studies examined 
cardiac function at the level of the whole heart and at the level of isolated 
papillary muscle fibers using cMyBP-C110kDa mice and their non-transgenic (NTG) 
littermates as controls. With this approach, I was able to determine that cMyBP-
C110kDa mice have significantly elevated levels of MYBPC3 gene expression and 
do express the cMyBP-C110kDa TG protein, which is not observed in NTG 
controls. Most significantly, my data revealed that between 3- and 6-months of 
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age, cMyBP-C110kDa animals harbored cardiac contractile dysfunction both at the 
whole-organ level (Specific Aim 1) and in isolated cardiac papillary fibers 
(Specific Aim 2) and developed cardiac hypertrophy compared to NTG animals. 
Of critical importance, I determined that the cMyBP-C110kDa TG protein localized 
properly within the cardiac sarcomere in the classical doublet pattern between α-
actinin, which is the known localization pattern for cMyBP-C (Kuster et al., 2015). 
This suggests that the dysfunction seen in cMyBP-C110kDa hearts is specifically 
instigated by the loss of the N’-C0-C1f region rather than aberrant mislocalization 
of the cMyBP-C110kDa TG fragment acting as a poison polypeptide that has been 
suggested for the C0-C1f fragment (Govindan, Sarkey, et al., 2012; Razzaque et 
al., 2013; Witayavanitkul et al., 2014). Finally, I observed a significant elevation in 
cMyBP-C phosphorylation within the M-domain in myofilament fractions from 
cMyBP-C110kDa hearts compared to NTG hearts. 
Based upon these data, I propose that the N’-C0-C1f region of cMyBP-C 
is a critical regulator of actomyosin interactions and controls aberrant contraction 
kinetics within the cardiac sarcomere. From the results of the data generated 
during my dissertation studies, I conclude that the N’-C0-C1f region of cMyBP-C 
regulates cardiac contractility and is necessary for maintaining normal cardiac 
function in vivo, suggesting the importance of the N’ region of cMyBP-C in both 
health and disease. 
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CHAPTER TWO 
 
LITERATURE REVIEW 
 
Cardiovascular Physiology in Health and Disease 
 
The heart is an organ that is both powerful and complex and that has been 
a point of fascination for scholars, poets, and physicians for centuries (Young, 
2010). Indeed, since the time of Ancient Greek philosophers such as 
Hippocrates, “the father of medicine,” and later Aristotle, who described the heart 
as a three-chambered organ that was the center of vitality in the body, to Galen 
who believed the heart was the source of the body’s innate heat and the organ 
most related to the soul, the heart has played a key role in understanding the 
function of the body (Aird, 2011). While to this day the heart remains a spiritual 
and religious component of the body to many, work by Sir William Harvey in the 
17th century confirmed the physiological role of the heart is to propel blood to the 
extremities through the arteries (Aird, 2011; Silverman, 1985). His theories and 
experiments are summarized in his notion that “…the chief function of the heart is 
the transmission and pumping of the blood through the arteries to the extremities 
of the body. Thus, the pulse which we feel in the arteries is nothing else than the 
impact of blood from the heart” (Silverman, 1985). Harvey postulated but could 
not prove that blood travels through the right heart through the lungs and then to 
the left heart stating, “In the more perfect warm-blooded adult animals, as man, 
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the blood passes from the right ventricle of the heart through the pulmonary 
artery to the lungs, from there through the pulmonary vein into the left auricle, 
and then into the ventricle” (Silverman, 1985). By the end of the 17th century, the 
anatomical knowledge of the heart was quite accurate with many accepting 
Harvey’s new theories that the heart was a pump (Silverman, 1985), a concept 
that still holds true today. Certainly, the heart has been a critical site for debate 
throughout the centuries, a debate that continues through many aspects of 
modern cardiovascular medicine and research today.  
The primary objective of this chapter is to provide an overview of cardiac 
anatomy and physiology in both health and disease. I will provide an overview of 
the structure and physiological function of the heart and the electrical regulation 
that controls contraction within the heart. Finally, I will discuss HF, the final 
clinical entity of many cardiovascular diseases, and two cardiac pathologies, MI 
and cardiomyopathies, which are relevant to the background of my dissertation 
work discussed here.  
Cardiac Anatomy 
 
The human heart is a muscular organ that pumps blood throughout the 
body via the circulatory system, supplying oxygen and nutrients to tissues and 
removing carbon dioxide and other wastes. To do so, the heart functions as a 
unidirectional pump that pressurizes blood in order to perfuse the body. The 
heart muscle is quite remarkable beating at an average rate of 70 beats min-1 
and contracting and relaxing more than 100,000 times a day (Pinnell, 2007). The 
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pump function of the heart can be explained by examining the anatomy of this 
organ.  
The heart is located within the thoracic cavity between the lungs and 
behind the sternum. The upper portion of the heart is attached to the aorta, the 
main artery that carries blood away from the heart to the rest of the body, as well 
as to pulmonary arteries and veins, and the vena cava. The lower tip of the heart, 
known as the apex, sits just above the diaphragm and points to the left. As such, 
2/3rd of the heart’s mass is on the left side of the body while the remaining 1/3rd 
sits to the right. Within the thoracic cavity, the heart beats inside of the fluid-filled 
pericardial cavity that is composed of a membranous structure referred to as the 
pericardium. The pericardium contains a visceral layer outside of the heart as 
well as a parietal layer outside of the pericardial cavity. The primary functions of 
the pericardium are to lubricate the heart to eliminate friction between the heart 
and local organs and to hold the heart in place.   
Structurally, the heart is composed of 3 layers. The outermost layer is the 
epicardium, which is synonymous with the visceral layer of the pericardium and, 
therefore, serves to lubricate and protect the external portion of the heart. The 
middle layer of the heart is the myocardium. The myocardium is the thick, 
muscular layer of the heart that comprises the majority of the mass of the heart 
and is responsible for cardiac contraction to pump blood throughout the body. 
Finally, the innermost layer of the heart is referred to as the endocardium, a 
simple squamous endothelial layer that prevents blood from sticking to the inside 
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of the heart and forming clots. In the healthy heart, the thickness of the walls 
varies such that the atria (discussed below) have a thin myocardial layer due to 
their requisite pumping to the nearby ventricles. In contrast, the ventricles 
(discussed below) have a larger myocardial layer than the atria in order to pump 
blood from the right heart to the lungs and the left heart to the body. Naturally, 
the ventricle of the left heart has the larger myocardial layer to pump blood 
throughout the body.  
The human heart is a four-chambered structure consisting of two atria 
(right and left) and two ventricles (right and left). As mentioned above, the atria 
are the smaller chambers that serve to receive blood from the venous system of 
the body and lungs (Figure 1). The ventricles, however, are larger and contract 
with greater force to send blood arriving from the atria to the lungs and body 
away from the heart via arteries. The healthy heart is a unidirectional pump 
through which blood flows from the right to the left. To prevent backflow or 
regurgitation of blood into the heart, a series of valves known as atrioventricular 
(AV) and semilunar valves comprise a portion of the cardiac anatomy. The AV 
valves are located in the middle of the heart between the atria and ventricles and 
only allow blood to flow from the atria to the ventricles. On the right side of the 
heart, the AV valve is referred to as the tricuspid valve as it is made of three 
cusps that separate and connect to either allow blood to enter the right ventricle 
(RV) or to prevent regurgitation of blood back into the RV, respectively. On the  
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Figure 1. The Human Heart. The human heart consists of two atria (left and 
right) and two ventricles (left and right). Blood enters the heart from the systemic 
circulation through the superior and inferior vena cava and then flows 
unidirectionally into the RA. From the RA, blood is pumped through the tricuspid 
valve into the RV. From the RV, blood is pumped through the pulmonary arteries 
into the lungs where carbon dioxide is exchanged for oxygen. From the lungs, 
blood flows through the pulmonary veins into the LA where it is then pumped 
through the bicuspid (mitral) valve into the LV. The LV pumps blood through the 
aortic valve into the aorta and to the systemic circulatory system and coronary 
circulation. For this reason, the LV is the largest of the four heart chambers. 
 
 
 
Right  
Atrium 
Right  
Ventricle 
Left  
Ventricle 
Left  
Atrium 
Aorta 
Superior 
Vena Cava 
Inferior Vena Cava 
Tricuspid  
Valve 
Pulmonary  
Valve 
Pulmonary  
Artery 
Pulmonary  
Vein 
Mitral 
Valve 
Aortic 
Valve 
12 
 
 
 
left side of the heart, the AV valve is referred to as the bicuspid or “mitral” valve 
as it has two cusps. The bicuspid valve functions similar to the tricuspid valve. 
The AV valves are attached to the ventricles through chordae tendineae. During 
contraction of the ventricles (discussed below) the chordae tendineae pull the AV 
valves preventing them from folding backwards into the atria and allow blood to 
pass through to the ventricles. The semilunar valves are situated between the 
ventricles and the arteries that carry blood to either the lungs or body. The 
semilunar valve on the right side of the heart is referred to as the pulmonary 
valve. The pulmonary valve prevents regurgitation of blood from the pulmonary 
trunk into the RV. The semilunar valve on the left side of the heart is known as 
the aortic valve and prevents the backflow of blood from the aorta into the LV. In 
contrast to the AV valves, the semilunar valves are not attached to chordae 
tendineae but rather, are cup shaped to catch regurgitating blood and use the 
pressure of the blood to close. 
The propagation of electrical signals throughout the myocardium regulates 
contraction of the heart. In fact, the heart is capable of setting its own rhythm and 
conducting these electrical signals throughout the myocardium. During the 
cardiac contraction cycle (discussed below) the right atria (RA) and left atria (LA) 
contract concomitantly followed by concomitant contraction of the RV and LV. 
The conduction system of the heart begins with the pacemaker, a small bundle of 
specialized cells in the RA known as the sinoatrial (SA) node. The SA node sets 
heart rate by initiating depolarization, which signals the atria to contract. 
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Sympathetic and parasympathetic inputs to the SA node modulate heart rate 
(Robinson, Epstein, Beiser, & Braunwald, 1966). When the SA node fires, it 
initiates a wave of depolarization that spreads across the RA and LA stimulating 
their contraction. The signal from the SA node is picked up by another mass of 
conductive tissue known as the AV node, which is located in the right atrium in 
the lower portion of the interatrial septum. While the AV node receives its signal 
from the SA node and transmits this signal through the AV bundle, the AV node 
has its own latent pacemaker activity and can rhythmically contract at the rate of 
AV node firing if the SA node is injured or ablated (Olshansky & Sullivan, 2013). 
The AV bundle is a network of conductive tissue that travels through the 
interatrial septum to the interventricular septum. The AV bundle splits into left 
and right branches in the interventricular septum that run inferiorly to the apex 
and up to the free walls of the LV and RV branching into Purkinje fibers. This 
conduction system is known as the His-Purkinje system (Haissaguerre, Vigmond, 
Stuyvers, Hocini, & Bernus, 2016). From the AV node, the action potential 
propagates through the conduction system through Purkinje fibers allowing both 
ventricles to contract in concert, with the endocardium contracting slightly prior to 
the epicardium, and the apex contracting before the base of the ventricle. This 
orientation and sequence of contraction causes the ventricles to contract from 
the apex up, allowing efficient ejection of blood from the ventricle. Action 
potentials also spread from cell-to-cell due to the electrical coupling of 
cardiomyocytes via gap junctions (typically Connexin 43 in ventricular tissue) that 
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allow propagation of depolarization through cells (Kreuzberg, Willecke, & 
Bukauskas, 2006). 
Cardiac Physiology 
 The primary role of the heart is to pump blood throughout the body by 
continuously and rhythmically relaxing to fill the heart with blood and contracting 
to eject blood to the lungs and body. Understanding the anatomy of the heart 
(discussed above) provides an understanding of its function. At any given time, 
the cardiac chambers are found in one of two states referred to as systole and 
diastole. Systole refers to the point in the cardiac cycle during which the heart 
muscle contracts to eject blood out of the chambers. Diastole, on the other hand, 
refers to the point in the cardiac cycle during which the heart and, more 
specifically, the heart muscle cells known as cardiomyocytes (discussed below), 
relax allowing the heart chambers to fill with blood. Ventricular systole is 
accompanied by an increase in arterial pressure that subsequently decreases 
during ventricular diastole. From this, we derive blood pressure. In a healthy 
cardiovascular system, blood pressure is typically reported as 120/80, which is 
systolic over diastolic pressure.  
 The rhythmic beating of the heart during systole and diastole is what 
makes the heart the engine that drives blood throughout the heart and 
throughout the body. Regarding blood flow throughout the heart, deoxygenated 
blood returning from the upper and lower portions of the body first arrives at the 
heart via the superior and inferior vena cava into the RA. This deoxygenated 
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blood is pumped through the tricuspid valve into the RV and then from the RV 
through the pulmonary semilunar valve into the pulmonary trunk and pulmonary 
arteries. Upon reaching the lungs, carbon dioxide is released and oxygen is 
absorbed into the blood, which then returns to the heart through the pulmonary 
veins into the LA. From the LA blood passes through the bicuspid valve into the 
LV and from the LV through the aortic semilunar valve into the aorta to the 
systemic circulation. Importantly, the heart, like every other organ or tissue in the 
body needs oxygen-rich blood to survive. As such, the heart is supplied by its 
own vascular system known as the coronary circulation. As oxygen-rich blood 
enters the aorta and travels to the systemic circulation, it also passes from the 
aorta into the right coronary artery and the left anterior descending coronary 
artery to supply the heart with blood. Blood returning from myocardial tissue does 
so through the coronary veins, which collect deoxygenated blood from the heart 
muscle and return it to the RA through the coronary sinus.   
Cardiac function in terms of the contraction and relaxation of the ventricles 
is best described using the four phases of the pressure-volume (PV) relationship 
(Figure 2) (Kass, Yamazaki, Burkhoff, Maughan, & Sagawa, 1986; Sagawa, 
1981; Suga & Sagawa, 1974). LV PV loops are derived from pressure and 
volume information found in the cardiac cycle diagram (Figure 2A). To generate 
a PV loop for the LV, LV pressure (LVP) is plotted against LV volume at multiple 
time points during a complete cardiac cycle (Figure 2B). The PV relationship for 
a single cardiac cycle is divided into 4 phases: ventricular filling (phase a;  
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Figure 2. The Pressure-Volume Relationship. (A) The cardiac cycle as 
depicted by LVP and LV volume changes. (B) The PV relationship depicting LVP 
plotted against LV volume during the cardiac contraction cycle. (C) Depiction of 
an ECG recording showing points of atrial and ventricular depolarization and 
repolarization during the cardiac cycle. 
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diastole), isovolumetric contraction (phase b; systole), ejection (phase c; systole), 
and isovolumetric relaxation (phase d; diastole). On the PV loop, point 1 denotes 
the pressure and volume in the LV at the end of the ventricular filling phase 
(diastole) and represents the end-diastolic pressure (EDP) and end-diastolic 
volume (EDV) for the LV. Pressure within the LV will rise to the point where 
compliance declines and the elastic elements of the heart resist additional filling. 
At the end of diastole, the pressure exerted by the total amount of blood filling the 
ventricle is considered to be the preload on the heart. Next, the ventricles begin 
to contract isovolumetrically (phase b) leading to closure of the mitral valve and 
an increase in LVP with no change in LV volume as all of the valves are closed. 
When the LVP is greater than the aortic diastolic pressure on the distal side of 
the aortic valve the aortic valve opens (point 2) and ejection (phase c) begins. It 
is during this time that LV volume decreases as LVP increases to a peak value 
known as peak systolic pressure, which then decreases during LV relaxation. 
The level of diastolic blood pressure the heart pumps against is referred to as the 
afterload. When the pressure in the heart drops below the systolic blood 
pressure, the aortic valve closes (point 3) leading to a cessation in blood ejection, 
the end of systole, and the start of isovolumetric relaxation of the LV. During this 
time, LVP falls but LV volume remains unchanged as all valves are closed 
(phase d). The volume of blood in the LV at this time is known as the end-systolic 
(residual) volume (ESV). When the pressure in the LV is less than the pressure 
in the LA, the mitral valve opens (point 4) allowing the LV to fill. During this time 
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of ventricular filling, the LVP continues to decline as the ventricle is still relaxing. 
However, when the LV is fully relaxed, LVP slowly rises again as LV volume 
increases (phase a) and the cardiac cycle repeats.  Importantly, the width of the 
PV loop depicts the difference between EDV and ESV, which is known as the 
stroke volume (SV). SV multiplied by heart rate (HR) is known as cardiac output 
(CO), which is the volume of blood being pumped by the heart in one minute 
(Vincent, 2008). Typically, at rest, the healthy heart pumps 5 to 5.5 liters of blood 
per minute. 
 In general, the filling phase of the heart follows the end-diastolic PV 
relationship (EDPVR), which is the passive filling curve for the LV. The slope of 
this curve is reciprocal of ventricular compliance. The end-systolic PV 
relationship (ESPVR) describes the maximal pressure that can be developed by 
the ventricle at any given LV volume and represents the inotropic (contractile) 
state of the ventricle. The PV loop cannot cross the ESPVR because this 
relationship describes the maximal pressure that is produced under a given 
inotropic state.  
 Electrical changes within the heart leading to atrial and ventricular 
depolarization and repolarization (discussed below) are the critical regulators of 
the rate at which the cardiac cycle occurs (HR). Such changes are measured 
using an electrocardiogram (ECG), which produces a waveform in response to 
electrical changes in the heart (Figure 2C). The first part of the wave is the P 
wave, which denotes a small increase in voltage corresponding to atrial 
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depolarization during atrial systole. Next, the QRS complex features a small drop 
in voltage (Q) a large voltage peak (R) and another small drop in voltage (S) that, 
together, correspond to ventricular depolarization during ventricular systole. It is 
also during this time that atrial repolarization occurs, which is largely undetected 
on the ECG. Finally, the T wave corresponds to a small peak following the QRS 
complex that represents ventricular repolarization during cardiac relaxation. 
Occasionally, a small positive U wave may also be seen following the T wave, 
which depicts the final stages of ventricular repolarization. Considering 
cardiovascular diseases, alterations in waveform and distance between the 
waves on an ECG are used clinically to diagnose such pathologies as heart 
attacks, congenital heart problems, electrolyte imbalances, etc. 
Heart Failure 
 
Abnormalities in cardiac anatomy and/or physiology are often the 
precursors to the development of HF. Indeed, HF is the final clinical entity of 
many cardiovascular diseases including CAD, diabetes, hypertension, cigarette 
smoking, arrhythmias, cardiomyopathies, congenital heart defects, heart valve 
disease, as well as alcohol and drug abuse, HIV/AIDS, thyroid disorders, 
excessive intake of vitamin E, radiation, and chemotherapy (Mozaffarian et al., 
2016). HF describes a condition in which the heart is unable to supply sufficient 
blood flow to peripheral tissues and organs to meet their demand for oxygen. 
This often results in fatigue, shortness of breath, and decreased exercise 
capacity (Cowie et al., 1997). Data from the National Health and Nutrition 
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Examination Survey (NHANES) from 2009-2012 estimate that approximately 5.7 
million Americans ≥ 20 years of age have HF (Mozaffarian et al., 2016). 
Projections estimate that the prevalence of HF will increase to 46% between 
2012 to 2030 resulting in > 8 million people ≥ 18 years of age with HF 
(Mozaffarian et al., 2016). Each year, there are approximately 915,000 new 
cases of HF (Mozaffarian et al., 2016). While HF is a common cause of morbidity 
and mortality worldwide mortality declines are attributed in approaches to treat 
HF including the use of angiotensin converting enzyme inhibitors, β-blockers, 
coronary revascularization, implantable cardioverter-defibrillators, and cardiac 
resynchronization therapeutic strategies (Merlo et al., 2014; Mozaffarian et al., 
2016). Among individuals with symptomatic HF, 55% are HFpEF. These cases 
are associated with a high mortality rate, comparable to that of HFrEF (Bursi et 
al., 2006; Mozaffarian et al., 2016). In 2012, the total cost for HF was estimated 
to be $30.7 billion with projections suggesting this number to rise to $69.7 billion 
by 2030, $244 for every US adult (Heidenreich et al., 2013; Mozaffarian et al., 
2016). 
Cardiac dysfunction results in changes in vascular function, blood volume, 
and neurohumoral status, which serve as compensatory mechanisms to maintain 
CO by the Frank-Starling mechanism. The Frank-Starling mechanism or 
Starling’s Law of the heart describes the ability of the heart to change its force of 
contraction and stroke volume in response to changes in venous return. That is, 
the more the LV is stretched prior to contraction, the greater the strength of the 
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contraction will be. This is analogous to the notion that increasing venous return 
to the heart, thereby increasing LVEDP, leads to an increased stroke volume 
(Moss & Fitzsimons, 2002). HF typically leads to a reduction in CO due to a 
decline in SV resulting from systolic or diastolic dysfunction, or both. Systolic 
dysfunction results from a loss in either contractility (inotropy) or a loss of viable 
muscle as occurs following MI (discussed below). Furthermore, in chronic HF, 
systolic dysfunction is often the result of remodeling of the LV that leads to LV 
dilation (discussed below) as well as from alterations in the signaling-
mechanisms regulating excitation-contraction coupling (discussed below) leading 
to reduced SV and a rise in preload due to incomplete emptying of the LV. This 
causes a rise in EDV and EDP and activates the Frank-Starling mechanism to 
maintain stroke volume regardless of the loss in contractility. When looking at the 
PV loop, the loss of inotropy accompanying systolic dysfunction decreases the 
slope of the ESPVR resulting in an increase in ESV, an elevation in EDV and a 
reduction in SV. The accompanying reduction in EF in systolic dysfunction is why 
this pathology is now referred to as HFrEF.  
Diastolic dysfunction occurs when the LV stiffens and becomes less 
compliant as occurs in LV hypertrophy. This leads to impaired ventricular filling. 
Since ventricular filling is dependent upon venous return and the compliance of 
the LV during diastole, reducing ventricular compliance causes a reduction in 
EDV, an increase in EDP and a reduction in SV. However, depending upon how 
much the SV and EDV change, EF may or may not be changed. As such, HF 
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caused by diastolic dysfunction is referred to as HFpEF. Diastolic dysfunction 
may also be due to diminished ventricular relaxation resulting from impairment of 
calcium (Ca2+) uptake into the sarcoplasmic reticulum (SR) or other mechanisms 
contributing to myocyte relaxation. In this case, filling of the LV is also reduced.  
Myocardial Infarction 
CAD is the number one cause of HF and is a pathology that reduces blood flow 
through the coronary arteries reducing oxygen delivery to the heart muscle 
(Gheorghiade et al., 2006). The result is hypoxia within the myocardium and 
impaired cardiac function. The final clinical entity of CAD is known as MI. MI is 
clinically defined by myocardial necrosis in the setting of prolonged myocardial 
ischemia and remains a leading cause of morbidity and mortality worldwide 
(Ahmad, 2012; Reichlin et al., 2009). Most MIs are caused by the occlusion of a 
coronary artery by thrombus formation following the rupture of an unstable 
atherosclerotic plaque (Figure 3) (Sotolongo, Smith, & Margolis, 1990). 
Myocardium lying distal to the occlusion will not be supplied with oxygen and 
nutrients and reduced perfusion will limit washout of cellular waste products. An 
occlusion lasting more than 20 min generates irreversible myocardial necrosis 
that first occurs within the endocardium and expands throughout the myocardium 
and epicardium (Thygesen et al., 2012). Complete necrosis of the area at risk 
occurs within several hours and depends upon such factors as the extent of 
collateral circulation and demand for oxygen and nutrients (Thygesen et al., 
2012). Since the amount of tissue damage is directly related to the duration of  
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Figure 3. Myocardial Infarction. Anatomical diagram of the heart showing 
cardiac vasculature. Inset illustrating MI. A leading cause of MI is the rupture of 
an unstable cholesterol plaque promoting thrombus formation, inflammatory cell 
infiltration, and occlusion of a coronary artery. The loss of blood supply to distal 
myocardial tissue inhibits the supply of oxygen and nutrients to the infarct zone 
and leads to tissue necrosis following prolonged ischemia. The duration of the 
occlusion determines the severity of tissue damage with irreversible necrosis 
occurring within several hours of the infarct. Important to my dissertation work, 
our group recently found that cMyBP-C is degraded into an N’ 40 kDa fragment 
(C0-C1f) following MI and that this fragment is released into the local tissue and 
systemic circulation. Figure from (T. L. Lynch & Sadayappan, 2014). Copyright 
Wiley-VCH Verlag GmbH & Co. KGaA. Reproduced with permission. 
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the occlusion, the therapeutic strategy is to reopen the coronary artery as quickly 
as possible (Sotolongo et al., 1990). Therefore, early detection of a MI is 
imperative for successful treatment. Large transmural infarctions can typically be 
detected by ECG ST-segment elevation (STEMI) (Kim, Lee, Park, Han, & Oh, 
2010). However, a large proportion of infarctions do not result in clear ST-
segment elevation (de Winter & Tijssen, 2012). In these non-ST segment 
elevation (NSTEMI) patients, diagnosis is based on the release of cardiac 
proteins (mostly cardiac troponins) into the circulation caused by necrotic 
cardiomyocytes (Hall, Hallen, Agewall, Atar, & Jensen, 2012). Unlike ECG 
changes in STEMI patients, an increase in serum levels of the cardiac troponins 
is only detectable after several hours (Ferguson, Beckett, Stoddart, Walker, & 
Fox, 2002; Reichlin et al., 2009). 
 In the healthy heart, contraction is regulated by a system that couples 
electrical excitation to elevated levels of intracellular Ca2+, triggering an 
interaction between actin and myosin filaments to generate cross-bridge cycling 
and shortening of the sarcomere (discussed below) (Bers, 2002). However, upon 
ischemic injury to the heart, loss of myocardial tissue alters the contractile 
properties of cardiomyocytes leading to further myocyte death and exacerbating 
cardiac dysfunction (Zhang et al., 2010). The heart attempts to compensate for 
the loss of contractile activity and diminished cardiac pump function by increasing 
myocyte Ca2+ transients (Zhang et al., 2010). However, maintaining contractile 
function by increasing Ca2+ influx induces continuous pathological stress in the 
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post-MI heart (Zhang et al., 2010). This stress causes structural remodeling of 
the left ventricle (discussed below) and dysfunction leading to hypertrophy and, 
eventually, dilation (Dhalla, Kaura, Liu, & Beamish, 1996; Gupta, Prahash, & 
Anand, 2000; Zhang et al., 2010).  
 Important to my dissertation work, our group recently found that cMyBP-C 
is degraded into an N’ 40 kDa fragment (C0-C1f) following MI and that this 
fragment is released into the local tissue and systemic circulation (Govindan, 
McElligott, et al., 2012; Govindan, Sarkey, et al., 2012; T. L. Lynch & 
Sadayappan, 2014; Razzaque et al., 2013). Notably, within cardiac tissue, C0-
C1f has been demonstrated to produce significant contractile dysfunction 
(Govindan, Sarkey, et al., 2012; Witayavanitkul et al., 2014), and HF (Razzaque 
et al., 2013). The discovery and role of C0-C1f in the heart will be discussed 
further below.  
Pathological Cardiac Remodeling  
 
Cardiac remodeling is generally accepted as a major factor determining 
the clinical course of HF. Indeed, as heart disease progresses to HF, heart size 
is augmented, cardiac function deteriorates, and HF symptoms are manifested 
(Cohn et al., 2000). Cardiac remodeling is defined as genome expression 
resulting in molecular, cellular and interstitial changes and is manifested clinically 
as changes in the size, shape, and function of the heart resulting from cardiac 
load or injury (Cohn et al., 2000). Cardiac remodeling is influenced by several 
factors including hemodynamic load and neurohormonal activation among other 
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factors (Cohn et al., 2000). Furthermore, many changes that occur during cardiac 
remodeling are associated with HF progression. The cardiac myocyte is the 
primary cell involved in the remodeling process. However, other cardiac 
components including the interstitium, fibroblasts, collagen, and coronary 
vasculature are involved (Cohn et al., 2000). Additionally, processes relevant to 
cardiac remodeling include ischemic injury to the heart, cellular necrosis, 
apoptosis, and autophagy as well as pressure or volume overload, myocarditis, 
and cardiomyopathies (Cohn et al., 2000).  
While the exact processes and cellular mediators of LV remodeling remain 
unclear, it is thought that as myocytes are stretched, norepinephrine activity and 
angiotensin and endothelin release are increased stimulating expression of 
altered proteins and myocyte hypertrophy (Cohn et al., 2000). This leads to 
further deterioration in cardiac function and increased neurohormonal activation. 
Increased aldosterone and cytokine activation may also stimulate collagen 
synthesis leading to fibrosis and remodeling of the extracellular matrix (Cohn et 
al., 2000). Although, in the series of events leading up to chronic HF, the early 
stages of cardiac remodeling are considered beneficial and/or compensatory as 
the heart attempts to maintain normal function in the face of overt stress. The 
cellular rearrangement of the ventricular wall associates with either maintained or 
improved CO as the heart hypertrophies (Cohn et al., 2000). As myocytes 
become elongated, the thickness of the ventricular wall increases. This stretch 
within myocytes may induce the expression of hypertrophy-associated genes and 
27 
 
 
 
the synthesis of new contractile proteins and the assembly of new sarcomeres 
(Cohn et al., 2000). It is thought that the pattern in which new sarcomeres are 
deposited determines whether cardiomyocytes increase their diameter or 
elongate (Francis & McDonald, 1992). Progressive dilation of the LV by cellular 
elongation is associated with an elevation in the volume of blood in the LV 
(increased preload) but a reduction in EF. Evidently, as the heart remodels, it 
changes its geometry and mass, which may adversely affect cardiac function 
leading to a maladaptive response (Cohn et al., 2000; Struijker-Boudier, Smits, & 
De Mey, 1995; K. T. Weber & Brilla, 1991). This plasticity of the LV is known as 
pathological remodeling (Burchfield et al., 2013). Surprisingly, in addition to 
myocyte hypertrophy, under certain conditions these cells may also atrophy 
leading to shrinkage of the heart and a reduction of LV mass (Ambardekar & 
Buttrick, 2011).  
The majority of clinically used therapies targeting HF with cardiac 
remodeling are for patients with HFrEF. However, as indicated previously, 
approximately 50% of HF patients are HFpEF (Borlaug & Paulus, 2011; 
Burchfield et al., 2013). CAD is a leading cause of HFrEF (Dorn, 2009) and most 
of the knowledge regarding LV remodeling comes from patients and animal 
models of MI (Burchfield et al., 2013). Current clinically proven therapies used in 
the treatment of pathological ventricular remodeling that have been shown to 
reduce morbidity and mortality include angiotensin-converting enzyme inhibitors, 
angiotensin receptor blockers, beta (β)-blockers and mineralocorticoid receptor 
28 
 
 
 
antagonists that have been shown to reduce cell death, hypertrophy, and fibrosis 
(Xie, Burchfield, & Hill, 2013). It has been further suggested that glucagon-like 
peptide-1 may be effective in treating metabolic imbalances (Xie et al., 2013). 
Ventricular assist devices have been shown to provide mechanical support by 
unloading the failing myocardium and limiting ventricular dilation while 
implantable cardioverter-defibrillators and cardiac resynchronization therapy 
target electrophysiological remodeling events. Lastly, although controversial, cell 
replacement therapy to replace lost cardiomyocytes may prove to be a promising 
future therapeutic (Xie et al., 2013).  
Within the categories of HFrEF and HFpEF, a wide range of etiologies 
dictates disease pathogenesis. HCM, a HFpEF disorder, is one such pathology 
use to parse out these etiologies (Burchfield et al., 2013) as it is associated with 
multiple distinct genetic variants that provide information regarding phenotype 
and disease outcome (Maron & Maron, 2013). HCM is caused by mutations in 
genes encoding sarcomeric proteins (Barefield, Kumar, de Tombe, & 
Sadayappan, 2014) that control myocyte contraction and Ca2+ handling. Of the 
identified genes, MYBPC3 is the most highly mutated gene in human HCM 
accounting for approximately 40% of all known mutations (Barefield et al., 2015). 
As many HFpEF patients have normal extracellular matrix proteins, myocyte 
stiffness resulting from sarcomeric abnormalities appears to contribute to disease 
pathogenesis. As such, early genetic testing for HCM may assist in the accurate 
and early diagnosis of HFpEF (Burchfield et al., 2013). In contrast to HCM, DCM 
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represents a HFrEF disorder that has been shown to be linked to mutations in 50 
sarcomeric genes (McNally, Golbus, & Puckelwartz, 2013). Similar to HCM, not 
all DCM patients display the same phenotype and often mutations within the 
same gene or the same genetic variant can cause HCM or DCM rendering 
diagnosis and risk prevention difficult (Burchfield et al., 2013). Conclusively, the 
cardiac myocyte appears to be at the center of cardiac remodeling and the 
etiology of HFpEF and HFrEF, indicating the need to better understand myocyte 
function in health and disease.  
The Structure and Function of the Cardiac Myocyte 
 
The myocardium is a highly organized tissue consisting of smooth muscle 
cells, fibroblasts, and cardiac myocytes (Walker & Spinale, 1999). The cardiac 
myocyte is the fundamental unit of contraction within the myocardium as well as 
the most physiologically energetic cell in the body, continuously contracting 3 
billion times in the average human lifespan (Severs, 2000; Walker & Spinale, 
1999). This leads to the pumping of 7,000 liters of blood per day along 100,000 
miles of blood vessels (Severs, 2000). This next section will highlight the 
structural components of the cardiomyocyte and their function during cardiac 
contraction.  
Basement Membrane 
 The basement membrane covers the outermost portion of the cardiac 
myocyte, forming a boundary between the extracellular and intracellular space. 
The primary constituents of the basement membrane include type IV collagen, 
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two glycoproteins known as laminin and fibronectin, as well as proteoglycans 
(Walker & Spinale, 1999). The basement membrane of the cardiomyocyte forms 
an interface with the extracellular space with anchoring fibers that adhere the 
basal lamina to collagen (Walker & Spinale, 1999). The primary function of the 
basement membrane is to form barrier between the extracellular space and the 
cardiac myocyte, influencing the exchange of macromolecules between them. 
The basement membrane also serves as an interface for myocyte continuity with 
the extracellular matrix (Walker & Spinale, 1999).  
Sarcolemma 
 Within cardiomyocytes, the sarcolemma is formed from a melding of the 
plasma membrane and the basement membrane, allowing the sarcolemma to 
interact with both the extracellular and intracellular environment (Walker & 
Spinale, 1999). The sarcolemma is composed of a lipid bilayer, having a 
hydrophobic core. Along with receptor membrane proteins, integrins, which are 
attached to the intracellular side of the sarcolemma, adhere the cardiac myocyte 
to the extracellular matrix and basement membrane forming a collagen-integrin-
cytoskeletal relation that may be essential for the transduction of cell shortening 
and ejection of blood from the ventricle (Hsueh, Law, & Do, 1998; Walker & 
Spinale, 1999).  
 Formed by the sarcolemma are intercalated disks and transverse tubules, 
or T tubules. Intercalated disks serve to conduct the action potential (discussed 
below) between myocytes and to provide a mechanical linkage between 
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myocytes (Walker & Spinale, 1999). T tubules are invaginations of the 
sarcolemma that contain and bring a high proportion of L-type Ca2+ channels in 
the proximity of the SR near Ca2+ release channels in the SR. As such, T tubules 
are a critical component in excitation-contraction coupling. The primary function 
of the sarcolemma is to provide a barrier for diffusion. Although, the sarcolemma 
also contains receptors, pumps, and channels that are essential to 
cardiomyocyte contraction (Walker & Spinale, 1999).  
Sarcolemmal Pumps and Ion Channels 
 In accordance with the review on the structure and function of the cardiac 
myocyte by Walker and Spinale (Walker & Spinale, 1999), describing the pumps 
and channels of the cardiac myocyte sarcolemma is most understandable in the 
context of the phases of the action potential (Figure 4). Phase 4 of the action 
potential is referred to as the resting membrane potential, which is sustained by 
an inward potassium (K+) rectifier and the sodium (Na+)/K+ 
adenosinetriphosphatase (ATPase), the Na+/Ca2+ exchanger, and the 
sarcolemmal Ca2+ ATPase (Figure 5). As the sarcolemma is only permeable to 
K+ during this time, the K+ equilibrium potential is responsible for the resting 
membrane potential of the myocyte.  In general, the K+ rectifier brings K+ into the 
myocyte, the Na+/K+ extrudes three Na+ for two K+ ions, and the Na+/Ca2+ 
exchanger and sarcolemmal Ca2+ ATPase extrude Ca2+ from the myocyte  
(Figure 5) (Walker & Spinale, 1999). Although, the Na+/Ca2+ exchanger is 
bidirectional and is the primary system leading to Ca2+ efflux from the myocyte.  
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Figure 4. The Phases of the Ventricular Myocyte Action Potential. The action 
potential is generated from sarcolemmal protein interactions and consists of 5 
phases. Phase 0 of the action potential is depicted as an upstroke to represent 
rapid cellular depolarization, which is followed by a brief early repolarization in 
Phase 1. During Phase 2, the action potential plateaus and then rapidly 
repolarizes in Phase 3. Phase 4 depicts the resting membrane potential.  
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Figure 5. Excitation-Contraction Coupling in the Cardiac Myocyte.  Ca2+ is 
removed from the cardiomyocyte by the Na+/Ca2+ exchanger and the Ca2+-
ATPase located in the sarcolemma. The release of Na+ extracellularly by the 
Na+/K+ ATPase contributes to the resting membrane potential. The Na+/Ca2+ 
exchanger is reversible. Upon myocyte depolarization, L-type Ca2+ channels are 
activated resulting in Ca2+ influx into the cardiac myocyte (ICA). This Ca2+ 
activates Ca2+ release channels on the sarcoplasmic reticulum. The 
subsequently released Ca2+ triggers myocyte contraction through actin-myosin 
cross-bridge formation. Cross-bridges are disengaged by the removal of Ca2+ 
from the cytosol by the actions of SERCA-2, the Na+/Ca2+ exchanger, and the 
sarcolemmal Ca2+ ATPase. 
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 Phase 0 of the action potential is due to activation of the fast Na+ channel, 
which allows Na+ to flow into the myocyte along electrical and chemical 
concentration gradients. Early repolarization of the myocyte is due to rapid 
inactivation of the Na+ channels and activation of two outward currents. The 
movement of chloride (Cl-) ions down their electrical and chemical gradient 
allows chloride into the cell and, also, the efflux of K+ down its electrochemical 
gradient. Together, these events give rise to the brief, small repolarization of the 
membrane potential during phase 1 of the action potential (Walker & Spinale, 
1999). 
 Phase 2 of the cardiac action potential represents a plateau caused by the 
influx of Ca2+ through L-type Ca2+ channels and an efflux of K+ through the K+ 
rectifier, a process that occurs during phase 0 and peaks during phase 2 (Balke 
& Shorofsky, 1998; Mukherjee & Spinale, 1998; Walker & Spinale, 1999).  Phase 
3 depicts myocyte repolarization due to increased K+ conductance through the 
delayed rectifier K+ channels that are activated at the end of the plateau phase. 
During this time, all other currents, as well as Na+ and Ca2+ movement are 
inactivated allowing for the membrane potential to be restored to the resting state 
(phase 4).  
Sarcolemmal Receptor Systems 
 Within the cardiac myocyte, muscarinic, alpha (α), endothelin, and β-
adrenergic receptor systems are present (Walker & Spinale, 1999). Of particular 
importance, the β-adrenergic receptor system is a common clinical target. The β-
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adrenergic receptor exists in either activated or inactivated states with the 
inactive state dominating at equilibrium (Johnson, 1998; Walker & Spinale, 
1999). Both catecholamines and synthetic β-adrenergic agonists bind this 
receptor leading to its conformational change and activation of a guanine 
nucleotide-dependent coupling protein. Subsequently, adenylate cyclase is 
stimulated and cyclic adenine monophosphate production is elevated, which 
activates the catalytic subunits of protein kinase A (PKA). PKA activation leads to 
phosphorylation of specific targets within the myocyte, including the sarcolemmal 
L-type Ca2+ channel, phospholamban (PLN), troponin I (TnI), along with other 
proteins, altering their activity (Walker & Spinale, 1999). 
Myocyte Cytoskeleton 
 The myocyte cytoskeleton is a vital interface between the contractile 
apparatus and the extracellular environment and may alter the form and function 
of the myocyte. Cytoskeletal proteins include α-actinin, talin, and desmin, which 
meet where integrins enter the cytosol of the myocyte. Importantly, 
phosphorylation of these proteins may change cellular conformation and, 
thereby, function. Furthermore, the giant protein titin gives the myocyte 
viscoelastic properties that may inhibit hyperstretching of the myocyte (Horowits, 
Kempner, Bisher, & Podolsky, 1986; Morano et al., 1994; Walker & Spinale, 
1999). Tubulins, which include α- and β-tubulin are also important cytoskeletal 
proteins that are involved in assembly of the myocyte and transduction of 
mechanical signals to the nuclear envelope and may influence myocyte 
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contractility (Walker & Spinale, 1999).  
Sarcoplasmic reticulum 
 Located within the SR membrane, the sarco/endoplasmic reticulum Ca2+ 
transport ATPase (SERCA-2) regulates Ca2+ accumulation within the myocyte. 
Along with the Na+/Ca2+ exchanger and sarcolemmal Ca2+ ATPase, SERCA-2 
plays an important role in the uptake of cytosolic Ca2+ in the contraction cycle 
allowing for cytosolic Ca2+ concentrations to change more than 100-fold during 
the excitation-contraction coupling process (discussed below) (Walker & Spinale, 
1999). SERCA-2 transports 2 moles of Ca2+ into the SR for every 1 mole of ATP 
hydrolyzed (Barry & Bridge, 1993; Walker & Spinale, 1999). While SR Ca2+ 
uptake is mediated by SERCA-2, SERCA-2 activity is reversibly regulated by 
PLN (Kranias & Hajjar, 2012). As a generalization, in the dephosphorylated state, 
PLN inhibits SERCA-2 activity (Kranias & Hajjar, 2012). When phosphorylated, 
PLN relieves this inhibition on SERCA-2 activity (Kranias & Hajjar, 2012). As 
such, the phosphorylation status of PLN is crucial to the rate and extent of Ca2+ 
removal from the cytosol, thereby regulating the process of excitation-contraction 
coupling.  
 Located at the interface between the SR and the T tubules are the calcium 
release channels known as the ryanodine receptors (RYRs) (Lanner, Georgiou, 
Joshi, & Hamilton, 2010). RYRs are responsible for Ca2+ release from the SR 
store and are highly sensitive to changes in cytosolic Ca2+ (Lanner et al., 2010; 
Walker & Spinale, 1999). A small, rapid influx of Ca2+ through L-type Ca2+ 
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channels causes a rapid, large release of Ca2+ into the myocyte cytosolic space 
(Figure 5) (Walker & Spinale, 1999). This process triggers the contractile 
apparatus within the myocyte leading to cellular contraction (Lanner et al., 2010; 
Walker & Spinale, 1999). 
Contractile Apparatus 
 The central focus of my dissertation work has been the mechanical 
processes underlying the function of the contractile apparatus of the cardiac 
myocyte. Within the cardiac myocyte, the sarcomere is the basic unit of 
contraction and is composed of interdigitating thick and thin filaments (Figure 6). 
The thick filament includes titin and myosin while the thin filament includes actin, 
the troponins, and α-tropomyosin (α-TM). The cardiac sarcomere consists of 
distinct regions and is defined as the segment between two neighboring Z-lines. 
In electron micrographs of cross-striated muscle, the Z-line appears as a series 
of dark lines. Surrounding the Z-line is the I-band (for isotropic), which contains 
only the thin filaments with no thick filament superimposition. Next is the A-band 
(for anisotropic), which contains the entire length of a single myosin thick 
filament, as well as thin filament proteins. Within the I-band is a region referred to 
as the H-zone, which contains the thick myosin filaments that are not 
superimposed by thin filaments. Finally, within the H-zone is a thin M-line, which 
is formed from cross-connecting constituents of the cytoskeleton. 
 
 
38 
 
 
 
 
 
Figure 6. The Structure of the Cardiac Sarcomere. The cardiac sarcomere 
consists of the thick-filament proteins myosin and titin and the thin filament 
proteins actin, α-TM, and troponins I, C, and T. cMyBP-C is a sarcomeric protein 
that participates in stabilizing sarcomere structure and regulating the kinetics of 
cross-bridge cycling by controlling the interaction between actin and myosin 
filaments. Figure from (T. L. Lynch & Sadayappan, 2014). Copyright Wiley-VCH 
Verlag GmbH & Co. KGaA. Reproduced with permission. 
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Important to my dissertation work, localized within the cardiac sarcomere 
in a region referred to as the C-zone that is set within the A-band is the 
contractile regulatory protein cMyBP-C. cMyBP-C regulates actomyosin 
interactions and the kinetics of cross-bridge cycling in a phosphorylation 
dependent manner (Barefield & Sadayappan, 2010; T. L. Lynch IV et al., 2015), 
which will be discussed later in detail. The resting length of the cardiomyocyte 
has been shown to be in the range of 1.8 to 2.4 micrometers (µm). The elevation 
of intracellular Ca2+ levels within the myocyte triggers interactions between thick 
and thin filament proteins leading to ATP hydrolysis and the development of 
cellular tension (Walker & Spinale, 1999). 
Myosin consists of a globular head and a filamentous tail. The globular 
head is the site of ATPase activity and contains the actin binding sites. Within the 
thin filament, actin is the primary contractile protein that comes in two forms, G- 
and F-actin. F-actin composes the backbone of the thin filament while G-actin 
provides stability (Walker & Spinale, 1999) and contains two myosin-binding 
sites. In the presence of ATP, myocyte contraction is orchestrated by the 
interaction between the globular myosin heads and the G-actin monomer in the 
presence of ATP. This results in cross-bridge formation and shortening of the 
sarcomere. α-TM, another thin filament protein, lies on either side of actin and 
provides rigidity to the thin filament while also blocking the myosin binding sites 
on actin. The troponin complex consists of cardiac troponin C (TnC), troponin T 
(TnT), and TnI. While also providing structural integrity to the sarcomere, the 
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troponins are crucial regulators of cross-bridge formation. By binding to α-TM, 
TnT anchors the troponin complex to the thin filament. When phosphorylated, TnI 
weakens the affinity of Ca2+ for TnC and thereby inhibits the binding of myosin to 
actin by preventing the shift of the troponin complex and α-TM off of the myosin 
binding sites on actin (Walker & Spinale, 1999). However, when Ca2+ binds to 
TnC, a conformational change occurs leading to dislocation of the troponin 
complex and α-TM from the myosin binding sites on actin leading to actin-myosin 
interactions, cross-bridge formation, and sarcomere contraction. 
Mitochondria 
  As contraction of the myocyte is an ATP dependent process, the cardiac 
myocyte is rich in mitochondria to maintain high ATP stores. Within the myocyte, 
the mitochondria comprise approximately 40% of the cell volume (Walker & 
Spinale, 1999), underscoring the enormous demand for energy required by the 
myocyte. Within the myocyte, the high concentrations of phosphocreatine, which 
are higher than the levels of adenosine diphosphate (ADP), serve as the primary 
source of high-energy phosphate transfer between the mitochondria and cytosol 
(Walker & Spinale, 1999). The high-energy phosphate of ATP is transferred to 
phosphocreatine, which is reconverted into ATP for use in cellular processes 
including excitation-contraction coupling (discussed below). An additional role of 
mitochondria within the cardiac myocyte is to take up and buffer large quantities 
of cytosolic Ca2+, thereby protecting the myocyte from Ca2+ overload (Walker & 
Spinale, 1999). 
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Excitation-Contraction Coupling 
 By definition, excitation-contraction coupling is the process by which 
action potentials generate contraction of the myocyte, thereby linking electrical 
excitation to contraction (Figure 5) (Pinnell, 2007; Walker & Spinale, 1999). 
Excitation-contraction coupling is produced through the fluctuation of intracellular 
Ca2+ from 100 nanomolar (nM) to 10 micromolar (µM). As described earlier, 
action potential propagation through the T tubule system of the myocyte activates 
voltage-sensitive L-type Ca2+ channels and triggers Ca2+ conductance from the 
extracellular space into the cytosol (Balke & Shorofsky, 1998; Mukherjee & 
Spinale, 1998; Walker & Spinale, 1999). However, because the quantity of Ca2+ 
entering into the cell through L-type Ca2+ channels is so small compared to Ca2+ 
release from the SR, this “trigger” Ca2+ does not contribute substantially to cross-
bridge formation and contraction (Walker & Spinale, 1999). Furthermore, it is this 
influx of extracellular Ca2+ that triggers further Ca2+ release from the SR via RyRs 
in a process known as Ca2+-induced Ca2+ release (CICR) (Pinnell, 2007).  
 As described earlier, Ca2+ release from the SR initiates a series of 
interactions within the sarcomere, best explained by the sliding filament theory. 
Under conditions of low intracellular Ca2+, phosphorylated TnI decreases the 
affinity of cytosolic Ca2+ for TnC, allowing for the strong interaction between TnI 
and actin. Under these conditions, the troponin-tropomyosin complex blocks the 
myosin binding sites on actin. As intracellular Ca2+ is increased, Ca2+ binds to 
TnC, shifting TnI affinity from actin to TnC and promoting movement of the 
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troponin-tropomyosin complex off of the myosin binding sites on actin. When the 
myosin head is bound to ATP it forms a low energy configuration not bound to 
actin. When the myosin head hydrolyzes ATP to ADP and inorganic phosphate, it 
forms a high-energy configuration and binds to actin forming a cross-bridge. The 
myosin head then releases ADP and inorganic phosphate, returning to its low-
energy configuration and moving the thin filament 10 nanometers (nm) relative to 
the thick filament (Walker & Spinale, 1999) towards the center of the sarcomere. 
This is known as the power-stroke. Finally, binding of a new molecule of ATP 
releases the cross-bridge and allows for formation of a new one, repeating the 
cycle. The contraction process is dynamic and depends upon the number of 
cross-bridges formed, the duration of the action potential, the Ca2+ levels in the 
cytosol, and ATP stores. Additionally, the strength of contraction can be altered 
by increasing the amount of free Ca2+ or by altering myofilament sensitivity to 
Ca2+ (Pinnell, 2007). The latter occurs during stretching of the myocyte and is 
responsible for the Frank-Starling mechanism discussed earlier. Cross-bridge 
cycling will occur until Ca2+ is removed from the cytosol by energy-dependent 
mechanisms or by a reduction in ATP stores.  
 Active relaxation of the myocyte depends upon SERCA-2, which is 
regulated by PLN. As discussed above, every mole of ATP that is hydrolyzed 
corresponds to two moles of Ca2+ being transported back into the SR. Other 
mechanisms contributing to Ca2+ removal include the Na+/Ca2+ exchanger, the 
sarcolemmal Ca2+ ATPase, as well as Ca2+ binding proteins such as calmodulin 
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and calsequestrin (Walker & Spinale, 1999). Importantly, variations in active 
relaxation during the excitation-contraction process will alter diastolic 
performance of the myocyte.  
Myocyte Contraction 
 Myocyte contraction is the dénouement of successful action potential 
transduction and Ca2+ release into the cytosol. In basic research, over the past 
two decades, technological advancements have made it possible to study 
cardiac contraction from the level of the whole heart using in vivo 
echocardiography imaging on live animals to in vitro studies at the level of the 
single isolated myocyte. By studying the single myocyte, one is able to examine 
and modulate sarcolemmal receptor systems and contractile performance in the 
absence of loading conditions and neurohormonal activity (Walker & Spinale, 
1999). A prominent example has been the alteration of the β-adrenergic receptor 
system. Incredibly, we are now able to even isolate electrically responsive 
myocytes from myocardial biopsies and measure contractile performance. Such 
techniques provide basic research scientists the ability to test the mechanisms 
regulating excitation-contraction coupling in health and disease, leading to a 
better understanding of the biophysics and mechanics of muscle contraction.  
 In addition to studying the single isolated myocyte, the mechanics of 
cardiac myocyte contraction can also be studied using an isolated muscle strip. 
During my dissertation studies, I used isolated mouse papillary muscle fibers to 
determine mechanical differences between healthy and HF hearts. The papillary 
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muscle is convenient for such studies as the fibers within this muscle run in 
approximately the same direction (Pinnell, 2007). In one type of assay, the 
muscle is anchored at both ends and placed under an initial tension (preload). As 
the initial length of the fiber is increased, mimicking alterations in preload, so too 
is the tension generated during isometric contraction. This leads to an elevation 
in the force of contraction and SV, which produces the familiar Starling curve. 
This is explained by the notion that the overlap of actin and myosin under resting 
conditions is not optimal, which is improved by increasing length of the muscle 
(sarcomere). The result is an augmentation of actin and myosin overlap and the 
amount of tension that is produced. However, under physiological conditions, this 
mechanism has been shown to not account for the shape of the Starling curve 
possibly indicating other processes such as stretch-induced sensitivity increases 
in troponin for Ca2+ (length-dependent Ca2+ sensitivity) and the enhancement of 
intracellular free Ca2+ (Pinnell, 2007).  
 Isotonic contraction of a muscle refers to shortening of a muscle against a 
load. In this situation, the muscle maintains the same tension but 
shortens/changes length. Afterload is represented by the amount of weight 
moved by the muscle. Throughout contraction, if force is maintained constant, 
one can measure both the change in muscle length and force with respect to 
time. Increasing afterload decreases the amount and velocity of shortening, and 
vice versa. Importantly, if the muscle is stretched to increase preload, an 
increase in velocity and shortening will be observed at a particular level of 
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afterload. In contrast to isotonic contraction, as indicated above, isometric 
contraction refers to a situation in which the muscle changes or develops tension 
without shortening/changing length. This is the type of contraction used in my 
fiber studies. In vivo, during the cardiac contraction cycle, isometric contraction 
occurs when both the AV and seminlunar valves are closed. Although tension 
develops, blood is not ejected from the ventricle, as muscle fiber shortening is 
absent. Once the semilunar valves open, the contraction becomes isotonic and 
tension is maintained. At this point, blood is ejected and isotonic shortening 
occurs (Pinnell, 2007).  
The Frank-Starling Relationship 
 As discussed earlier, the Frank-Starling relationship refers to the process 
by which increasing muscle length (or ventricular volume) leads to enhanced 
contractile performance during the subsequent contraction (Moss & Fitzsimons, 
2002). Thus, increased venous return to the ventricles leads to a greater SV and 
increased blood volume ejection from the heart. The cellular basis of the Frank-
Starling relationship is not well understood (Moss & Fitzsimons, 2002). As 
mentioned above, a common thought for the mechanism underlying the Frank-
Starling relationship is that increasing sarcomere length reduces the lateral 
spacing between thick and thin filaments leading to increased cross-bridge 
interaction and increased contractile force. Interestingly, in permeabilized 
myocardium held at a constant length, osmotic compression can increase force 
at every Ca2+ concentration indicating that the same Ca2+ sensitivity of force 
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observed at long lengths can be achieved at short sarcomere lengths by 
reducing fiber diameter (Moss & Fitzsimons, 2002). Furthermore, osmotic 
compression can eliminate the length dependence of Ca2+ sensitivity (McDonald 
& Moss, 1995; Moss & Fitzsimons, 2002). Therefore, lattice filament spacing is a 
key contributor to the Frank-Starling relationship. This was elegantly shown by 
Konhilas et al. who used X-ray diffraction to quantify lateral spacing of thin and 
thick filaments in cardiac muscles while also measuring force and length 
(Konhilas, Irving, & de Tombe, 2002). In this study, the authors reported a 
decrease in filament lattice spacing upon stretching of the muscle or osmotic 
compression with dextran (Konhilas et al., 2002). Dextran reduced the stretch-
dependent decrease in filament lattice spacing but did not alter the length 
dependence of Ca2+ sensitivity of force. Also, osmotic compression mimicking 
lattice spacing of longer sarcomere lengths did not alter Ca2+ sensitivity of force. 
Primarily, the authors suggested that compression of lattice spacing at short 
sarcomere lengths to mimic the spacing observed at long lengths does not mirror 
the increased Ca2+ sensitivity seen at longer lengths (Konhilas et al., 2002; Moss 
& Fitzsimons, 2002). This data contrasted to many findings that have only 
mimicked length-dependent changes in Ca2+ sensitivity by altering fiber diameter, 
besides altering muscle length (Fuchs & Smith, 2001; Fuchs & Wang, 1996; 
McDonald & Moss, 1995; Moss & Fitzsimons, 2002). As such, Konhilas et al. 
proposed that the effect of myofilament lattice spacing on myofilament Ca2+ 
sensitivity is variable and depends upon the extent of compression of the lattice 
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(Konhilas et al., 2002). Indeed, it has been suggested that cross-bridge formation 
increases the affinity of Ca2+ for TnC (Hofmann & Fuchs, 1988; Moss & 
Fitzsimons, 2002). However, this is a chicken-and-egg situation. Does, increased 
Ca2+ binding result from cross-bridge binding or does increased Ca2+ binding 
promote additional cross-bridge binding to the thin filament and increased force? 
Another variable may include the effect of stretch on thick filament structure or 
strain of the elastic protein titin such that reducing strain diminishes the length 
dependence of Ca2+ sensitivity of force in the heart (Cazorla, Vassort, Garnier, & 
Le Guennec, 1999; Cazorla, Wu, Irving, & Granzier, 2001; Fukuda, Sasaki, 
Ishiwata, & Kurihara, 2001; Moss & Fitzsimons, 2002). Furthermore, length-
dependent changes in cooperative processes in the myocardium that modulates 
activation may contribute to the effect of myofilament lattice spacing on 
myofilament Ca2+ sensitivity (Moss & Fitzsimons, 2002). 
 Cooperation in cross-bridge binding is the process in which the initial 
recruitment of cross-bridge binding facilitates further binding, which leads to 
increases in force at any given Ca2+ concentration. Stated differently, cooperative 
recruitment of cross-bridges to the thin filament is triggered by binding of Ca2+ to 
TnC followed by the spread of cross-bridge binding away from the Ca2+ bound 
TnC, leading to increases in force at any given Ca2+ concentration. At low Ca2+ 
concentrations, this mechanism would predominate, as few TnC’s would have 
Ca2+ bound leaving many extended regions of the thin filament available for 
cooperative activation (Moss et al., 2015). However, at saturating concentrations 
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of Ca2+, this mechanism would not predominate, as the thin filament would be 
fully activated with no regions available for recruitment of cross-bridges (Moss et 
al., 2015). Therefore, any changes in force observed would be largely due to 
increases in Ca2+ concentration and the kinetics of force development would 
approach the fundamental rate of cross-bridge cycling (Moss et al., 2015). 
Relating back to the Frank-Starling mechanism, at long sarcomere lengths, 
increased cooperativity could result from increased probabilities of initial cross-
bridges binding to actin due to decreased lattice spacing. Importantly, the 
contractile regulatory protein cMyBP-C has also been suggested to play an 
important role in cooperative cross-bridge recruitment to the thin filament, as 
discussed below.  
Cardiac Myosin Binding Protein-C 
 Central to my dissertation has been studying the necessity of the N’ region 
of cMyBP-C in maintaining normal cardiac function in vivo. Currently, studying 
the function of cMyBP-C in health and disease is the focus of many labs 
worldwide given its important role in regulating actomyosin interactions and the 
kinetics of cross-bridge cycling and high mutation rate in human cardiomyopathy. 
While this protein has been well studied since its initial discovery and while 
researchers are coming ever closer to definitively defining its true function and 
mechanism of action in the cardiac sarcomere, the exact role and mechanisms 
by which cMyBP-C regulates cardiac contraction remain incompletely 
understood. As such, the results of my dissertation work have provided direct 
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evidence for the importance of this protein in maintaining normal cardiac function 
in vivo and have, hopefully, provided a better understanding of the mechanistic 
function of cMyBP-C in both health and disease, as discussed below. In the next 
section, I will describe the discovery of cMyBP-C, its structure and localization 
within the cardiac sarcomere, the current understanding of its role in health and 
disease, and, finally, the discovery and importance of a specific N’ region of 
cMyBP-C that is the focus of my dissertation work.  
Discovery, Isoforms, and Localization of cMyBP-C 
Between 1971 and 1973, Offer, Moos, and Starr discovered MyBP-C in 
mammalian skeletal muscle as an impurity of isolated myosin (Offer et al., 1973; 
Starr & Offer, 1971). Starr and Offer were the first to separate several 
unidentified myosin-associated proteins using sodium dodecyl sulfate (SDS) 
polyacrylamide gel electrophoresis (PAGE) (Ackermann & Kontrogianni-
Konstantopoulos, 2010; Starr & Offer, 1971). MyBP-C was originally referred to 
as C-protein due to its localization on SDS-PAGE as band C and was later 
characterized as an approximately 1270 amino acid (mice) 140 kDa (runs at 150 
kDa on SDS-PAGE) myosin binding protein using several experimental 
techniques including gel filtration, ammonium sulfate fractionation, and single 
molecule electron microscopy (Ackermann & Kontrogianni-Konstantopoulos, 
2010; Hartzell & Sale, 1985; T. L. Lynch & Sadayappan, 2014; Offer et al., 1973; 
Starr & Offer, 1971).  
The MyBP-C family consists of three isoforms including slow skeletal, fast 
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skeletal, and cardiac, which are encoded by the genes MYBPC1, MYBPC2, and 
MYBPC3, respectively, and which localize to chromosomes 12, 19, and 11, 
respectively (Ackermann & Kontrogianni-Konstantopoulos, 2010). The cloning 
and sequencing of these isoforms from various species including human, 
chicken, rabbit, and mouse indicated an approximately 65% sequence identity 
among the individual isoforms across species, with an approximately 50% 
homology shared among the human cardiac, slow, and fast forms of MyBP-C 
(Ackermann & Kontrogianni-Konstantopoulos, 2010; Furst, Vinkemeier, & Weber, 
1992; Reinach, Masaki, & Fischman, 1983; F. E. Weber, Vaughan, Reinach, & 
Fischman, 1993; Yasuda, Koshida, Sato, & Obinata, 1995). In mammals, 
cMyBP-C is expressed early in development along with titin and myosin 
(Ackermann & Kontrogianni-Konstantopoulos, 2010). However, the skeletal 
isoforms of MyBP-C are detectable only at later stages of development following 
the expression of titin and myosin with the slow isoform preceding the expression 
of the fast isoform (Ackermann & Kontrogianni-Konstantopoulos, 2010). The slow 
and fast MyBP-C isoforms can coexpress in the same muscle type and coexist in 
the same sarcomere (Ackermann & Kontrogianni-Konstantopoulos, 2010) with 
slow MyBP-C having been found to express in both slow and fast-type skeletal 
muscles and fast MyBP-C expression having been found to be largely restricted 
to fast skeletal muscles (Lin et al., 2013). Intriguingly, slow and fast MyBP-C 
expression was shown to be upregulated in myopathic skeletal muscles from 
mdx mice (Lin et al., 2013). Also, the expression of the fast isoform was 
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demonstrated to be elevated in cMyBP-C null hearts undergoing dilation (Lin et 
al., 2013). Moreover, expression of slow MyBP-C has been detected in the RA 
and the interatrial septum of the heart (Dhoot & Perry, 2005). The expression of 
the cardiac isoform of MyBP-C is restricted to the developing and mature heart 
(Ackermann & Kontrogianni-Konstantopoulos, 2010). However, in avian species, 
cMyBP-C is expressed transiently in some skeletal muscles during 
embryogenesis, but was shown to be dispensable for the development of 
mammalian skeletal muscle with no functional or structural consequences in 
adult myocytes from cMyBP-C deficient animals and dystrophic mice (Lin et al., 
2013).  
The implementation of X-ray diffraction and immunoelectron microscopy 
allowed for determination of the location of MyBP-C at striped intervals within the 
C-zone of the A-band of rabbit skeletal muscle (Craig & Offer, 1976). This finding 
further confirmed MyBP-C’s association with myosin thick filaments. Later studies 
demonstrated that MyBP-C arranges in a doublet pattern along the length of the 
A-band on either side of the H-zone in 7-9 transverse stripes separated at 
approximately 43 nm, with approximately 2-4 molecules of MyBP-C associating 
with each myosin cross-bridge (Ackermann & Kontrogianni-Konstantopoulos, 
2010; Bennett, Craig, Starr, & Offer, 1986; Pepe, 1975; Pepe, Ashton, Street, & 
Weisel, 1986; Rome, Offer, & Pepe, 1973). More recently, a similar striping 
pattern of the cardiac isoform of MyBP-C in cardiac muscles was shown (P. 
Luther et al., 2008). While myosin tails comprise the backbone of the thick 
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filament, their heads point outwards and may extend towards actin. The heads 
are arranged along three-stranded helices with three pairs of heads at each 14.3 
nm layer and an axial repeat of 43 nm. The defined spacing of cMyBP-C stripes 
indicates that only every third level of myosin heads in the C-zone are associated 
with a molecule of cMyBP-C (Craig & Offer, 1976). As such, cMyBP-C is likely 
only activated during thick-thin filament interaction in the central part of the 
sarcomere during the contraction cycle when the myosin-actin interaction 
extends into the central region of the A-band (Barefield & Sadayappan, 2010).   
 In total, cMyBP-C comprises 2% of the contractile proteins within the heart 
and has been suggested to play a role in myofibril organization and assembly 
during myofibrillogenesis and muscle regeneration (Ehler, Rothen, Hammerle, 
Komiyama, & Perriard, 1999; Schultheiss et al., 1990). Of particular interest, 
mouse cardiomyocytes from hearts in which cMyBP-C was either knocked-out (-
/-) (Harris et al., 2002) or ablated by C-terminal truncation (t/t) (McConnell et al., 
1999) developed abnormal sarcomere structures with the absence of M-lines and 
modifications in thick filament size (Barefield & Sadayappan, 2010). Although 
these animals are viable, they develop severe cardiac remodeling and contractile 
dysfunction by 3 months of age demonstrating that while cMyBP-C is necessary 
for sarcomere organization and for proper contractile dysfunction, it is 
dispensable for sarcomere formation during embryogenesis (Barefield & 
Sadayappan, 2010). Importantly, cardiomyocytes from heterozygous mice with 
either cMyBP-C knockout (+/-) or C-terminal truncation (+/t) develop normal 
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sarcomeres and have normal contractile function, indicating haploinsufficiency 
resulting from a null allele is not sufficient to trigger cardiac remodeling (Barefield 
& Sadayappan, 2010).  
Molecular Structure of cMyBP-C  
 Structurally, cMyBP-C contains eight immunoglobulin I-like domains, three 
fibronectin type III domains, a proline-alanine-rich region between domains C0 
and C1, and a 100 residue long phosphorylatable M domain, also referred to as 
the MyBP-C motif (Figure 7) (T. L. Lynch & Sadayappan, 2014). While all three 
MyBP-C isoforms share a highly homologous modular architecture, specific to 
the cardiac isoform is an extra immunoglobulin domain at its N’ region (C0), an 
LAGGGRRIS insertion in the M domain, and an insertion loop of 28 residues 
within the C5 domain (Figure 7) (Barefield & Sadayappan, 2010; Flashman, 
Redwood, Moolman-Smook, & Watkins, 2004). The M domain has a unique 
structure that has been suggested to have a more N’ region that is flexible and 
mostly disordered and a C’ region containing three α-helices in a three-helix 
bundle (Craig, Lee, Mun, Torre, & Luther, 2014). Most notably, the mouse 
cardiac isoform contains four phosphorylation sites at serine residues within the 
M domain at positions 273, 282, 302, and 307 corresponding to human residues 
275, 284, 304, and 311 (Jia, Shaffer, Harris, & Leary, 2010), which are 
phosphorylated by PKA (Gautel, Zuffardi, Freiburg, & Labeit, 1995). As I have 
used mouse models during my dissertation studies, I will focus on the mouse  
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Figure 7. The Structure of Cardiac Myosin Binding Protein-C. cMyBP-C 
contains eight immunoglobulin I-like domains (blue), three fibronectin type III 
domains (orange), a proline-alanine-rich region between domains C0 and C1 
(purple), and a 100 residue long phosphorylatable M domain (red), also referred 
to as the MyBP-C motif. Phosphorylation sites at serine residues 273, 282, 302, 
and 307 (mouse sequence) within the M domain are depicted as diamonds. 
Specific to the cardiac isoform of MyBP-C is an extra immunoglobulin domain at 
its N’ region (C0), an LAGGGRRIS insertion in the M domain, and an insertion 
loop of 28 residues within the C5 domain (green line). Indicated at the N’ region 
of cMyBP-C is the C0-C1f region (below), which contains domains C0 through 
C1 and the first 17 amino acid residues of the M domain. Relevant cMyBP-C 
protein interaction partners are indicated (above). 
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phosphorylation sites in the experiments presented here. In addition to PKA, 
additional kinases have been found to phosphorylate cMyBP-C at these and 
other sites within the protein. These kinases include calmodulin kinase II, protein 
kinase C, protein kinase D and the 90 kDa ribosomal S6 kinase (Bardswell, 
Cuello, Kentish, & Avkiran, 2012; Knoll, 2012; Kuster et al., 2012) (Pfuhl & 
Gautel, 2012). Recent evidence also established that glycogen synthase kinase 
3 beta phosphorylates cMyBP-C in the proline-alanine-rich linker region on Ser-
128 (Ser-133 in humans) (Kuster, Sequeira, et al., 2013). Importantly, during the 
development of HF, total phosphorylation of cMyBP-C has been shown to be 
decreased, with a major loss of tri-phosphorylated protein (Decker et al., 2005; 
Sadayappan et al., 2005). Furthermore, it has been shown that the reduction in 
cMyBP-C phosphorylation is accompanied by contractile dysfunction, reduced 
force generation, and increased cleavage of cMyBP-C (discussed below) 
(Decker et al., 2005; Sadayappan et al., 2006b). Clearly, phosphorylation of 
cMyBP-C is a critical regulator of its interactions and function within the cardiac 
sarcomere (Barefield & Sadayappan, 2010). 
Physical Interactions and Function of cMyBP-C 
 An important feature to consider when elucidating the function of cMyBP-
C is that this protein (and the skeletal isoforms) contains no enzymatic activity 
indicating that it must accomplish its biological function in the myocardium 
through its interaction with other molecules (Figure 7). cMyBP-C is not known to 
bind to Ca2+, nucleic acids, or sugars (Pfuhl & Gautel, 2012). While it has been 
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shown to have a binding site for zinc in domain C1 (Ababou et al., 2008), this 
interaction is of low affinity and likely lacks physiological importance (Pfuhl & 
Gautel, 2012). As such, protein-protein interactions are likely the primary 
mechanism by which cMyBP-C functions. It is well established that the C’ region 
of cMyBP-C interacts with the LMM region of myosin and with titin to position and 
intricately incorporate cMyBP-C into the thick filament and to anchor the thick 
filament (Freiburg & Gautel, 1996; Gilbert et al., 1999; Miyamoto et al., 1999; 
Okagaki et al., 1993; Pfuhl & Gautel, 2012). This interaction may stabilize and 
organize the thick filament, however, this has yet to be confirmed (Nyland et al., 
2009). In stark contrast to cMyBP-C’s C’ region, the interactions, role, and 
necessity of the N-terminal (N’) region of cMyBP-C remain incompletely 
understood (Pfuhl & Gautel, 2012). As such, understanding the necessity of the 
N’ region of cMyBP-C in cardiac function has been the principal focus of my 
dissertation work.  
 Beginning with the interactions of cMyBP-C with the thick filament, following 
cMyBP-C’s discovery, it was suggested that myosin contains at least two sites at 
which cMyBP-C may bind, one in the LMM region and one in the S2 region (Starr 
& Offer, 1978). Myosin is a hexameric protein containing two heavy chains 
(MHC) and two light chains (regulator and essential light chain, RLC and ELC, 
respectively) (Ackermann & Kontrogianni-Konstantopoulos, 2011). The rod (LMM 
region) of myosin is comprised of a coiled-coil helix that, towards its N’ region, 
unwinds at each MHC producing a catalytic head, the subfragment 1 (S1) region. 
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The S1 region of myosin has ATPase activity and is involved in the formation of 
cross-bridges with actin (Ackermann & Kontrogianni-Konstantopoulos, 2011; 
Rayment, Rypniewski, et al., 1993; Woodhead et al., 2005). The lever arm, or S2 
region of myosin divides the S1 region from the rod portion of myosin and 
transduces the chemical energy produced from ATP hydrolysis into mechanical 
movement of myosin along the thin filament (Rayment, Holden, et al., 1993). 
Bound to the S1 region is RLC and ELC, which regulate the speed and force of 
contraction (Colson et al., 2010; Morano, 1999). Intriguingly, cMyBP-C has been 
shown to interact at its C0 domain with RLC (Ratti, Rostkova, Gautel, & Pfuhl, 
2011). More recently, the S2 binding site for cMyBP-C was mapped to the vicinity 
of the S1-S2 junction on myosin and to the N’ cardiac C1C2 fragment (Ababou, 
Gautel, & Pfuhl, 2007; Ababou et al., 2008; Gruen & Gautel, 1999). Importantly, 
the M and C2 domains have been shown to bind directly to the first 126 residues 
of the S2 fragment (Ababou et al., 2007; Gruen & Gautel, 1999) while the C1 
domain binds the hinge region between the S1 heads and S2 fragment (Ababou 
et al., 2008). Critical to cMyBP-C’s regulation of actomyosin interactions, it has 
been extensively reported that phosphorylation of serines 273, 282, and 302 (and 
more recently 307) within the M domain of cMyBP-C by PKA following β-
adrenergic receptor activation abolishes the interaction of the M domain with 
myosin’s S2 region (Gruen, Prinz, & Gautel, 1999; Sadayappan et al., 2009; 
Sadayappan et al., 2005; Sadayappan et al., 2006a). In studies of intact 
myocardium in mouse models, PKA phosphorylation of cMyBP-C led to an 
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increase in cross-bridge turnover rate and accelerated the rise of force 
development under submaximal Ca2+ activation but had no effect on the kinetics 
of force development at saturating Ca2+ concentrations (Barefield & Sadayappan, 
2010; Stelzer, Patel, Walker, & Moss, 2007). This supports the observation that 
cMyBP-C functionally interacts with myosin’s S2 region to affect contractile 
function (Barefield & Sadayappan, 2010; Stelzer et al., 2007). Furthermore, 
phosphorylation has been proposed to cause rearrangement of the structure of 
the M-domain and may expose additional serine residues for phosphorylation by 
kinases, establishing a hierarchy of phosphorylation (Bezold, Shaffer, Khosa, 
Hoye, & Harris, 2013; Karsai, Kellermayer, & Harris, 2013; Previs et al., 2012; A. 
Weith et al., 2012). Recently, Moss et al. have proposed a mechanism by which 
cMyBP-C phosphorylation modulates the cooperative recruitment of cross-
bridges (discussed above) to regulate contraction and speed the rate of force 
development (Moss et al., 2015). In their model, Moss et al. suggest that cMyBP-
C is able to slow the cooperative recruitment of cross-bridges by placing a 
physical restraint on myosin leading to a reduction in myosin binding to actin and 
slowing the cooperative spread of cross-bridge binding. However, when 
phosphorylated, cMyBP-C relieves its constraint on myosin increasing the 
probability of myosin binding to actin or of its own binding to the thin filament 
(discussed below) (Moss et al., 2015). This would then increase the activation 
state of the thin filament and accelerate cross-bridge binding while augmenting 
the rate of force development (Moss et al., 2015). The variable phosphorylation 
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of cMyBP-C in mono-, di- and tri-phosphorylated forms has been shown to 
correlate with the rate of movement of labeled thin filaments over bound myosin 
in motility assays such that increased phosphorylation led to increased rate of 
movement (A. E. Weith et al., 2012). This implies that the actions of cMyBP-C 
can be modulated based upon degree of phosphorylation rather than a complete 
on/off mechanism (Moss et al., 2015). Remarkably, during the development of 
HF, total phosphorylation of cMyBP-C is decreased, with a major loss of tri-
phosphorylated protein (Decker et al., 2005; Sadayappan et al., 2005). 
Intriguingly, reduced phosphorylation of cMyBP-C is accompanied by contractile 
dysfunction, reduced force generation, and increased cleavage of cMyBP-C 
(Decker et al., 2005; Sadayappan et al., 2006b). Therefore, in my dissertation 
work, I have examined the phosphorylation status of cMyBP-C in a novel mouse 
model that lacks the C0-C1f region of cMyBP-C in the heart and develops HF 
(discussed below). While it is evident that total phosphorylation of cMyBP-C by 
PKA alters the orientation of the thick filament (discussed below) and myosin 
kinetics, how the phosphorylation of cMyBP-C coordinates with phosphorylation 
of thin filament proteins leading to the regulation of Ca2+ sensitivity requires 
further elucidation (Barefield & Sadayappan, 2010).  
As indicated previously, cMyBP-C interacts at its C10 domain with 
myosin’s LMM region (Flashman, Watkins, & Redwood, 2007; Miyamoto et al., 
1999). Furthermore, domains C8-C10 have been shown to bind with titin, which 
is also tightly bound to the thick myosin filament (Kontrogianni-Konstantopoulos, 
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Ackermann, Bowman, Yap, & Bloch, 2009). Interestingly, it was demonstrated 
that cMyBP-C binds to the first immunoglobulin domain of an 11-domain super-
repeat in the A-band portion of titin, thereby contributing to cMyBP-C’s periodicity 
within the C-zone (Freiburg & Gautel, 1996). While the C’ region of cMyBP-C 
may interact with the rod domain of myosin contributing to stability of the thick 
filament, it is the binding of the N’ region of cMyBP-C that regulates contraction 
(Flashman et al., 2004; Oakley, Chamoun, Brown, & Hambly, 2007). Indeed, 
considering both of these interactions, determining the consequences of cMyBP-
C ablation in the heart is a relevant question. As such, two mouse models were 
developed to examine the effect of the absence of cMyBP-C on cardiac function 
(Harris et al., 2002; McConnell et al., 1999). While the t/t mouse model generated 
by McConnell et al. displayed a null cMyBP-C background and developed 
cardiac hypertrophy and contractile dysfunction while remaining viable, this 
model was not a genetic model of cMyBP-C ablation as it expressed detectable 
levels of the cMyBP-C protein (McConnell et al., 1999; Sadayappan & de Tombe, 
2012). Therefore, to test the hypothesis that cMyBP-C is essential for sarcomere 
assembly, structure, and function, a cMyBP-C knockout mouse model was 
generated in which exons 3-10 of MYBPC3 were replaced with a gene encoding 
neomycin resistance (Harris et al., 2002). Accordingly, there was no detectable 
cDNA and protein for cMyBP-C in these animals. cMyBP-C knockout animals 
developed cardiac hypertrophy and reduced diastolic and systolic function but 
were viable (Harris et al., 2002). These data suggest that while cMyBP-C is not 
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necessary for cardiac development, it is essential for normal contractile function. 
In vitro studies on myocytes and tissue from cMyBP-C knockout hearts 
demonstrated their reduction in myofilament Ca2+ sensitivity of tension (Harris et 
al., 2002), deficit in diastolic relaxation and increased LA myofilament Ca2+ 
sensitivity (Pohlmann et al., 2007), acceleration of stretch activation (Stelzer, 
Dunning, & Moss, 2006) and force development (Stelzer, Fitzsimons, & Moss, 
2006), and loss of PKA mediated stretch activation (Stelzer, Patel, & Moss, 
2006). Additionally, cMyBP-C knockout mice failed to compensate for increased 
load and demonstrated a significant reduction in systolic and diastolic function 
when challenged with pressure overload (Brickson et al., 2007). Finally, ablation 
of cMyBP-C led to radial displacement of myosin cross-bridges in cMyBP-C 
knockout myofibrils compared to wild-type controls (Colson, Bekyarova, 
Fitzsimons, Irving, & Moss, 2007). Together, these data suggest that cMyBP-C 
serves as a mechanical tether on myosin acting as a structural restraint on 
myosin heads and that phosphorylation or ablation of cMyBP-C releases this 
constraint resulting in the acceleration of myocardial force generation 
(Sadayappan & de Tombe, 2012). 
From the current available data in the cMyBP-C field it is evident that 
through the interactions at its N’ and C’ regions, cMyBP-C appears to contribute 
to the structure of the cardiac sarcomere and the regulation of cross-bridge 
formation, thereby controlling the kinetics of contraction. Several models have 
been proposed to explain how cMyBP-C regulates the formation of actomyosin 
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cross-bridges. In terms of cMyBP-C’s regulation of contraction, the “tether model” 
suggests that both of the myosin binding sites on cMyBP-C act together to limit 
the movement of the S1 head relative to LMM and actin, restricting the formation 
of actomyosin cross-bridges (Calaghan, Trinick, Knight, & White, 2000). In this 
model, PKA phosphorylation of serines 273, 282, and 302 within the M domain 
regulates the interaction between cMyBP-C and myosin (Ackermann & 
Kontrogianni-Konstantopoulos, 2011; Barefield & Sadayappan, 2010). The 
proposed mechanism is that when dephosphorylated, the N’ region binds to 
myosin and limits its interaction with actin but when phosphorylated, this 
inhibition is relieved allowing myosin to interact with actin and form cross-bridges 
(Ackermann & Kontrogianni-Konstantopoulos, 2011). Generally, this model 
focuses on the dynamic and highly regulated interaction of cMyBP-C with both 
actin and myosin filaments. Regarding the topology of cMyBP-C within the 
sarcomere, two models have been proposed. The “collar model” suggests that a 
trimer of cMyBP-C molecules wraps around the rod domain of myosin 
(Ackermann & Kontrogianni-Konstantopoulos, 2011; Moolman-Smook et al., 
2002) while the “axial model” proposes that the C’ region of cMyBP-C runs along 
the length of the rod domain (Ackermann & Kontrogianni-Konstantopoulos, 2011; 
Squire et al., 2003). The collar model stipulates that cMyBP-C forms a dimer 
through C’ interactions. Indeed, the interactions between domains C5 with C8 
and C7 with C10 have been demonstrated (Flashman, Korkie, Watkins, 
Redwood, & Moolman-Smook, 2008; Moolman-Smook et al., 2002). However, X-
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ray diffraction, computational modeling and electron microscopy with three-
dimensional reconstructions of cardiac thick filaments supported the axial model 
and the notion that domains C8, C9, and C10 lay along the length of the myosin 
rod (Rome et al., 1973; Squire et al., 2003; Zoghbi, Woodhead, Moss, & Craig, 
2008). However, the axial model does not refute the dimerization of cMyBP-C. 
Regardless of the model, it still stands that the N’ region of cMyBP-C extends 
into the interfilament space where it binds the S2 portion of myosin and, possibly, 
actin (discussed below). As cMyBP-C is approximately 40 nm in length (Hartzell 
& Sale, 1985), it is capable of spanning the interfilament space where it can 
interact with both thick and thin filament proteins as the distance between these 
proteins is approximately 9-16 nm (Julian, Moss, & Waller, 1981). 
While the N’ region of cMyBP-C has been shown to interact with the S2 
fragment of myosin (Gruen & Gautel, 1999), the same interacting region of 
cMyBP-C was suggested to bind to F-actin (Razumova et al., 2006; Squire et al., 
2003). The ability of MyBP-C to bind to actin was suggested soon after its 
discovery (Moos, 1981; Yamamoto, 1986) and the interaction between actin and 
MyBP-C was later found to occur at the N’ region (Gautel et al., 1995). This 
interaction was initially thought to occur between domains C0 and C1 in the 
proline-alanine rich region (Squire et al., 2003; Squire, Roessle, & Knupp, 2004). 
However, this interaction was controversial and no experimental or theoretical 
evidence for the proline-alanine rich sequence as an actin-binding region had 
surfaced (Pfuhl & Gautel, 2012). Instead, the M domain, between domains C1 
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and C2, was then suggested to bind to actin (Razumova, Bezold, Tu, Regnier, & 
Harris, 2008; Saber, Begin, Warshaw, & VanBuren, 2008; A. Weith et al., 2012; 
Whitten, Jeffries, Harris, & Trewhella, 2008). However, other recent work has 
suggested that the C0 domain is the actin-binding site (Kensler, Shaffer, & 
Harris, 2011; Lu, Kwan, Trewhella, & Jeffries, 2011; Mun et al., 2011; Whitten et 
al., 2008). Interestingly, it was also suggested that there is no specific interaction 
of the N’ fragment of cMyBP-C with F-actin but rather it is the C’ region that binds 
with high affinity (Rybakova, Greaser, & Moss, 2011). Yet, it is well established 
that this region of cMyBP-C binds unequivocally with the myosin filament 
backbone and titin, leaving the F-actin binding site on cMyBP-C questionable 
(Pfuhl & Gautel, 2012). 
 Further work on the interaction of cMyBP-C with actin had more 
convincingly revealed that domains C0C2 and C1C2 bound with high affinity to F-
actin and that C0-C1 bound extremely weakly suggesting that domain C0 and the 
C0-C1 linker is not involved in F-actin binding (Shaffer, Kensler, & Harris, 2009). 
Additional work suggested that the M domain linker between domains C1 and C2 
contained multiple binding sites capable of binding F-actin (Mun et al., 2011). 
Importantly, using in vitro motility assays, it has been demonstrated that actin 
filament sliding over myosin is slowed by N’ fragments of cMyBP-C to the same 
extent as whole cMyBP-C (Razumova et al., 2006). These results suggested that 
cMyBP-C either slowed the myosin detachment rate from actin (Razumova et al., 
2006) or tethered the thick filament to the thin filament (Razumova et al., 2006; 
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A. Weith et al., 2012). Intriguingly, using an assay that better mimicked the in 
vivo situation, the sliding of F-actin over native cardiac thick filaments was 
slowed specifically in the C-zone, which was ablated by the removal of C0-C1 
and the first 17 residues of the M-domain (the C0-C1f region [Figure 7]) (Previs 
et al., 2012; A. Weith et al., 2012). Critically, this finding is central to the 
hypothesis of my dissertation work and suggests the fundamental importance of 
the C0-C1f region of cMyBP-C, particularly, the first 17 residues of the M domain 
(the “f” region of C0-C1f), in regulating cMyBP-C’s interaction with actin. 
Additionally, this finding suggests a potential functional importance of the C0-C1f 
region of cMyBP-C in this protein’s ability to regulate cross-bridge formation and 
contraction within the sarcomere, myocyte, and whole heart. Therefore, to 
determine the necessity of the C0-C1f region of cMyBP-C in maintaining normal 
cardiac function in vivo, our lab has developed a TG mouse model lacking the 
C0-C1f region of cMyBP-C, but that still expresses the remaining 110 kDa more 
C’ region of cMyBP-C in the heart (cMyBP-C110kDa mouse model). 
Characterization of this mouse model has been the primary focus of my 
dissertation work presented here. Following the reports by Previs et al. and Weith 
et al., additional work using yeast two-hybrid experiments led to the conclusion 
that the C1 and M domains were necessary for actin binding as replacement of 
endogenous cMyBP-C with actin binding-ablated cMyBP-C resulted in its 
abnormal sarcomeric distribution and altered sarcomeric structure (Bhuiyan, 
Gulick, Osinska, Gupta, & Robbins, 2012). Furthermore, electron tomography 
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observations show MyBP-C extending from thick to thin filaments in the intact 
sarcomere, indicating that the N’ region of MyBP-C binds to the thin filament (P. 
K. Luther & Craig, 2011; P. K. Luther et al., 2011). Together, these results 
suggest that cMyBP-C binding to actin is physiologically relevant and that 
slowing of actin filament sliding may be one mechanism by which cMyBP-C 
regulates cardiac contractility (Mun et al., 2014). 
 Electron microscopy and neutron scattering studies of F-actin decorated 
with N’ fragments of cMyBP-C have shed light onto the nature of the actin-
cMyBP-C complex. These data suggest that the C0 and C1 domains bind near 
subdomain 1 and the DNase I binding loop of actin (Whitten et al., 2008) while 
the M domain bridges over subdomain 2 and that domains C2 and C3 extend 
above the filament (Mun et al., 2011). This suggests that the N’ region of cMyBP-
C may modulate thin filament activation by interfering with or displacing α-TM 
binding in its low Ca2+ blocked position on actin. This notion was confirmed in an 
important study using electron microscopy and light microscopy to demonstrate 
that under low Ca2+ conditions, the C0C2 region of cMyBP-C binds to thin 
filaments and displaces α-TM toward the high Ca2+ (closed) position in which 
myosin binding sites on actin are exposed (Mun et al., 2014). This suggested that 
cMyBP-C could activate the thin filament, which the authors further confirmed in 
a motility assay. They showed that C0C2 has no effect on α-TM position under 
high Ca2+ conditions but inhibits maximal sliding velocity in the motility assay 
(Mun et al., 2014). Of particular importance to my dissertation work, the authors 
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found that the C0-C1f fragment of cMyBP-C binds the thin filament under low 
Ca2+ conditions but does not displace α-TM or activate thin filament sliding. 
However, C0-C1f was still able to inhibit thin filament sliding at high Ca2+ to the 
same extent as the larger C0C2 N’ fragment (Mun et al., 2014). These findings 
suggest that regions of the M-domain beyond the first 17 amino acids appear to 
be required for fully productive binding to thin filaments. Indeed, as mentioned 
earlier, yeast two-hybrid and NMR data suggest that positively charged residues 
of the M domain beyond the first 17 are important for actin binding (Bhuiyan et 
al., 2012; Howarth, Ramisetti, Nolan, Sadayappan, & Rosevear, 2012). Together, 
these data suggest that the N’ region of cMyBP-C may play two physiological 
roles in intact muscle. First, at low levels of Ca2+, cMyBP-C may displace α-TM 
from the blocked position (in which α-TM blocks the binding of myosin to actin) 
thereby activating the thin filament (Mun et al., 2014). Second, the N’ region of 
cMyBP-C may govern maximal sliding velocity at high Ca2+ by a potentially 
independent molecular mechanism (Mun et al., 2014), perhaps by placing a load 
on the thin filament, reducing its rate of sliding. Interestingly, it has also been 
suggested that cMyBP-C phosphorylation within the M domain can reduce, but 
not abolish, cMyBP-C binding to actin and that under these conditions, α-TM is 
only slightly displaced (Barefield & Sadayappan, 2010; Craig et al., 2014). In the 
intact myocardium, this may translate to a reduction in cMyBP-C’s slowing of 
filament sliding or a reduction in its ability to activate the thin filament (Craig et 
al., 2014). Given the complexity of the interactions of cMyBP-C’s N’ region and 
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the dual biphasic activation and inhibition observed in actin motility assays, 
Walcott et al. developed a novel mathematical model for the interaction of 
cMyBP-C with the contractile proteins actin and myosin and the regulatory 
protein α-TM to explain the elusive mechanism of cMyBP-C function (Walcott, 
Docken, & Harris, 2015). The authors referred to this as the drag-activation-
competition model (Walcott et al., 2015). 
 The complex activating and inhibitory effects of cMyBP-C have proven 
challenging to explain by a single mechanism. Although activation might be 
explained by the ability of cMyBP-C N’ domains to bind actin and shift α-TM and 
expose the myosin binding sites on actin, inhibition may be due to competition of 
cMyBP-C with myosin heads for binding to actin (Moos, Mason, Besterman, 
Feng, & Dubin, 1978) or by transient links formed between cMyBP-C and the 
flow cell surface in the motility assay creating a viscous drag that slows motility 
(A. Weith et al., 2012). In their model, Walcott et al. propose that myosin 
competes with cMyBP-C binding to actin. Once bound, either cMyBP-C or 
myosin displaces α-TM towards its open position. If nearby molecules bind, they 
activate intervening molecules. However, if distant molecules bind, they do so 
independently (Walcott et al., 2015). Further explained, the authors propose that 
the mechanism of drag-activation-competition for cMyBP-C is consistent with 
actin motility data in that cMyBP-C binding to actin is capable of displacing α-TM 
at low Ca2+, activating the thin filament. However, increasing cMyBP-C 
concentration leads to competition for binding sites between myosin and cMyBP-
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C as the higher cMyBP-C concentration leaves fewer sites available for myosin 
binding. Then, links formed by cMyBP-C binding to actin or the flow cell surface 
creates a viscous drag that slows actin filament sliding motility (Walcott et al., 
2015).  
 Considering the complex functional implications for an actin-cMyBP-C 
interaction, a crosslink between the thick and thin filaments would likely slow 
down actin filament sliding but would not alter maximum force (Pfuhl & Gautel, 
2012). If the interaction of cMyBP-C with the thin filament extends to the 
troponin-α-TM complex, this may alter contraction such that the concentration of 
Ca2+ required to reach half-maximal contraction would be modified producing a 
left-shift in the force/pCa (pCa = -log[Ca2+]) curve (Pfuhl & Gautel, 2012). This 
shift has been observed in systems in which N’ fragments of cMyBP-C were 
added (Harris, Rostkova, Gautel, & Moss, 2004; Herron et al., 2006; Kunst et al., 
2000; Razumova et al., 2008; Razumova et al., 2006). Additionally, a competition 
of cMyBP-C with the S1 head region of myosin has been suggested to lead to a 
reduction in velocity and maximum force (Pfuhl & Gautel, 2012). 
Recently, Kampourakis et al. have attempted to clarify the function of the 
regulatory N’ C1C2 region of rat cMyBP-C by examining the effect(s) of these 
regions on thick and thin filament structure using intact sarcomeres from skinned 
rat ventricular trabeculae (Kampourakis, Yan, Gautel, Sun, & Irving, 2014). They 
show that the C1C2 region of cMyBP-C induced larger structural changes in thin 
filaments than did Ca2+ activation, even when active force was blocked by 
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blebbistatin, indicating that C1C2 directly activates the thin filament 
(Kampourakis et al., 2014). In contrast, they further demonstrate that structural 
changes in thick filaments induced by C1C2 were smaller than those associated 
with Ca2+ activation, which were abolished or reversed upon blebbistatin 
treatment. Furthermore, they suggest that low concentrations of C1C2 do not 
alter resting force but increase Ca2+ sensitivity and reduce cooperativity of force 
and structural changes in both filament types. They conclude that the N’ region of 
cMyBP-C stabilizes the “on” state of thin filaments and the “off” state of thick 
filaments and that this is how cMyBP-C regulates cardiac contractility. However, 
given the complexity of cMyBP-C’s interactions, future research is required to 
confirm the true mechanism of action of this protein in the cardiac muscle. This 
will be particularly important in understanding the role of this protein in various 
cardiovascular diseases and in the development of novel therapeutics to treat 
these pathologies.  
cMyBP-C in Disease 
 While the project that I have undertaken for my dissertation work has been 
mechanistic in nature, that is, examining the function of the N’ region of cMyBP-C 
in regulating cardiac contraction, the implication is that this work will lead to a 
better understanding of how cMyBP-C functions in both health and disease. 
Therefore, it is essential to mention relevant pathologies in which cMyBP-C has 
been shown to participate. Over the past decade, over 200 mutations have been 
identified in the MYBPC3 gene, several of which are at the N’ region of cMyBP-C 
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(Ackermann & Kontrogianni-Konstantopoulos, 2011). These mutations include 
missense, nonsense, deletion/insertion, and frame-shift mutations that are linked 
to the development of modest and late onset familial HCM (Ackermann & 
Kontrogianni-Konstantopoulos, 2011). Consequently, MYBPC3 is the most highly 
mutated gene in human HCM accounting for approximately 40% of the identified 
mutations (Barefield et al., 2015), further suggesting the importance of cMyBP-C 
in regulating cardiac function within the sarcomere. Mutations within MYBPC3 
have also been identified in patients with DCM (McNally et al., 2013). Most of the 
mutations that occur in the MYBPC3 gene are nonsense and frame-shift 
mutations leading to C’ truncated forms of cMyBP-C that cannot incorporate into 
the sarcomere leading to a loss in the regulation of contractile function by 
cMyBP-C (Oakley, Hambly, Curmi, & Brown, 2004). However, missense 
mutations have also been identified to cause a less severe cardiomyopathic 
phenotype (Xu, Dewey, Nguyen, & Gomes, 2010) and do not appear to alter the 
structure or stability of the protein but may weaken the myosin binding capacity 
of cMyBP-C (Ababou et al., 2008). In addition to cardiomyopathies, cMyBP-C 
has been shown to play a role in the ischemic myocardium during MI. 
cMyBP-C Cleavage During Ischemic Injury 
 Considering the involvement of cMyBP-C in cardiovascular pathologies, 
our lab has recently focused on the role of this protein during MI (Govindan et al., 
2013; Govindan, McElligott, et al., 2012; Govindan, Sarkey, et al., 2012; Kuster, 
Barefield, Govindan, & Sadayappan, 2013; T. L. Lynch & Sadayappan, 2014; 
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Witayavanitkul et al., 2014). As mentioned earlier, the central focus of my 
dissertation research has been on elucidating the necessity of the N’-C0-C1f 
region of cMyBP-C in maintaining normal cardiac function in vivo. The critical 
importance of C0-C1f in relation to its interactions with myosin and actin was 
previously discussed above. To provide additional background information into 
the functional importance of this region, I will next describe the discovery of the 
C0-C1f fragment and its recently identified pathogenicity to the heart as 
discussed in my recently published review article on this topic (T. L. Lynch & 
Sadayappan, 2014).  
Throughout ischemia and in early reperfusion, increased levels of Ca2+ 
activate the Ca2+-dependent protease calpain, which degrades intracellular 
proteins, including contractile proteins, during myocardial necrosis (Kusuoka & 
Marban, 1992). Post-ischemic dysfunction has been associated with Ca2+-
dependent degradation of α-actin (Matsumura, Kusuoka, Inoue, Hori, & Kamada, 
1993) and cTnI (Gao et al., 1997). Models of ischemia-reperfusion also show 
degradation of cTnT and myosin light chain-1. Previous work has identified 
cMyBP-C as a substrate for calpain proteases (Previs et al., 2012; Sadayappan, 
Greis, & Robbins, 2008), and that dephosphorylation makes cMyBP-C 
susceptible to proteolysis. Tandem mass spectrometry analyses revealed that 
the calpain cleavage site in cMyBP-C is set within the M-domain at 272-
TSLAGAGRR-280 in mice. This finding indicated that the predominant 40 kDa 
cleavage fragment of cMyBP-C was the C0-C1f region. Following ischemic injury, 
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the 40 kDa fragments of cMyBP-C could be readily detected in cardiac tissue 
(Sadayappan et al., 2008). Furthermore, in an in vivo rat model of MI and in 
samples from post-MI patients, it was determined that C0-C1f is released into the 
systemic circulation, where it was suggested to serve as a biomarker for 
ischemic injury (Govindan, McElligott, et al., 2012; Kuster et al., 2014). 
Furthermore, cMyBP-C dephosphorylation was found to correlate with its 
increased degradation and release in vitro and in ischemic areas of the in vivo MI 
heart (Govindan, McElligott, et al., 2012). Remarkably, constitutive 
phosphorylation of cMyBP-C prevented its degradation and was found to be 
cardioprotective (Sadayappan et al., 2006a). The removal of the N’ residues of 
cMyBP-C by a Ca2+ activated protease raises many interesting questions, 
especially when considered along with the evidence that the major regulator of 
actomyosin interaction is found within the M-domain, which is also the location of 
the cleavage site. It is possible that cleavage of cMyBP-C may provide a short-
term advantage in terms of increased contractility, although the long-term effects 
of this modification may be deleterious, which I am to prove here. Given the role 
of the N’ region of cMyBP-C as a regulator of actin-myosin interaction, the 
released C0-C1f fragment was also suggested to be involved in pathological 
dysfunction following ischemic injury to the heart (Sadayappan et al., 2008).  
The N’-C0-C1f Cleavage Fragment of cMyBP-C is Pathogenic 
Pathogenic consequences of cMyBP-C degradation in the heart post-MI 
could arise through disruption of normal full-length (FL) protein function, through 
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direct pathogenicity of C0-C1f within the sarcomere, or both. The pathogenic 
properties of C0-C1f were determined upon adenoviral infection of neonatal rat 
ventricular cardiomyocytes and adult rabbit ventricular cardiomyocytes with FL 
cMyBP-C, C0-C1f, or the 110 kDa C-terminal fragment of cMyBP-C that remains 
following the removal of C0-C1f (Govindan, Sarkey, et al., 2012). This work 
revealed that C0-C1f binds to the actin thin filament within the cardiac 
sarcomere. Using liquid chromatography-tandem mass spectrometry analysis, it 
was determined that the C0-C1f fragment contains several acetylation sites that 
may be involved in regulating the interaction between actin and myosin filaments 
(Govindan, Sarkey, et al., 2012). Furthermore, C0-C1f expression significantly 
elevated caspase-3 activity, as well as the release of lactate dehydrogenase, 
which is an indicator of increased cell injury, demonstrating the toxicity of this 
fragment to cardiomyocytes (Govindan, Sarkey, et al., 2012). C0-C1f reduced 
cell viability, altered Ca2+ handling, and significantly decreased sarcomere length 
shortening and the velocities of contraction and relaxation by inhibiting 
actomyosin function (Govindan, Sarkey, et al., 2012). It was later established in 
vivo that the TG expression of the C0-C1f fragment could cause sarcomere 
dysgenesis, altered cardiac geometry, and myofibrillar disarray as well as 
fibrosis, myocardial hypertrophy, and HF in mice between twelve and seventeen 
weeks of age (Razzaque et al., 2013). Most recently, Witayavanitkul et al. 
examined the association between C0-C1f and altered contractility in human 
cardiac myofilaments in vitro. They found that C0-C1f decreased myofilament 
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Ca2+ sensitivity and maximum force generation, but increased cooperative 
activation, the kinetics of cross-bridge cycling, and tension cost at short 
sarcomere lengths (Witayavanitkul et al., 2014). Furthermore, it was shown that 
C0-C1f interacted with actin and α-TM to exert its effects by reducing contractility, 
suggesting that reduced cardiac function following MI may result from C0-C1f 
taking on the characteristics of a poison polypeptide by interfering with the ability 
of native cMyBP-C to interact normally with the thin filament (Witayavanitkul et 
al., 2014). Overall, delineating the toxic effects of cMyBP-C degradation and the 
subsequent release of C0-C1f on sarcomere function has provided insight into 
the mechanisms underlying contractile dysfunction in MI patients. Therefore, 
preserving the phosphorylation status of cMyBP-C may be necessary to protect 
from its degradation and from the pathogenic consequences of C0-C1f in the 
post-MI heart.  
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CHAPTER THREE 
 
HYPOTHESIS AND AIMS 
 
Together, the data implicating the importance of the C0-C1f region in 
controlling cMyBP-C’s N’ interactions at the thick and thin filament, as well as the 
data supporting the pathogenicity of this fragment when expressed separate from 
the FL protein, suggest a critical importance of this region in regulating 
actomyosin interactions and the kinetics of cross-bridge cycling. However, to 
date, there have been no in vivo studies examining whether the N’-C0-C1f region 
of cMyBP-C is necessary for maintaining normal cardiac function. Therefore, 
throughout my dissertation studies, I characterized a novel mouse model 
developed in our lab that lacks the N’-C0-C1f region but that still expresses the 
remaining 110 kDa more distal C’ region of cMyBP-C within the cardiac 
sarcomere (cMyBP-C110kDa mouse model) to determine whether the C0-C1f 
region of cMyBP-C is necessary for regulating cardiac contractility and 
maintaining normal heart function in vivo. My central hypothesis was that the 
N’-C0-C1f region of cMyBP-C is critical for normal cardiac function in vivo. 
To test this hypothesis, I developed two Specific Aims.  
In Specific Aim 1, I elucidated the necessity of the N’-C0-C1f region of 
cMyBP-C on regulating cardiac morphology and contractile function at the whole-
organ level and performed studies to initially characterize the novel cMyBP-
C110kDa mouse model. I hypothesized that the N’-C0-C1f region of cMyBP-C is 
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necessary for maintaining physiological global cardiac function and 
morphology. To test this hypothesis, I performed echocardiography and 
histological and morphometric analyses on hearts from cMyBP-C110kDa and NTG 
mice to assess cardiac function and morphology. mRNA levels of pathological 
hypertrophy markers were measured to evaluate pathological remodeling in 
cMyBP-C110kDa  versus NTG hearts. RNA-Seq was performed to assess 
alterations in global gene expression levels in the hearts of cMyBP-C110kDa mice 
compared to NTG mice. Immunofluorescence analysis and coupled with second 
harmonic generation (SHG) imaging of isolated cardiac myocytes revealed the 
incorporation status of the cMyBP-C110kDa TG protein into the cardiac sarcomere 
of cMyBP-C110kDa hearts. Additionally, FL cMyBP-C and cMyBP-C110kDa TG 
protein levels and phosphorylation status were determined by Western blot 
analysis in myofilament fractions from cMyBP-C110kDa and NTG hearts.  
In Specific Aim 2, I determined how the absence of the N’-C0-C1f region 
of cMyBP-C in cMyBP-C110kDa hearts alters myofilament function to elucidate 
whether this region is necessary for controlling physiological contraction kinetics 
in the heart. I hypothesized that the absence of the N’-C0-C1f region of 
cMyBP-C in cMyBP-C110kDa mice disrupts steady-state myofilament 
function. To test this hypothesis, I performed a steady-state fiber force-ATPase 
experiment using isolated cardiac LV papillary muscle fibers from cMyBP-C110kDa 
and NTG mice at 3-months of age. The parameters measured included force 
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production, Ca2+ sensitivity of force development, tension cost, cross-bridge 
stiffness and rate of tension redevelopment (ktr). 
The results of the data I present here directly address these two Specific 
Aims and support the proposal that the N’-C0-C1f region of cMyBP-C is a critical 
regulator of actomyosin interactions that controls aberrant contraction kinetics 
within the cardiac sarcomere and that the N’-C0-C1f region of cMyBP-C is 
necessary for maintaining normal cardiac function in vivo. 
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CHAPTER FOUR 
 
MATERIALS AND METHODS 
 
cMyBP-C110kDa Mouse Model 
To determine whether the N’-C0-C1f region of cMyBP-C is necessary for 
cardiac function, I characterized cardiac function in a novel mouse model 
developed in our lab that lacks the N’-C0-C1f region of cMyBP-C but that still 
expresses the remaining more distal C’ fragment of cMyBP-C (110 kDa region). 
We referred to this mouse as the cMyBP-C110kDa mouse model (Figure 8). The 
data obtained from these animals was compared to age-matched NTG controls 
expressing only endogenous cMyBP-C in their hearts (Figure 8). All experiments 
conducted during my dissertation work were performed on animals between 3- 
and 8-months of age. Prior to my involvement in this project, my PhD mentor Dr. 
Sakthivel Sadayappan developed the cMyBP-C110kDa mouse model. Briefly, the 
cMyBP-C wild type cDNA (~3.82 kb) was made by polymerase chain reaction 
(PCR) and multiple clones were completely sequenced. cMyBP-C cDNA was 
subjected to site direct mutagenesis in which the first 813 nucleotides were 
removed, resulting in loss of the C0-C1f region. The presumptive mutant PCR 
products were cloned into pCR-Blunt II-TOPO vector (Invitrogen) for sequence 
confirmation. The sequence encoding the c-Myc epitope (10 amino acids, EQKLI 
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Figure 8. The cMyBP-C110kDa Transgenic Protein. (A) Illustration of 
endogenous full-length (FL) cMyBP-C and the cMyBP-C110kDa TG protein missing 
the N’-C0-C1f region (first 271 amino acid residues of FL cMyBP-C 
corresponding to domains C0 through C1 and the first 17 amino acid residues of 
the M domain) of cMyBP-C. cMyBP-C domains C0 through C10 are shown in FL 
cMyBP-C. The cMyBP-C110kDa TG protein is c-Myc-tagged at its N’ region prior to 
the residue that would correspond to the endogenous residue at position 272 of 
FL cMyBP-C. Phosphorylation sites within the M domain are depicted as 
diamonds. Deletion of C0-C1f results in loss of the PKA recognition motif for 
phosphorylation at serine residue 273. Protein-protein interaction domains and 
binding partners are indicated. (B) Representation of the predicted myofilament 
protein organization within the sarcomeres of NTG and cMyBP-C110kDa hearts. 
NTG hearts are expected to express the FL endogenous cMyBP-C protein while 
cMyBP-C110kDa hearts are proposed to express the cMyBP-C110kDa TG protein 
lacking the C0-C1f region. Removal of the N’-C0-C1f region of cMyBP-C is 
hypothesized to be deleterious to the ability of cMyBP-C to regulate cardiac 
contractile function through its N’ region. This is suggested to result in aberrant 
cardiac contractile function in cMyBP-C110kDa hearts leading to myocardial 
remodeling and HF. 
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SEEDL [Roche]) was incorporated into the primer such that the tag was placed 
after the initiator methionine residue at the N’ region of the protein prior to the 
residue that would correspond to the endogenous residue at position 272 of FL 
cMyBP-C. This allowed us to distinguish and determine the localization of the 
cMyBP-C110kDa TG protein compared to endogenous FL cMyBP-C by 
immunofluorescence techniques (described below). Previous in vivo studies 
showed that the c-Myc epitope tag at this location does not interfere either with 
normal sarcomerogenesis or the recombinant cMyBP-C’s capability to 
incorporate into the sarcomere (Yang, Hewett, et al., 2001; Yang, Osinska, 
Klevitsky, & Robbins, 2001; Yang et al., 1998, 1999). After the correct sequence 
was confirmed, the entire cDNA fragment was ligated into a vector containing an 
α-MHC promoter using the unique Sal I site (Figure 9) (Gulick et al., 1997). The 
construct was then re-sequenced to ensure the correct orientation. The final 
construct was digested free of the vector with Not I, purified from agarose gels, 
and used to generate multiple TG lines on an NTG background (C57BL/6 strain) 
to obtain replacement of endogenous cMyBP-C in the heart with the cMyBP-
C110kDa TG protein. Founders were identified by PCR using primers 
corresponding to the 5’-UTR’s with an internal control. Mouse line 62 was the line 
of choice for all experiments conducted during my dissertation work as it had the 
highest levels of replacement of endogenous cMyBP-C with the cMyBP-C110kDa 
TG protein, based upon previous work done by our former postdoctoral 
researcher Dr. Diederik W.D. Kuster (Figure 10). Following selection of line 62, I 
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Figure 9. cMyBP-C110kDa Vector Construct. DNA vector construct containing 
the cDNA coding region for the cMyBP-C110kDa TG protein. The 5’ c-Myc tag was 
inserted immediately after translation start codon (ATG). The entire cDNA 
fragment was ligated into the α-MHC promoter vector at the unique Sal I site. 
The α-MHC promoter allows for cardiac specific expression of the TG protein. 
The dark vertical boxes represent the three (non-coding) exons of the 5’ 
untranslated region of α-MHC that are included in the promoter. The human 
growth hormone (hGH) sequence at the 3’ end of the construct served as a 
polyadenylation sequence to maintain mRNA stability. The construct was 
sequenced to ensure the correct orientation and sequence. The final construct 
was then digested free of vector sequence with Not I, purified from agarose gels 
and used to generate multiple TG lines on an NTG background (C57BL/6 mouse 
strain) to obtain replacement of endogenous cMyBP-C in the heart with the 
cMyBP-C110kDa TG protein. 
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Figure 10. Initial cMyBP-C110kDa Transgenic Mouse Line Characterization. 
(A) SDS-PAGE gel Coomassie stained to show myofilament fractions from NTG 
and cMyBP-C110kDa line 62 mouse hearts. Myofilament proteins are indicated, 
including the cMyBP-C110kDa protein (red script), which is present only in the 
myofilament fraction from cMyBP-C110kDa line 62 heart. (B) Western blot analysis 
using myofilament fractions from NTG and cMyBP-C110kDa lines 60 and 62 mouse 
hearts. Relative protein abundance of endogenous FL cMyBP-C and the cMyBP-
C110kDa TG protein are shown. The endogenous FL cMyBP-C protein is more 
highly expressed in cMyBP-C110kDa line 60 mouse hearts than in line 62 hearts. 
Endogenous FL cMyBP-C expression is highest in NTG hearts, which do not 
express the cMyBP-C110kDa TG protein. (C) Quantification of percent replacement 
of endogenous FL cMyBP-C (black bars) with the cMyBP-C110kDa TG protein (red 
bars) in several cMyBP-C110kDa TG mouse lines. cMyBP-C110kDa TG mouse line 62 
showed the highest percent replacement of the endogenous FL cMyBP-C protein 
with the cMyBP-C110kDa TG protein and was used for all experiments performed 
throughout my dissertation studies. 
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then joined this project and performed the experiments described below to 
characterize the cMyBP-C110kDa mouse model (mouse line 62). All of the 
experiments using animals detailed in this work were approved by the 
Institutional Animal Care and Use Committees at Loyola University Chicago and 
followed the policies of the Guide for the Use and Care of Laboratory Animals 
published by the National Institutes of Health. 
Echocardiography 
To assess cardiac function in NTG and cMyBP-C110kDa animals at 3- and 
6-months of age, non-invasive M-mode echocardiography was performed using a 
VisualSonics Vevo 2100 imaging system (FUJIFILM VisualSonics Inc.) with an 
MS-550D 22-55 MHz transducer. Under isoflurane anesthesia (5% for knock-
down and 1.5% for sedation), the hearts were monitored to assess function and 
morphology. Chamber dimensions and wall thicknesses at end diastole and 
systole were measured using short-axis M-mode images (Figure 11) and the 
Vevo2100 analysis package (FUJIFILM Visual Sonics Inc.), as described 
previously (T. L. Lynch IV et al., 2015). From these values, percent FS 
(measured as ((LVID;d – LVID;s) / LVID;d) x 100) and percent EF were 
determined. Parasternal long-axis M-mode images were used to measure 
percent global longitudinal strain (GLS), which was quantified using VevoStrain 
software in Vevo Lab (FUJIFILM VisualSonics Inc.). 
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Figure 11. Echocardiography. Representative cartoon depiction of M-mode 
echocardiography showing the thickness of the interventricular septum (IVS) at 
end diastole (IVSd) and systole (IVSs) as well as LVIDd, LVIDs, and LV posterior 
wall thickness (LVPW) at end diastole (LVPWd) and systole (LVPWs). From 
these measurements, quantifications of percent EF and percent FS were 
calculated. 
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Histopathology 
 To assess the gross morphology of NTG and cMyBP-C110kDa hearts, the 
hearts were removed from anesthetized mice and were then drained of blood 
and fixed in 10% formalin. Hearts were bisected longitudinally or cross-sectioned 
at the base and dehydrated with a graded series of alcohols before being 
embedded in paraffin. Then, 5 µm step-serial sections were taken from NTG and 
cMyBP-C110kDa hearts, which were stained with hematoxylin and eosin (H&E) or 
Masson’s trichrome (MT). The H&E and MT stained sections were imaged using 
the slide scanning system (Nanozoomer RT 2.0, Hamamatsu Corporation, 
Tokyo, Japan) and a 20x Uplansapo objective at a resolution of 0.23 µm under 
bright field mode. To analyze the cellularity (nuclear area) and fibrosis, high-
resolution images were exported from whole heart scanned sections. Images 
were thresholded based on RGB values for either nuclei (using the H&E labeled 
sections) or fibrosis (using MT labeled sections) and the area of pixels occupied 
by these components were quantified in the program Axiovision (version 4.9.1, 
Carl Zeiss Microimaging). 
Mouse Ventricular Myocyte Isolation 
 To determine whether cMyBP-C110kDa incorporates properly within the 
cardiac sarcomere of cMyBP-C110kDa mice, cardiomyocytes were isolated from 
cMyBP-C110kDa hearts as well as NTG hearts for comparison. Prior to isolation, all 
animals were placed under isoflurane anesthesia (5% for knock-down) followed 
by cervical dislocation. Hearts were immediately harvested from the chest by 
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cutting above the aorta. The aorta was cannulated with a blunted 23-gauge 
needle and the hearts were fastened to the cannula with a 4-0 suture tied around 
the aorta. The hearts were then subjected to 5 minutes of retrograde perfusion 
with Perfusion Buffer (NaCl [120.4 mM], KCl [14.7 mM], KH2PO4 [0.6 mM], 
Na2HPO4], MgSO47H2O [1.2 millimolar (mM)], Na-HEPES [10 mM], NaHCO3 
[4.6 mM], Taurine [30 mM], 2,3-butanedione monoxime [10 mM], D-glucose [5.5 
mM]) via the Langendorff technique (Skrzypiec-Spring, Grotthus, Szelag, & 
Schulz, 2007). To remove the extracellular matrix, the hearts were then digested 
for 20 minutes via Langendorff retrograde perfusion with 40 milliliters (ml) of 
Digestion Buffer (50 ml Perfusion buffer, 6.25 microliters (µl) of 100 mM CaCl2, 
and 18 milligrams (mg) Liberase TH Research Grade [Cat. No. 05401151001, 
Roche Diagnostics]). Following the digestion, the hearts were removed from the 
cannula and placed into a 35 millimeter (mm) petri dish containing 2.5 ml of 
Digestion Buffer. The hearts were manually torn apart and triturated to disperse 
cardiomyocytes, which were filtered through a 200 µm Nylon Mesh (Cat. No. 
146487, Spectrum Labs) into a 15 ml conical tube to remove any remaining 
clumps of tissue. The petri dish was then washed with 2.5 ml of Myocyte 
Stopping Buffer 1 (9 ml Perfusion Buffer, 1 ml Fetal Bovine Serum, 12.5 µl of 10 
mM CaCl2), which was filtered into the 15 ml conical tube to collect the remaining 
cardiomyocytes. The cardiomyocytes were allowed to settle by gravity for 10 
minutes. The supernatant was then removed and replaced with 10 ml of Myocyte 
Stopping Buffer 2 (28.5 ml Perfusion Buffer, 1.5 ml Fetal Bovine Serum, 12.5 µl 
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of 10 mM CaCl2). Serial reintroduction of CaCl2 was then added to the 
cardiomyocyte solution as follows: 50 µl of 10 mM CaCl2 for 4 minutes, 50 µl of 
10 mM CaCl2 for 4 minutes, 100 µl of 10 mM CaCl2 for 4 minutes, 30 µl of 100 
mM CaCl2 for 4 minutes, and 50 µl of 100 mM CaCl2 for 15 minutes. 
Cardiomyocytes were triturated between CaCl2 reintroduction steps. 
Cardiomyocyte yield and quality was determined using the light microscopy 
imaging feature on the ZOE Fluorescent Cell Imager (Cat. No. 1450031, Bio-Rad 
Laboratories, Inc.) (Figure 12). 
Immunofluorescence 
Following their isolation, cardiomyocytes from either NTG or cMyBP-
C110kDa hearts were cultured for 1 hour on Lab-Tek II Chamber Slides (Cat. No. 
154461, Thermo Fisher Scientific Inc.) coated with ECM Gel from Engelbreth-
Holm-Swarm murine sarcoma (Cat. No. E6909, Sigma-Aldrich Co. LLC.). After 
adhering to the chamber slides, cardiomyocytes were washed twice with 
phosphate buffered saline (PBS) (4°C) and fixed with ice-cold (-20°C) methanol 
for 1 minute as well as cold (4°C) 4% paraformaldehyde for 3 minutes. 
Cardiomyocytes were then permeabilized in 0.5% Triton X-100 in PBS for 20 
minutes and 0.1% Triton X-100 twice for 15 minutes. Antigen retrieval was 
performed by placing the cardiomyocytes in antigen retrieval solution (0.1M 
glycine in PBS, pH 7.4) for 30 minutes followed by washing three times with PBS. 
Non-specific binding of antibodies was prevented by incubating cells for 30 
minutes in blocking solution (0.1% BSA, 0.1% gelatin, 0.1% tween-20, 0.0001%  
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Figure 12. Isolated Mouse Cardiomyocytes. Representative image of mouse 
cardiomyocytes post-isolation that were used for immunofluorescence studies. 
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NaN3) diluted 1:1 in PBS. Cardiomyocytes were then incubated overnight at 4°C 
with combinations of the following primary antibodies diluted 1:200 in blocking 
solution: MYBPC3 (E-7) antibody (Cat. No. sc-137180, Santa Cruz 
Biotechnology, Inc.), Anti-C5 fragment of MYBPC3 IgG (custom made antibody 
gifted from Dr. Saul Winegrad), Anti-c-Myc antibody produced in rabbit (Cat. No. 
C3956, Sigma-Aldrich Co. LLC.), Anti-α-Actinin antibody produced in rabbit (Cat. 
No. A2543, Sigma-Aldrich Co. LLC.), and Monoclonal Anti-α-Actinin (Sarcomeric) 
antibody produced in mouse (Cat. No. A7811, Sigma-Aldrich Co. LLC.). 
Following washing three times with PBS, the cardiomyocytes were then 
incubated in the dark for 1 hour at 4°C with a combination of Goat anti-rabbit IgG 
(H+L) Secondary Antibody, Alexa Fluor 488 conjugate (Cat. No. A-11008, 
Thermo Fisher Scientific Inc.) and Goat anti-Mouse IgG (H+L) Secondary 
Antibody, Alexa Fluor 568 conjugate (Cat. No. A-11004, Thermo fisher Scientific 
Inc.) secondary antibodies diluted 1:100 in blocking solution. Cardiomyocytes 
were then washed three times with PBS and covered with VECTASHIELD Hard 
Set Mounting Medium with DAPI (Cat. No. H-1500, Vector Laboratories, Inc.) and 
a coverslip that was sealed to the slide with nail polish. Cardiomyocytes were 
then imaged as described below. 
Two-Photon Fluorescence and SHG Microscopy of Cardiomyocytes 
 The immunofluorescence labeled cardiomyocytes from NTG and cMyBP-
C110kDa hearts were imaged using a hybrid of two-photon fluorescence and SHG 
microscopy and an LSM 710 system (Carl Zeiss) with a two-photon laser with 70 
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femtosecond pulses (MaiTai, DeepSee, eHp, Spectraphysics) and NDD 
detectors. A C-Apchromat 40x/1.20 NA W Korr objective was used to image α-
actinin, cMyBP-C and the c-Myc-labeled cMyBP-C110kDa TG protein under a two-
photon fluorescence modality using a 780 nm two-photon excitation wavelength, 
with appropriate emission filters (500-550 nm, green cMyBP-C or c-Myc-cMyBP-
C110kDa TG protein labeled with Alexa Fluor 488 and 570-615 nm, red α-actinin 
labeled with Alexa fluor 568). The same excitation was used to create a SHG 
image as described previously (Sivaguru et al., 2010; Sivaguru, Fried, Miller, & 
Fouke, 2014). Briefly, the frequency doubled label-free SHG signals from myosin 
based on the inherent non-centrosymmetric nature of its molecular structure 
using the same excitation of 780 nm. Note that this is the same wavelength used 
for two-photon fluorescence of the aforementioned molecules α-actinin, cMyBP-
C, and the c-Myc-labeled cMyBP-C110kDa Tg protein in backward/reflected 
direction using NDD detectors. Simultaneously, the myosin signals were 
collected in the forward direction using the TPMT of the LSM 710 detector after 
passing the emission beam through a 690 nm short pass filter to block any stray 
IR signals. This was coupled with a SHG filter in the range of 380-400 nm, 
centered at 390 nm, which is exactly twice the frequency of the excitation beam 
of 780 nm (Sivaguru et al., 2014). The image acquisition parameters, which 
included digital zoom (4X), pixel size (52x52 nm in XY), 1024x1024 total pixel 
dimension constituting ~53x53 µm size of frame XY, with an 8-bit dynamic range, 
four line averages and ~4.4% laser power, 1.58 us pixel dwell time and a master 
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gain of ~655-690 across the channels, were kept constant across the different 
immunofluorescence labeled cardiomyocyte samples acquired from NTG and 
cMyBP-C110kDa mouse hearts. Raw data are pseudocolored to their emission 
wavelength (blue-SHG, green cMyBP-C or the c-Myc-labeled cMyBP-C110kDa TG 
protein, red α-actinin) and adjusted to reveal the entire dynamic range in min/max 
intensity profile to best represent the image in the program Zen 2012 (Carl 
Zeiss). 
Cardiac Muscle Organization Analysis 
 To examine whole heart morphology, hearts from NTG and cMyBP-C110kDa 
animals were processed and imaged as described previously (Sivaguru et al., 
2015). Four-month old NTG and cMyBP-C110kDa animals were heparinized in 0.25 
ml 1000 USP/ml heparin sodium (Sagent Pharmaceuticals) to prevent blood clots 
from forming during heart removal. Mice were then anesthetized with 5% 
isoflurane and subjected to cervical dislocation. Hearts were rapidly excised from 
the chest taking care to ensure the aorta remained attached. The hearts were 
then cannulated through the aorta, as described previously, and perfused with 5 
ml of ice-cold cardioplegic solution (50 mM KCL, 5% dextrose, 1x PBS) to allow 
for complete cardiac muscle relaxation. Afterwards, the hearts were perfused 
with 5 ml of ice-cold NOTOXhisto fixative (Cat. No. 614-05, Science Device 
Laboratory). Each heart was then dehydrated in a graded ethanol series (25%, 
50%, 75%, and 100% in PBS under vacuum) for a total time of approximately 30 
to 45 minutes per step. The dehydrated hearts were then taken through 
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increasing benzyl alcohol:benzyl benzoate (BABB)-to-ethanol ratios (1:2, 1:1, 
2:1) for 2 hours per step, and placed three times in absolute BABB until the heart 
sank and appeared clear (approximately 45 minutes to 2 hours depending on the 
heart size). Each heart was then rehydrated using a decreasing ethanol series 
from 100% to 25% for approximately 2 to 3 hours and was then labeled with a 
Periodic Acid-Schiff (PAS) kit (Cat. No. 395B, Sigma-Aldrich Co. LLC.) for 30 
minutes according to the manufacturer’s protocol until the hearts turned 
translucent purple. The hearts were then washed, and dehydrated through the 
ethanol series and BABB:ethanol series as before ending with three 100% BABB 
washes. Cleared and labeled hearts were placed in a custom-made cover glass-
bottom dish (#1.5 or 0.17 mm) to which a glass tube was glued. The diameter of 
the glass tube and height of the BABB solution were adjusted and the cover 
glass of the glass tube was sealed with glue (Loctite, Prism, 46040, Electron 
Microscopy Sciences). To prevent evaporation and tissue movement from drafts 
during imaging, the top chamber was closed with a cover glass. Heart samples 
were imaged on a Zeiss LSM 710 NLO system with a two-photon laser (Mai Tai 
eHP with DeepSee, Newport Corporation), 488 and 561 nm single photon lasers 
with a regular photomultiplier tube or a 32-channel quasar spectral detector to 
characterize the emission peaks for PAS-stained samples. The 780 nm excitation 
wavelength was used to exploit the peak power of the two-photon laser and 
improve the penetration depth and excite the PAS dye. A Zeiss LSM 700 system 
with 488 and 55 nm lasers were used for single-photon microscopy tiling. The 
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images were stitched with 0% overlap using the native Zeiss 2 Black Edition 
software. Two-dimensional image calculations were performed using Zeiss 
Axiovision software to obtain morphometric measurements of heart length, width, 
height, ventricular area, and muscle and myocardial wall dimensions. Each 
measurement was made from four different locations, which were averaged. The 
whole-heart, atrial and ventricular volumes were traced in 40 to 50 µm steps 
through the z-axis using the Surpass module (Contour Tracing Algorithm) in the 
Imaris Suite software (version 8.0, Bitplane, Inc.). The whole-heart volume was 
created with the Isosurface module in Imaris following background subtraction, 
smoothing, and thresholding for the muscle based on the muscle volume 
intensity. The high-resolution snapshots and movies were made in Imaris. The 
final images and their intensities were adjusted at min/max display settings to 
optimize the dynamic range of the gray values of a given image.  
Cardiac Myofilament Isolation 
Protein analysis was performed using homogenized whole-heart tissue 
from NTG and cMyBP-C110kDa animals with myofilament-enriched fractions. 
Homogenization was performed using a mechanical bead beater, F-60 buffer (60 
mM KCl, 30 mM Imidazole, 2 mM MgCl2) with protease (Roche) and 
phosphatase (cocktail I [Cat. No. p5726] and II [Cat. No. p0044], Sigma-Aldrich 
Co. LLC.) inhibitors for myofilament isolations and with or without 1% Triton-X 
100. Briefly, the hearts were minced with a scalpel and transferred to a 
homogenization tube with beads in F60 buffer without Triton-X 100. Hearts were 
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homogenized twice for 40 seconds while being placed on ice for 5 minutes in 
between homogenization steps. The samples were centrifuged at 13,000 rpm for 
10 minutes at 4°C. The supernatant was then saved (total protein fraction) and 
F-60 buffer with Triton-X 100 was added to the homogenization tubes. Samples 
were mixed with a pipette tip, vortexed, homogenized for 30 seconds, and 
centrifuged as before followed by discarding of the supernatant. This was 
repeated seven more times. After the final wash, F-60 buffer without Triton-X 
100 was added to the samples, which were then vortexed, homogenized for 30 
seconds, and centrifuged as before. Urea buffer (50 mM Tris-HCL, pH 7.5, 4 M 
Urea, 1 M thiourea, 0.4% CHAPS, 20 mM spermine, 20 mM DTT) was then 
added into heart homogenate samples, which were mixed, vortexed, and 
centrifuged as before. The resulting supernatant was the myofilament fraction, 
which was quantified by the Bradford assay (Cat. No. 23236, Thermo Fisher 
Scientific Inc.) and diluted to 1 µg/ml with 2X gel loading dye. Myofilament 
samples from NTG and cMyBP-C110kDa hearts were then resolved on 4-15% 
SDS-PAGE gel cassettes (Cat. No. 456-1083, Bio-Rad Laboratories, Inc.) and 
stained with Coomassie Brilliant Blue to detect protein (Figure 13). 
Western Blot Analysis 
 
Western blot analysis to detect FL cMyBP-C, the cMyBP-C110kDa TG 
protein, and phosphorylation sites of cMyBP-C at serine residues 273, 282, and 
302, as well as phosphorylation of cTnI at serine residues 23/24 in NTG and 
cMyBP-C110kDa myofilament fractions was performed using a Bio-Rad transfer  
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Figure 13. Myofilament Fractions from NTG and cMyBP-C110kDa Hearts. 
Following myofilament fractionation of NTG and cMyBP-C110kDa hearts, 
myofilament fractions were run on diagnostic 4-15% SDS-PAGE and stained with 
Coomassie Brilliant Blue. These samples were then used for Western Blot 
analysis of the expression levels of total FL cMyBP-C and the cMyBP-C110kDa TG 
protein as well as for the level of phosphorylation of cMyBP-C at serine residues 
273, 282, and 302 and phosphorylation of cTnI at serines 23/24. n = 3 hearts per 
group. 
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system. Briefly, myofilament fractions from NTG and cMyBP-C110kDa hearts were 
resolved on 4-15% SDS-PAGE as described above. Proteins were then 
transferred to nitrocellulose membranes for 3 hours at 300 milliamps at 4°C. To 
ensure protein transfer, the membranes were stained with Ponceau S solution 
(Cat. No. 500-0205, Sigma-Aldrich Co. LLC.) followed by destaining with tris-
buffered saline containing 1% Tween-20 (TBS-T) for 5 minutes. To prevent non-
specific binding of antibodies, membranes were blocked for 30 minutes with 
Western Blocking Reagent (Cat. No. 11921673001, Sigma-Aldrich Co. LLC.) 
diluted 1:10 in TBS-T. Membranes were then incubated overnight at room 
temperature with the following primary antibodies diluted in blocking solution: 
anti-cMyBP-CC2-14 (Copeland et al., 2010) to detect cMyBP-C’s N’ region (C0 
domain), anti-cMyBP-CC10 to detect cMyBP-C’s C’ region (C10 domain), anti-c-
Myc (Cat. No. MA1-980, Thermo Fisher Scientific Inc.) to specifically detect the 
c-Myc-tagged cMyBP-C110kDa protein, anti-cMyBP-C phosphorylation site-specific 
antibodies to detect cMyBP-C phosphorylation levels at serine residues 273, 
282, and 302 (Govindan, McElligott, et al., 2012), anti-cTnI (Cat No. MAB3150, 
EMD Millipore Corporation), and an anti-cTnI serine 23/24 phosphorylation site-
specific antibody (Cat. No. 4004S, Cell Signaling Technology, Inc.) to detect cTnI 
phosphorylation levels at serine residues 23/24. The next day, the membranes 
were washed three times for 5 minutes with TBS-T and were then incubated for 
1 hour at room temperature with either donkey anti-mouse IgG-HRP (Cat. No. 
sc-2314, Santa Cruz Biotechnology, Inc.) or donkey anti-rabbit IgG-HRP (Cat. 
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No. sc-2305, Santa Cruz Biotechnology, Inc.) secondary antibodies diluted in 
blocking solution. All membranes were exposed to Amersham ECL Prime 
Western Blotting Detection reagent (Cat. No. RPN2232, General Electric 
Company) and were imaged using a Chemidoc XRS+ System with Image Lab 
Software (Cat. No. 1708265, Bio-Rad Laboratories). Protein and phosphorylation 
levels were quantified by densitometry using ImageJ (NIH), with the target 
protein or phosphorylation target normalized to β-actin.  
mRNA Isolation and qPCR Analysis 
Minced heart tissue from NTG and cMyBP-C110kDa mice was homogenized 
in 1mL of TriZol (BioRad) using a bead homogenizer, and total RNA was isolated 
using the Aurum Total RNA Fatty and Fibrous Tissue Kit (Cat. No. 732-6820, 
Bio-Rad Laboratories) per the manufacturers instructions. Synthesis of cDNA 
from the mRNA samples was performed using the iScript cDNA synthesis kit 
(Cat. No. 170-8891, Bio-Rad Laboratories) with 1µg of mRNA template used in 
each reaction. Templates for qPCR analysis were also generated using no 
reverse transcriptase, which were used as negative controls. Gene expression 
levels were analyzed using TaqMan primers recognizing MYBPC3 with FAM dye 
(Cat. No. Mm.PT.53a.42655843.g, Integrated DNA Technologies, Inc.), MYH7-
FAM (Cat. No. Mm.PT.53a.17465550.g, Integrated DNA Technologies, Inc.), 
NPPA-FAM (Cat. No. Mm.PT.56a.10008284.g, Integrated DNA Technologies, 
Inc.), and GAPDH-VIC Dye, (Cat. No. 4352339E, Thermo Fisher Scientific Inc.) 
with iTaq Universal Probes Supermix (Cat. 172-5131, Bio-Rad Laboratories) and 
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analyzed using a CFX96 Touch Real-Time PCR Detection System (Cat. No. 
1855196, Bio-Rad Laboratories). The cycle protocol was 94°C for 10 minutes, 
followed by 40 cycles at 94°C for 15 seconds and 60°C for 60 seconds. Analysis 
of qPCR data was performed using the ΔΔCq method, normalized to the 
geometric mean of GAPDH values and corrected for primer efficiency as 
described previously (Pfaffl, 2001) 
RNA-Seq 
Total RNA was isolated from four hearts from NTG and three hearts from 
cMyBP-C110kDa mice using the same isolation method as described for qPCR 
analysis above. The four samples from the NTG hearts and the three samples for 
the cMyBP-C110kDa hearts were pooled by genotype prior to sequencing. These 
samples were then used for RNA-sequencing at the Loyola Genomics Facility 
under the direction of Michael Zilliox and Gina Kuffel at Loyola University 
Chicago. The quality of the total RNA was confirmed with the use of an Agilent 
2100 Bioanalzyer. Using the TruSeq® Stranded mRNA Library Prep kit (Cat. No. 
RS-122-2201, Illumina, Inc.), the mRNA in the total RNA was converted into a 
library of template molecules of known strand origin. Specifically, the mRNA was 
isolated using poly-T oligos attached to magnetic beads. The resulting mRNA 
was fragmented and reverse transcribed. The product cDNA was amplified and 
sequencing adapters and barcodes were ligated onto the fragments for each 
respective sample to create cDNA libraries ready for sequencing. The samples 
were sequenced on the Illumina HiSeq platform rendering 100 bp paired-end 
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reads. The reads for each sample were aligned to University of California, Santa 
Cruz’s hg19 build of the human genome using STAR aligner. Aligned reads were 
counted and assigned to genes assuming a negative binomial distribution and 
DESeq2 was used to perform differential expression.  
Mouse Papillary Muscle Extraction 
To perform mechanical measurements of muscle function in NTG and 
cMyBP-C110kDa hearts at 3-months of age, whole hearts were rapidly excised and 
underwent retrograde perfusion with 1X Krebs-Henseleit Buffer (68.91 g NaCl, 
3.727 g KCl, 12  ml of 1 M MgCl2, 2.04 g NaH2PO4 diluted in 1 L for 10X and then 
diluted to 1X in 500 ml followed by the addition of 1 g D-glucose, 0.84 g 
NaHCO3, and 0.76 g BDM) via the aorta. The heart was cut to carefully expose 
the papillary muscles in the LV (Figure 14). Papillary muscles were excised 
under a dissecting scope (Zeiss Discover.V8 Stereo, PlanAPO S 0.63x FWD 81 
mm) and permeabilized overnight in 1% Triton X-100 pre-diluted to 10% in 
mounting relaxing solution (6.3 mM ATP, 6.48 mM MgCl2, 10mM EGTA, 10 mM 
Na2CrP, 49.76 mM Kprop, 100 mM BES, pH 7.0) at 4°C to remove the cell 
membrane and membrane-bound proteins. The papillary muscles were then 
further trimmed into fiber bundles of approximately 1 mm in length under the 
dissecting microscope. Straight fiber bundles were selected based upon 
uniformity and attached at each end with aluminum t-clips. NTG and cMyBP-
C110kDa papillary muscle and whole heart images were taken under the dissecting 
scope using an attached digital camera (Canon EOS Rebel T3i). Each fiber  
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Figure 14. Mouse Papillary Muscle Extraction. Representative image of a 
mouse heart cut open through the LV to expose the papillary muscles (indicated 
by white arrows). Papillary muscles were extracted from NTG and cMyBP-C110kDa 
hearts and were then permeabilized, trimmed, and used to perform mechanical 
measurements of muscle function using the Force-ATPase assay. 
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bundle was gently cleansed by washing with fresh relaxing solution on ice and 
was used within 12 hours. The t-clipped fibers were attached to a force 
transducer (BAM21-LC; World Precision Instruments) and a high-speed length 
controller (Aurora Scientific, Inc.). Muscle dimensions (cross-sectional area, 
length, and volume) were determined using an ocular micrometer mounted in the 
dissection microscope (resolution, ~10 µm). These muscle dimensions were 
used to normalize contractile force, sarcomere length, and ATPase activity. 
Sarcomere length was measured in a passive relaxed condition by laser 
diffraction as previously described (de Tombe & ter Keurs, 1990), adjusted to and 
maintained at 2 µm. Briefly, a helium-neon laser beam was directed through the 
isolated muscle fiber bundle, in which the muscle striation pattern splits the laser 
beam into a diffraction pattern (Figure 15). The striations of the muscle fiber 
bundle acted as a grating, with known angles of diffraction, and the projected 
pattern was then used to measure average sarcomere length.  
Force-ATPase Assay 
Following their preparation, the permeabilized T-clipped papillary muscle 
fibers from NTG and cMyBP-C110kDa hearts were used on a force-ATPase assay 
to determine maximal force production, Ca2+ sensitivity of force development, 
tension cost, ktr, and cross-bridge stiffness. The permeabilized fibers were 
incubated for 3 minutes in relaxing solution followed by 3 minutes in preactivating 
solution before measuring force in activating solution (Witayavanitkul et al., 
2014). Activating solution contained 20 mM Ca2+-EGTA, 1.55 mM potassium  
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Figure 15. Setting Sarcomere Length by Laser Diffraction. Sarcomere length 
was measured in a passive relaxed condition by laser diffraction using a helium-
neon laser beam directed through the isolated muscle fiber bundle. The muscle 
striation pattern splits the laser beam into a diffraction pattern and this was used 
to set and maintain the sarcomere length at 2 µm depicted by laser light 
intensities at 2.0 in the figure.  
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propionate, 6.59 mM MgCl2, 100 mM N,N-bis (2-hydroxyethyl) taurine; N,N-Bis-
(2-hydroxyethyl)-2-aminoethanesulfonic acid, 5 mM sodium azide, 1 mM DTT, 10 
mM phosphoenolpyruvate, 0.01 mM oligomycin, 0.1 mM PMSF, and 0.02 mM 
A2P5, and a commercial protease inhibitor cocktail (Sigma). Relaxing solution 
was the same as activating solution, but contained 20 mM EGTA, 21.2 mM 
potassium propionate, 7.11 mM MgCl2, and no calcium. Preactivating solution 
was the same as the activating solution, but contained 0.5 mM EGTA, 19.5 mM 
1,6-diaminohexane-N,N,N,N’-tetraacetic acid, 21.8 mM potassium propionate, 
and no calcium. All solutions contained 0.5 mg/ml pyruvate kinase and 0.05 
mg/ml lactate dehydrogenase (Sigma) and had an ionic strength of 180 mM, 5 
mM free ATP, and 1 mM free magnesium. Isometric tension and ATPase activity 
were measured at various levels of Ca2+ activation as previously described (de 
Tombe & Stienen, 1995; Rundell, Manaves, Martin, & de Tombe, 2005). Briefly, 
the isolated muscle was exposed to a range of calcium solutions obtained by 
proportional mixing of activating and relaxing solutions (described below). The 
force generated and ATP consumed during muscle contraction were measured 
simultaneously. Force-pCa relationships were determined by titrating the 
activation and relaxing solutions (Witayavanitkul et al., 2014). Maximal isometric 
tension was measured at 100% activation solution, followed by sequential 
washes in relaxing and preactivating solutions for 3 minutes each. Subsequent 
measurements of isometric tension occurred in solutions titrated with decreasing 
ratios of activation-to-relaxation solutions: 100%, 95%, 90%, 85%, 80%, 75%, 
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70%, 60% and 0% activation solution, which corresponded to pCa values of 
approximately 4.50, 5.11, 5.38, 5.58, 5.74, 5.96, 6.07, 6.25, and 10.00, 
respectively, as determined by the Fabiato program (van der Velden, Moorman, 
& Stienen, 1998). The integrity of the fibers was tested afterwards by measuring 
maximal tension after the experiment (100% activation). Any fibers that did not 
maintain 80% or greater maximal tension were excluded from analysis. Force-
ATPase relationship was determined using an optical absorbance enzyme assay 
(Guth & Wojciechowski, 1986). Briefly, ATP consumption was determined by 
measuring the absorbance of UV light at a wavelength of 340 nm. ATP 
hydrolyses into ADP and inorganic phosphate inside the fiber, which is 
stoichiometrically coupled to the oxidation of NADH to NAD+. This oxidization 
reaction is catalyzed by pyruvate kinase and lactate dehydrogenase in the 
activating solutions. NADH, but not NAD+, absorbs light specifically at 340 nm. A 
series of 50 nanoliters (nl) of 10 mM ADP were injected into the activating 
chamber. Each injection of ADP induced a rapid reduction in fluorescence and 
allowed the calculation of the rate of ATP consumption, determined by measuring 
the fluorescent decay rate at 340 nm. After completion of the Force-ATPase 
assay, papillary muscles underwent a rapid release-restretch maneuver in order 
to break previously formed cross-bridges and allow cross-bridges to reform. The 
ktr was then measured at maximal activation, as previously described (Rundell et 
al., 2005; Swartz & Moss, 1992). Force-pCa and Force-ATPase relationships 
were fitted with a modified Hill equation (Chandra et al., 2001; Rundell et al., 
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2005; Sumandea, Pyle, Kobayashi, de Tombe, & Solaro, 2003). Stiffness and 
tension costs were fit linearly to the force-stiffness and force-ATPase data, 
respectively. Stiffness is a measure of attached cross-bridges and is proportional 
to tension. Stiffness is measured by applying rapid, oscillating length changes 
and recording the change in force (Δforce/Δlength) (Ford, Huxley, & Simmons, 
1977). 
Statistical Analysis  
All data are represented as the mean ± standard error of the mean (SEM). 
Statistical analysis was performed using Graph Pad Prism (version 6.0). Data 
were analyzed using a one-way ANOVA with a Tukey’s post-hoc test or a 
Student’s t-test where appropriate. Statistical significance was defined as P < 
0.05.  
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CHAPTER FIVE 
 
RESULTS  
 
cMyBP-C110kDa Transgenic Mouse Line Characterization 
To determine whether cMyBP-C110kDa mice expressed the cMyBP-C110kDa 
TG protein missing the N’-C0-C1f region of cMyBP-C compared to NTG animals, 
which should not express the cMyBP-C110kDa TG protein, I performed Western 
blot analysis using antibodies against the N’ and C’ regions of cMyBP-C. Using 
the previously reported cMyBP-CC2-14 antibody that binds the C0 domain of 
cMyBP-C (Copeland et al., 2010), endogenous FL cMyBP-C protein expression 
was detected in myofilament fractions from NTG and cMyBP-C110kDa hearts 
(Figure 16A). Endogenous FL cMyBP-C expression was significantly reduced (p 
< 0.001) in myofilament fractions from cMyBP-C110kDa compared to NTG animals 
(Figure 16C). The cMyBP-C110kDa mice were expected to have marginal 
expression of endogenous FL cMyBP-C as these animals were developed on a 
NTG background and would likely still express some of the endogenous FL 
protein. Importantly, the cMyBP-CC2-14 N’ antibody did not detect the cMyBP-
C110kDa TG protein as this protein does not contain the C0 domain to which this 
antibody binds. The minimal expression levels of endogenous FL cMyBP-C in 
cMyBP-C110kDa myofilament fractions indicated that the cMyBP-C110kDa TG protein  
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Figure 16. cMyBP-C110kDa Transgenic Mouse Line Characterization. (A) 
Western blot analysis using cardiac myofilament fractions from NTG and cMyBP-
C110kDa mice stained with N’, C’, and c-Myc antibodies to detect endogenous FL 
cMyBP-C and the cMyBP-C110kDa TG protein (n = 3 hearts per group). (B) 
Quantification of sarcomeric percent replacement of endogenous FL cMyBP-C 
with the cMyBP-C110kDa TG protein in cMyBP-C110kDa hearts quantified from 
Western blot data presented in A. (C) Densitometry quantifications of 
endogenous FL cMyBP-C from NTG and cMyBP-C110kDa myofilament fractions 
measured from Western blot data presented in A. (D) qPCR quantifications of 
MYBPC3 gene expression normalized to GAPDH in whole hearts from NTG and 
cMyBP-C110kDa mice (n = 4 hearts per group). ***p < 0.001.  
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was located within, and may replace, the endogenous FL protein in cMyBP-
C110kDa sarcomeres. Western blot analysis using a C’ antibody against cMyBP-
C’s C10 domain detected the cMyBP-C110kDa TG protein within myofilament 
fractions from cMyBP-C110kDa hearts but not NTG hearts (Figure 16A). The 
expression of the cMyBP-C110kDa TG protein was detected at 110 kDa and was 
significantly elevated (p < 0.001) compared to the expression of FL cMyBP-C in 
cMyBP-C110kDa myofilament fractions (Figure 16C). As expected, the cMyBP-
C110kDa TG protein was not detected in NTG myofilament fractions (Figure 16A). 
Importantly, cMyBP-C110kDa TG protein expression was significantly increased 
compared to endogenous FL cMyBP-C expression (81 ± 2.2% cMyBP-C110kDa TG 
protein vs 19 ± 2.2% FL cMyBP-C; p < 0.0001) in cMyBP-C110kDa myofilament 
fractions (Figure 16B). The cMyBP-C110kDa TG protein is c-Myc-tagged at its N’ 
region. Therefore, using an anti-c-Myc antibody, the cMyBP-C110kDa TG protein 
was exclusively detected within cMyBP-C110kDa myofilament fractions and not in 
those from NTG hearts (Figure 16A). The endogenous FL cMyBP-C protein is 
not c-Myc-tagged. Accordingly, the endogenous FL cMyBP-C protein was not 
detected by the anti-c-Myc antibody in myofilament fractions from cMyBP-
C110kDa and NTG hearts (Figure 16A). As the cMyBP-C110kDa mouse is a TG 
animal, expectedly, the levels of total cardiac MYBPC3 gene expression 
(quantified from FL MYBPC3 mRNA expression in NTG hearts and FL MYBPC3 
plus cMyBP-C110kDa-MYBPC3 mRNA expression in cMyBP-C110kDa hearts) were 
significantly augmented (p < 0.001) in cMyBP-C110kDa hearts compared to NTG 
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hearts (Figure 16D). Together, these data demonstrate that the cMyBP-C110kDa 
TG protein is expressed only within cMyBP-C110kDa hearts and replaces 
endogenous FL cMyBP-C within the cardiac sarcomere, verifying the mouse 
model. 
cMyBP-C110kDa Mice Display Reduced Cardiac Function 
After confirming that the cMyBP-C110kDa TG protein is expressed only 
within cMyBP-C110kDa hearts, I next performed short-axis M-mode 
echocardiography on NTG and cMyBP-C110kDa mice to evaluate cardiac function 
in these animals at 3- and 6-months of age (Figure 17). No significant difference 
in IVSd (Figure 17A), IVSs (Figure 17B), LVIDd (Figure 17C), LVPWd (Figure 
17E), LVPWs (Figure 17F), or LV volume at end diastole (Figure 17I) was 
observed between NTG and cMyBP-C110kDa hearts at either 3- or 6-months of 
age. However, LVIDs (Figure 17D) and LV chamber volume at end systole 
(Figure 17J) were significantly increased (p < 0.05) in cMyBP-C110kDa compared 
to NTG hearts at 6-months of age. Crucially, there was a significant decrease (p 
< 0.05) in LV percent EF (Figure 17G) and percent FS (Figure 17H) in cMyBP-
C110kDa hearts compared to NTG hearts at 3-months of age. Percent EF (Figure 
17G) and percent FS (Figure 17H) were even further reduced (p < 0.0001) in 
cMyBP-C110kDa hearts compared to NTG hearts by 6-months of age. 
Furthermore, percent EF and percent FS were significantly reduced (p < 0.05) in 
cMyBP-C110kDa hearts at 6-months of age compared to cMyBP-C110kDa hearts at 
3-months of age, indicating disease progression. Summarized short-axis M-mode  
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Figure 17. cMyBP-C110kDa Mice Display Reduced Cardiac Function. Short-axis 
M-mode echocardiography data quantified from NTG and cMyBP-C110kDa hearts 
at 3- and 6-months of age depicting (A) IVSd, (B) IVSs, (C) LVIDd, (D) LVIDs, (E) 
LVPWd, (F) LVPWs, (G) percent EF, (H) percent FS, (I) LV chamber volume 
during diastole, (J) LV chamber volume during systole, and (K) percent GLS. n = 
7-10 hearts per group. *p < 0.05, **p < 0.01, ****p < 0.0001.  
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echocardiography quantification values by age and genotype are presented in 
Table 1. Summarized short-axis M-mode echocardiography quantification values 
by age, genotype, and gender are presented in Table 2. Finally, percent GLS 
was significantly reduced in cMyBP-C110kDa hearts compared to NTG hearts at 3-
months of age (p < 0.01) (Figure 17K). Together, these data demonstrate that 
cMyBP-C110kDa mice develop cardiac dysfunction that begins near 3-months of 
age and progresses to severity by 6-months of age. 
Cardiac Enlargement in cMyBP-C110kDa Mice  
  
Echocardiography analysis revealed overt cardiac dysfunction and 
increased LV chamber size in cMyBP-C110kDa compared to NTG animals. 
Therefore, I next performed whole heart cardiac imaging by two-photon confocal 
microscopy to evaluate cardiac muscle organization, size, and morphology using 
hearts from cMyBP-C110kDa and NTG animals at 4-months of age. These 
experiments were performed to better understand if and how the heart 
compensates and remodels when the N’-C0-C1f region of cMyBP-C is absent to 
determine whether the N’ region of cMyBP-C is necessary for maintaining normal 
cardiac morphology. Imaging of isolated, perfused whole hearts depicted an 
increase in the size of cMyBP-C110kDa hearts compared to NTG hearts (Figure 
18A). This was further confirmed by 2-D confocal microscopy images of whole 
hearts from NTG and cMyBP-C110kDa animals, which revealed an increase in the 
size of the LV and RV chambers in cMyBP-C110kDa heart sections compared to 
those from NTG animals (Figure 18 B, C). Quantifications of 3-D confocal  
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Table 1. Short-Axis M-Mode Echocardiography Data from NTG and cMyBP-
C110kDa Mice at 3- and 6-Months of Age. 
 
  
NTG cMyBP-C110kDa NTG cMyBP-C110kDa 
IVS;d (mm) 0.81 ± 0.04 0.83 ± 0.03 0.84 ± 0.06 0.78 ± 0.05
IVS;s (mm) 1.19 ± 0.05 1.16 ± 0.04 1.22 ± 0.07 1.10 ± 0.06
LVID;d (mm) 4.16 ± 0.11 4.48 ± 0.20 4.47 ± 0.10 4.82 ± 0.15
LVID;s (mm) 3.15 ± 0.10 3.54 ± 0.18 3.35 ± 0.09 3.94 ± 0.14
LVPW;d (mm) 0.90 ± 0.06 0.80 ± 0.05 0.79 ± 0.05 0.73 ± 0.05
LVPW;s (mm) 1.16 ± 0.09 0.99 ± 0.06 1.11 ± 0.07 0.89 ± 0.05
%EF 48.81 ± 1.35 43.20 ± 1.06 49.60 ± 1.45 37.58 ± 1.61
%FS 24.38 ± 0.79 21.18 ± 0.57 25.04 ± 0.90 18.17 ± 0.88
LV Volume;d (µl) 77.22 ± 4.76 94.07 ± 9.86 91.55 ± 4.69 109.50 ± 8.04
LV Volume;s (µl) 39.75 ± 3.12 53.99 ± 6.38 46.29 ± 3.06 68.55 ± 5.54
%GLS -12.94 ± 0.73 -8.98 ± 0.74 -10.86 ± 0.74 -9.86 ± 0.72
3-Months 6-Months
d = diastole; EF = Ejection Fraction; GLS = Global Longitudinal Strain; FS = Fractional
Shortening; IVS = Interventricular Septum; LVID = Left Ventricular Internal Diameter;
LVPW = Left Ventricular Posterior Wall; s = systole
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Table 2. Short-Axis M-Mode Echocardiography Data from NTG and cMyBP-
C110kDa Mice at 3- and 6-Months of Age Dichotomized by Gender. 
  
NTG Female NTG Male cMyBP-C110kDa Female cMyBP-C110kDa Male NTG Female NTG Male cMyBP-C110kDa Female cMyBP-C110kDa Male
IVS;d (mm) 0.79 ± 0.06 0.86 ± 0.06 0.79 ± 0.06 0.85 ± 0.04 0.81 ± 0.08 0.88 ± 0.04 0.67 ± 0.06 0.85 ± 0.04
IVS;s (mm) 1.16 ± 0.06 1.25 ± 0.07 1.08 ± 0.07 1.21 ± 0.05 1.20 ± 0.10 1.27 ± 0.01 0.97 ± 0.13 1.18 ± 0.04
LVID;d (mm) 3.99 ± 0.09 4.44 ± 0.13 4.24 ± 0.27 4.64 ± 0.29 4.40 ± 0.14 4.62 ± 0.07 4.36 ± 0.08 5.09 ± 0.12
LVID;s (mm) 3.00 ± 0.10 3.39 ± 0.13 3.32 ± 0.21 3.68 ± 0.25 3.29 ± 0.13 3.48 ± 0.05 3.55 ± 0.14 4.18 ± 0.10
LVPW;d (mm) 0.92 ± 0.05 0.89 ± 0.18 0.79 ± 0.05 0.81 ± 0.09 0.76 ± 0.06 0.86 ± 0.12 0.71 ± 0.09 0.74 ± 0.06
LVPW;s (mm) 1.17 ± 0.13 1.14 ± 0.13 1.03 ± 0.08 0.96 ± 0.08 1.05 ± 0.05 1.22 ± 0.20 0.91 ± 0.07 0.88 ± 0.08
%EF 49.58 ± 1.92 47.52 ± 1.82 44.19 ± 1.59 42.55 ± 1.47 50.05 ± 2.22 48.69 ± 0.21 38.78 ± 3.24 36.85 ± 1.94
%FS 24.78 ± 1.15 23.72 ± 1.06 21.66 ± 0.90 20.86 ± 0.77 25.31 ± 1.37 24.50 ± 0.14 18.69 ± 1.77 17.85 ± 1.07
LV Volume;d (µl) 69.75 ± 3.86 89.67 ± 6.16 81.96 ± 11.86 102.14 ± 14.25 88.24 ± 6.62 98.17 ± 3.42 86.08 ± 3.56 123.55 ± 6.74
LV Volume;s (µl) 35.29 ± 2.90 47.19 ± 4.33 45.78 ± 6.63 59.46 ± 9.47 44.25 ± 4.41 50.37 ± 1.70 52.92 ± 4.86 77.93 ± 4.49
%GLS -11.54 ± 0.64 -14.8 ± 0.46 -10.33  ± 1.4 -7.91 ± 0.55 -9.45 ± 0.63 -12.70 ± 1.17 -9.79  ± 1.19 -9.9 ± 1.02
3-Months 6-Months
d = diastole; EF = Ejection Fraction; GLS = Global Longitudinal Strain; FS = Fractional Shortening; IVS = Interventricular Septum; LVID = Left Ventricular Internal Diameter; LVPW = Left
Ventricular Posterior Wall; s = systole
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Figure 18. Cardiac Enlargement in cMyBP-C110kDa Mice. (A) A representative 
whole heart image from NTG and cMyBP-C110kDa mice showing relative heart 
size. (B) 2-D long-axis imaging by confocal microscopy of hearts from NTG and 
cMyBP-C110kDa mice showing wall thickness and chamber size. (C) 2-D long-axis 
imaging by confocal microscopy of hearts from NTG and cMyBP-C110kDa mice 
with RV and LV volumes filled in to represent blood volume. 3-D confocal 
microscopy images of NTG and cMyBP-C110kDa hearts were used to quantify (D) 
total heart volume, (E) LV plus RV chamber volume, and (F) whole heart muscle 
volume. 2-D confocal microscopy images of NTG and cMyBP-C110kDa hearts were 
used to quantify (G) heart height and (H) heart width. Quantifications in D-H are 
from n = 5 hearts per group. (I) Quantification of HW/TL ratio in cMyBP-C110kDa 
and NTG mice (n = 4 hearts per group). Scale bar = 1 mm in B and C. *p < 0.05, 
**p < 0.01, ***p < 0.001. 
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microscopy images demonstrated a significant increase (p < 0.05) in total heart 
volume (Figure 18D), LV plus RV chamber volume (Figure 18E), and whole 
heart muscle volume (Figure 18F) in hearts from cMyBP-C110kDa compared to 
NTG animals. Additionally, quantifications of 2-D confocal microscopy images 
demonstrated a significant elevation in both the height (p < 0.01) (Figure 18G) 
and width (p < 0.001) (Figure 18H) of hearts from cMyBP-C110kDa compared to 
NTG animals. cMyBP-C110kDa mice also had a significant elevation in the ratio of 
heart weight (HW) to tibia length (TL) compared to NTG mice (Figure 18I). 
Together, these data indicate that the N’-C0-C1f region of cMyBP-C is necessary 
for maintaining normal global cardiac morphology as the absence of this region 
leads to pathological remodeling in cMyBP-C110kDa hearts. 
Cardiac Hypertrophy Markers are Elevated in cMyBP-C110kDa Mice 
Whole isolated heart and confocal microscopy imaging revealed cardiac 
hypertrophy in cMyBP-C110kDa mice. Therefore, I next determined whether 
pathological hypertrophy markers were increased in the hearts of cMyBP-C110kDa 
mice compared to hearts from NTG mice at 7-8 months of age. Indeed, qPCR 
analysis showed a significant increase in mRNA expression levels of the 
hypertrophy markers MYH7 (Figure 19A) and NPPA (Figure 19B) in cMyBP-
C110kDa compared to NTG hearts, verifying myocardial hypertrophy in cMyBP- 
C110kDa hearts at the molecular level. This was further confirmed by RNA-
sequencing of mRNA isolated from cMyBP-C110kDa and NTG hearts (Figure 
19C). As expected, MYBPC3 gene expression levels were found to be  
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Figure 19. Cardiac Hypertrophy Markers are Elevated in cMyBP-C110kDa 
Hearts. qPCR quantifications of (A) MYH7 and (B) NPPA gene expression levels 
normalized to GAPDH in whole hearts from NTG and cMyBP-C110kDa mice (n = 4 
hearts per group). Heat map depicting the top 50 upregulated and bottom 29 
downregulated genes in cMyBP-C110kDa hearts compared to NTG hearts as 
determined by RNA-sequencing (n = 4 NTG hearts, 3 cMyBP-C110kDa hearts, 
mRNA samples were pooled within each group). Upregulated sarcomeric protein 
genes are listed to the left of the heat map. *p < 0.05. 
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upregulated by RNA-sequencing, confirming our qPCR data (Figure 16D). 
Surprisingly, RNA-sequencing further revealed a significant upregulation in 
several sarcomeric proteins including many skeletal isoforms of these proteins 
(Figure 19C). Importantly, gene expression levels MYBPC2, which encodes the 
fast-skeletal isoform of MyBP-C, were found to be upregulated in cMyBP-C110kDa 
hearts compared to NTG hearts (Figure 19C). The expression of fast-skeletal 
MyBP-C has been previously detected in cMyBP-C null hearts undergoing 
dilation (Lin et al., 2013). Total global gene expression changes of the top 
upregulated and bottom downregulated genes in cMyBP-C110kDa compared to 
NTG hearts are presented in Table 3 and Table 4, respectively. Together, these 
data further support that the N’-C0-C1f region of cMyBP-C is necessary for 
regulating cardiac contraction as its absence leads to overt cardiac hypertrophy 
at the level of the cardiomyocyte that translates into global cardiac remodeling. 
Fibrosis and Sarcomere Area are Increased in cMyBP-C110kDa Hearts 
I next sought to investigate whether the cardiac remodeling observed in 
cMyBP-C110kDa hearts was accompanied by myocardial fibrosis and altered 
myocyte sarcomere area. H&E and MT staining of myocardial sections from NTG 
and cMyBP-C110kDa hearts (Figure 20A) revealed no significant difference in 
percent nuclear area (Figure 20B) quantified from H&E labeled sections 
between these groups. However, a highly significant (p < 0.0001) elevation in 
percent fibrosis (Figure 20C) quantified from MT labeled sections was observed 
in cMyBP-C110kDa hearts compared to NTG hearts. This was largely localized 
119 
 
 
 
 
Table 3. Top Upregulated Genes in cMyBP-C110kDa Compared to NTG Hearts 
by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Ucp1 6 1194 199.00
Spag11b 1 128 128.00
Lgals12 1 85 85.00
Acsm3 1 70 70.00
Adrb3 3 139 46.33
Tmem45b 6 210 35.00
Pck1 27 942 34.89
Otop1 2 66 33.00
Adipoq 18 497 27.61
Acvr1c 2 53 26.50
Plin1 18 382 21.22
Cidec 26 523 20.12
Car3 179 3282 18.34
Ptger3 4 70 17.50
Lep 10 118 11.80
Pon1 4 46 11.50
Nfasc 10 108 10.80
Cfd 103 1082 10.50
AW551984 6 59 9.83
Scd1 1262 12237 9.70
Apoc1 11 104 9.45
Hamp 35 317 9.06
Vgll2 15 131 8.73
Alox8 10 86 8.60
Hapln1 5 43 8.60
Aspg 10 79 7.90
Uts2d 6 44 7.33
Gucy2g 5 36 7.20
Vsnl1 7 50 7.14
Cyp2e1 64 449 7.02
Fcamr 5 35 7.00
Retn 13 89 6.85
Ces1f 5 34 6.80
Coch 9 61 6.78
Aldh1a7 9 59 6.56
Cilp2 230 1478 6.43
Gata5 17 108 6.35
Gcgr 18 113 6.28
Hcn1 67 417 6.22
Sphkap 31 191 6.16
Hp 115 699 6.08
Tmem79 12 72 6.00
Rab33a 6 36 6.00
Clstn3 20 118 5.90
Fras1 71 416 5.86
Slc9a3 14 82 5.86
Prss35 7 41 5.86
Rpph1 6 35 5.83
Npnt 31 178 5.74
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Mlana 49 277 5.65
Tmem163 212 1182 5.58
Cd207 29 160 5.52
Elovl6 75 413 5.51
Rbp4 18 99 5.50
4833424O15Rik 19 103 5.42
Cdh3 12 65 5.42
Cdo1 156 823 5.28
Mpz 16 84 5.25
Myl7 8057 41920 5.20
Igj 24 123 5.13
Lingo1 52 260 5.00
Gpr81 11 55 5.00
Hydin 11 55 5.00
Prr15l 9 45 5.00
Acaa1b 8 40 5.00
Mybphl 1337 6621 4.95
Stmnd1 7 34 4.86
Rxfp1 36 174 4.83
Prkar2b 107 512 4.79
Dmkn 9 43 4.78
Lrp8 39 186 4.77
Dkk3 1772 8355 4.72
Nsg2 7 33 4.71
Apol9b 7 33 4.71
Fgf12 356 1656 4.65
Myl4 9363 43345 4.63
Vwc2 12 55 4.58
Casq1 446 2040 4.57
Miat 9 41 4.56
Nwd1 9 41 4.56
Capn6 15 68 4.53
Cpne5 95 428 4.51
Lypd1 12 54 4.50
Sln 2373 10632 4.48
Lman1l 23 103 4.48
Myh7 15849 70398 4.44
Ntrk3 49 217 4.43
Dfna5 12 53 4.42
Tbx15 23 101 4.39
Ipcef1 8 35 4.38
Sh2d5 8 35 4.38
Unc5c 15 65 4.33
Frmpd1 19 82 4.32
Ifltd1 152 655 4.31
Adamts19 46 198 4.30
1700055N04Rik 17 73 4.29
Plekha7 313 1341 4.28
E030013I19Rik 13 55 4.23
Arxes2 18 76 4.22
Cacna2d2 278 1157 4.16
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Slc7a7 225 931 4.14
Pnpla3 106 438 4.13
Fasn 2008 8291 4.13
Trim10 16 66 4.13
Mybpc3 269005 1108179 4.12
Glb1l2 19 78 4.11
Camk1g 25 102 4.08
Acp5 38 152 4.00
Tnni1 19 76 4.00
Shank2 12 48 4.00
Tmem132e 11 44 4.00
Wnt2b 10 40 4.00
Paqr6 17 67 3.94
Itih2 23 90 3.91
Dkk2 9 35 3.89
Nppa 37866 146881 3.88
Igfbpl1 36 139 3.86
Slc6a7 20 77 3.85
Nnat 30 115 3.83
Sytl1 12 46 3.83
Apol6 34 130 3.82
Gm1078 1876 7087 3.78
Mdfi 52 196 3.77
Sytl2 137 516 3.77
1500015O10Rik 25 94 3.76
Stk32b 52 195 3.75
Ccl3 12 45 3.75
Pitx2 22 82 3.73
Necab3 11 41 3.73
Tub 13 48 3.69
Itih4 101 372 3.68
Gypa 31 113 3.65
Acta1 12784 46462 3.63
Gpr158 16 58 3.63
Sost 45 163 3.62
Lpar3 13 47 3.62
2900041M22Rik 10 36 3.60
Dlgap1 27 97 3.59
Klf8 17 61 3.59
E2f2 47 168 3.57
Flrt1 28 100 3.57
Psd 14 50 3.57
2610307P16Rik 18 64 3.56
Krt8 24 85 3.54
Vdr 61 216 3.54
Cib2 41 145 3.54
Arnt2 19 67 3.53
Cacna2d3 58 203 3.50
Fam180a 12 42 3.50
Ikzf3 15 52 3.47
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Cacna1h 1487 5145 3.46
Dock3 31 107 3.45
Apol11b 64 218 3.41
Ppp1r1b 204 694 3.40
Vat1l 10 34 3.40
Cacna1d 123 417 3.39
Car5b 40 135 3.38
Gm11627 22 74 3.36
Cnn1 169 565 3.34
Nrtn 140 465 3.32
Sypl2 68 225 3.31
Diras2 13 43 3.31
Adamts8 63 208 3.30
Epyc 24 79 3.29
Proca1 24 79 3.29
Nox4 60 195 3.25
Camk1d 299 958 3.20
Clic6 18 57 3.17
Ntrk2 55 174 3.16
Bmp3 32 101 3.16
Piezo2 41 129 3.15
Krt7 35 110 3.14
Tro 75 235 3.13
Wnt2 16 50 3.13
Fcho1 33 103 3.12
Slc4a1 111 345 3.11
Trim46 38 118 3.11
Greb1 31 96 3.10
Peg12 13 40 3.08
Fbln7 40 123 3.08
Lck 15 46 3.07
Cyp26b1 417 1273 3.05
Dok5 20 61 3.05
Ifitm10 21 64 3.05
Prdm6 19 57 3.00
Ngef 14 42 3.00
Gpr75 13 39 3.00
Gpr21 13 39 3.00
Syn1 13 39 3.00
Bmp10 756 2262 2.99
Rgs1 51 152 2.98
Neb 281 835 2.97
Edn3 317 940 2.97
Bnc1 24 71 2.96
A2m 37 109 2.95
Clec11a 45 132 2.93
Wisp1 100 293 2.93
Inhba 14 41 2.93
Drp2 27 79 2.93
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Ptgs2 311 909 2.92
Stra6 12 35 2.92
Xylb 12 35 2.92
Scml2 31 90 2.90
Col4a6 156 450 2.88
Faim2 17 49 2.88
Gja5 704 2029 2.88
Pou2f2 24 69 2.88
Adcy1 341 979 2.87
Aif1l 124 356 2.87
Xlr4a 15 43 2.87
Epha1 14 40 2.86
Srcin1 20 57 2.85
Slc4a11 12 34 2.83
Bex4 12 34 2.83
Gpr162 58 164 2.83
Bend6 40 113 2.83
Xpnpep2 40 113 2.83
Nr5a2 34 96 2.82
Nkain2 16 45 2.81
1600029D21Rik 16 45 2.81
Comp 335 940 2.81
Olfm1 462 1295 2.80
Srgap3 66 185 2.80
Kcnn4 14 39 2.79
Fam167a 18 50 2.78
Cdcp1 18 50 2.78
Adam33 133 369 2.77
Selp 31 86 2.77
Dio2 75 208 2.77
Upk1b 77 213 2.77
Zfp579 466 1286 2.76
Adig 48 132 2.75
Prrt1 28 77 2.75
Sfrp5 245 670 2.73
Col14a1 822 2245 2.73
Hs6st2 26 71 2.73
Scara3 146 398 2.73
Lrrn4 98 267 2.72
Ebi3 21 57 2.71
Pou2af1 21 57 2.71
Kcnq5 14 38 2.71
Irs3 14 38 2.71
Ephb2 31 84 2.71
Duox2 17 46 2.71
Mpzl2 27 73 2.70
Gli1 93 251 2.70
Nlrp5-ps 23 62 2.70
Flywch2 13 35 2.69
Mfap4 535 1440 2.69
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Fgfr2 42 113 2.69
Rbm47 32 86 2.69
Map3k9 16 43 2.69
St8sia1 16 43 2.69
Panx2 74 198 2.68
Ptprv 24 64 2.67
Prss12 15 40 2.67
Stk32a 44 117 2.66
Stard10 2321 6152 2.65
Gpr39 17 45 2.65
Rnf43 18 47 2.61
Podn 1425 3719 2.61
Tnnt3 28 73 2.61
Rab3b 91 236 2.59
Cybrd1 63 163 2.59
4833418N02Rik 24 62 2.58
Galnt12 24 62 2.58
Enkur 35 90 2.57
1190002F15Rik 14 36 2.57
Vstm5 14 36 2.57
Mmp3 262 673 2.57
Nkain4 67 172 2.57
Pycr1 30 77 2.57
Ap1s3 27 69 2.56
Nov 253 646 2.55
Gpr114 20 51 2.55
Spsb4 285 726 2.55
Cit 44 112 2.55
Slc1a7 35 89 2.54
Clec4a2 50 127 2.54
Shisa2 63 160 2.54
H1fx 26 66 2.54
Acsbg1 26 66 2.54
9330179D12Rik 34 86 2.53
Tpm2 2002 5061 2.53
3-Sep 57 144 2.53
Rpp25 84 212 2.52
Edil3 24 60 2.50
Esr1 14 35 2.50
Atp6v0a4 14 35 2.50
Xist 4181 10414 2.49
Gas2l3 99 246 2.48
Slc38a1 458 1136 2.48
Chad 25 62 2.48
Mum1l1 90 223 2.48
Kif1a 132 327 2.48
Brsk1 105 260 2.48
1700034H15Rik 19 47 2.47
Ms4a1 19 47 2.47
6330403K07Rik 17 42 2.47
125 
 
 
 
 
Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Gbp8 30 74 2.47
Slc1a3 102 251 2.46
Timp1 85 209 2.46
Nlrc3 66 162 2.45
Krt18 58 142 2.45
Mthfd2 112 274 2.45
A830082K12Rik 27 66 2.44
Snora81 18 44 2.44
Rspo1 77 188 2.44
Col8a2 39 95 2.44
Gpx3 14720 35760 2.43
Upk3b 368 894 2.43
Rgs11 28 68 2.43
Lat 21 51 2.43
Snord47 14 34 2.43
Fcrla 14 34 2.43
Dlg2 82 199 2.43
Slc24a2 144 349 2.42
Myl1 1861 4504 2.42
Lrrc55 55 133 2.42
Snca 331 800 2.42
Efhd1 224 541 2.42
Gng2 429 1035 2.41
Scand1 267 644 2.41
Itga8 370 892 2.41
C530008M17Rik 191 460 2.41
Ikbke 89 214 2.40
Neto2 92 221 2.40
Olfml2a 100 240 2.40
Atp2a1 70 168 2.40
Slc26a3 35 84 2.40
Crb2 25 60 2.40
Esco2 20 48 2.40
Gpr173 20 48 2.40
Enpp6 93 223 2.40
Met 66 158 2.39
Vsig4 85 203 2.39
Plac8 31 74 2.39
Heatr8 39 93 2.38
Cilp 439 1043 2.38
Rasl11a 48 114 2.38
Cep72 32 76 2.38
Csrp2 611 1450 2.37
Fmod 278 659 2.37
Gjc3 30 71 2.37
Gm12409 22 52 2.36
Spp1 22 52 2.36
Nipal2 58 137 2.36
Sox9 75 177 2.36
Atp10a 129 304 2.36
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Ube2c 62 146 2.35
Actn3 17 40 2.35
Stx1b 17 40 2.35
Kcnd1 17 40 2.35
Actg2 54 127 2.35
Kcnj10 20 47 2.35
Slc12a8 29 68 2.34
Tmem158 35 82 2.34
Megf6 291 679 2.33
Rasal3 42 98 2.33
Fkbp1b 30 70 2.33
Mfap2 94 219 2.33
Fam46c 101 235 2.33
AI854703 40 93 2.33
Armcx4 535 1242 2.32
Rn45s 126192 292902 2.32
Col12a1 69 160 2.32
Cdkn2b 19 44 2.32
Loxl4 51 118 2.31
Lamc3 48 111 2.31
Sema3d 159 367 2.31
Ier2 3085 7115 2.31
Cx3cr1 151 348 2.30
2210404O09Rik 23 53 2.30
Gprasp2 143 329 2.30
Alas2 2830 6501 2.30
Ifi27l2a 492 1129 2.29
Omd 34 78 2.29
Fgl2 2255 5173 2.29
Pirt 378 866 2.29
Kmo 21 48 2.29
Fdx1l 46 105 2.28
Rps6ka6 50 114 2.28
Pcdhgc4 25 57 2.28
Mlph 43 98 2.28
Akap5 176 401 2.28
Stard6 18 41 2.28
Lif 40 91 2.28
Pam 44909 101993 2.27
Tspan8 15 34 2.27
Dhh 34 77 2.26
Cd46 23 52 2.26
Ltbp2 211 477 2.26
Aass 35 79 2.26
Lefty1 43 97 2.26
Lgals3 291 656 2.25
Susd5 100 225 2.25
Fhdc1 20 45 2.25
Lrrn3 16 36 2.25
Klra2 16 36 2.25
127 
 
 
 
 
Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Cdk1 57 128 2.25
Unc5a 140 314 2.24
Gnal 25 56 2.24
A230056P14Rik 25 56 2.24
Sox5 96 215 2.24
Slc27a3 59 132 2.24
Mt3 52 116 2.23
Gnao1 1371 3057 2.23
Junb 4148 9249 2.23
C2 120 267 2.23
Pvt1 40 89 2.23
5033406O09Rik 18 40 2.22
Beta-s 38840 86291 2.22
Slc25a1 361 801 2.22
Caskin1 23 51 2.22
Fam60a 56 124 2.21
Cd79a 42 93 2.21
Megf10 47 104 2.21
Mir208a 38 84 2.21
Cpz 24 53 2.21
Lrrn2 352 777 2.21
Prnd 347 765 2.20
1810041L15Rik 35 77 2.20
Adamts20 20 44 2.20
Tmem30b 15 33 2.20
Prph 15 33 2.20
Cebpa 262 576 2.20
Chst4 56 123 2.20
Fzd2 159 349 2.19
Bex1 52 114 2.19
Msantd1 26 57 2.19
Itgb7 79 173 2.19
Sertad4 301 659 2.19
1700084E18Rik 16 35 2.19
Tcf7 43 94 2.19
Jsrp1 27 59 2.19
Prox2 38 83 2.18
Ccl8 60 131 2.18
Gm20605 82 179 2.18
ORF63 88 192 2.18
Tbc1d1 1384 3019 2.18
Sbk2 481 1049 2.18
Mybpc2 1040 2267 2.18
4933436C20Rik 167 364 2.18
Grhl1 28 61 2.18
1700109H08Rik 28 61 2.18
Zbtb7c 135 294 2.18
Ms4a4b 17 37 2.18
Iglon5 17 37 2.18
2410076I21Rik 17 37 2.18
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Shisa4 182 396 2.18
Hoxb3 23 50 2.17
Fam198a 58 126 2.17
Emb 94 204 2.17
Mbp 272 590 2.17
Scml4 95 206 2.17
Camkk1 90 195 2.17
B230312C02Rik 18 39 2.17
Fam167b 18 39 2.17
Thrsp 990 2144 2.17
Fam227a 49 106 2.16
Snai1 68 147 2.16
Fam84a 31 67 2.16
Adamts17 25 54 2.16
Itgae 19 41 2.16
AU023871 26 56 2.15
Blk 33 71 2.15
Tusc5 170 365 2.15
Kcnn3 41 88 2.15
Aacs 242 519 2.14
Gpm6a 391 838 2.14
Cep55 21 45 2.14
Ccl12 86 184 2.14
Twist1 58 124 2.14
Gdf10 124 265 2.14
Nat8l 207 442 2.14
Fam83g 30 64 2.13
Chst10 23 49 2.13
B3gnt9 205 436 2.13
Zdhhc15 48 102 2.13
Ccr7 24 51 2.13
Slc13a4 24 51 2.13
Pdzd7 16 34 2.13
Cd24a 236 501 2.12
Cfb 150 318 2.12
Aldh3a1 25 53 2.12
Cxcr6 25 53 2.12
Olfr920 17 36 2.12
Itga11 174 368 2.11
Cpt1c 184 389 2.11
5031414D18Rik 79 167 2.11
Lrp2 36 76 2.11
Tsku 136 287 2.11
Lrfn3 73 154 2.11
Bdh2 28 59 2.11
Osr1 86 181 2.10
Cxcl1 575 1209 2.10
Tbxa2r 89 187 2.10
Slc41a2 91 191 2.10
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
Gene NTG cMyBP-C110kDa FoldChange
Dbp 3262 6845 2.10
Npy1r 187 392 2.10
Olfml1 168 352 2.10
Cdh24 21 44 2.10
Rbp1 537 1125 2.09
Cnbd2 33 69 2.09
Nphp4 68 142 2.09
Casp3 81 169 2.09
Aoah 60 125 2.08
1700056E22Rik 24 50 2.08
Mmp23 371 772 2.08
Cd79b 50 104 2.08
Cyp2s1 89 185 2.08
Myl9 2139 4446 2.08
Lpar2 26 54 2.08
Peg3 288 598 2.08
Lrrc17 171 355 2.08
Baiap3 53 110 2.08
Cd180 40 83 2.08
Morn4 81 168 2.07
Rnf165 27 56 2.07
Arl5c 42 87 2.07
Ccnb1 28 58 2.07
Sec14l5 86 178 2.07
Ube2l6 976 2016 2.07
Foxc1 291 601 2.07
Alx4 31 64 2.06
Map1a 498 1028 2.06
Gabra3 142 293 2.06
G530011O06Rik 64 132 2.06
Gpr35 32 66 2.06
Itih5 595 1227 2.06
Pamr1 178 367 2.06
Efcc1 50 103 2.06
Pygl 310 638 2.06
Sall1 69 142 2.06
Prdm1 180 370 2.06
Fstl3 235 483 2.06
Nap1l5 164 337 2.05
Phgdh 76 156 2.05
Fos 4929 10110 2.05
Kcnj15 60 123 2.05
Plagl1 365 748 2.05
Dct 167 342 2.05
Unc13d 63 129 2.05
Rgs14 42 86 2.05
Xylt1 21 43 2.05
Pcdhb9 22 45 2.05
Tmprss5 22 45 2.05
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Table 3 (Continued). Top Upregulated Genes in cMyBP-C110kDa Compared to 
NTG Hearts by RNA-Sequencing. 
 
 
Gene NTG cMyBP-C110kDa FoldChange
Igf1 732 1496 2.04
Il22ra1 23 47 2.04
Itga10 162 331 2.04
Lss 96 196 2.04
Ptn 98 200 2.04
Dennd2d 49 100 2.04
Hivep3 75 153 2.04
Rab36 52 106 2.04
Tat 27 55 2.04
Cdon 541 1101 2.04
Shisa3 91 185 2.03
Cd44 614 1247 2.03
Cd22 35 71 2.03
Gm1673 36 73 2.03
Pak1 75 152 2.03
Fst 38 77 2.03
Col18a1 799 1619 2.03
Brdt 43 87 2.02
Galnt6 47 95 2.02
Zfp273 64 129 2.02
Sv2a 193 389 2.02
Zfp951 66 133 2.02
Tubb3 68 137 2.01
Slc22a17 276 556 2.01
Ephx3 75 151 2.01
Hist1h2be 78 157 2.01
Mycn 89 179 2.01
Lair1 102 205 2.01
Smim1 313 629 2.01
2610203C20Rik 502 1005 2.00
Grin2c 131 262 2.00
2210404O07Rik 55 110 2.00
Basp1 53 106 2.00
Tvp23a 45 90 2.00
Slc18a2 43 86 2.00
Klhl29 38 76 2.00
Havcr2 35 70 2.00
Treml2 34 68 2.00
Zfp184 32 64 2.00
Twist2 31 62 2.00
Gng4 29 58 2.00
Efcab4b 29 58 2.00
Cyp7b1 26 52 2.00
Rasgef1c 23 46 2.00
Mirg 17 34 2.00
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Table 4. Bottom Downregulated Genes in cMyBP-C110kDa Compared to NTG 
Hearts by RNA-Sequencing. 
 
 
 
 
Gene NTG cMyBP-C110kDa FoldChange
Gm5506 109 10 10.9
Gbp10 392 52 7.538461538
Cyp2b10 159 31 5.129032258
Il1r2 39 10 3.9
Cyp1a1 80 24 3.333333333
Kcnk1 85 26 3.269230769
Ddn 34 11 3.090909091
Capn11 182 59 3.084745763
Cacng6 78 26 3
Prom2 45 15 3
Lrrc52 106 36 2.944444444
Trem1 40 15 2.666666667
Pde11a 46 18 2.555555556
Aldob 1107 434 2.550691244
Eif2s3y 2224 934 2.381156317
Mettl11b 56 24 2.333333333
Mfsd4 382 167 2.28742515
Nat1 36 16 2.25
Acsm5 550 252 2.182539683
Adra1a 814 381 2.13648294
Mcph1 373 178 2.095505618
Cngb3 176 84 2.095238095
Fut2 54 26 2.076923077
Agt 666 323 2.061919505
2410137M14Rik 45 22 2.045454545
Gabrr2 134 66 2.03030303
Gsta1 71 35 2.028571429
Acot3 34 17 2
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Figure 20. Fibrosis and Sarcomere Area are Increased in cMyBP-C110kDa 
Hearts. (A) Representative H&E and MT stained myocardial sections from 
cMyBP-C110kDa and NTG hearts. Quantification of percent (B) nuclear area and 
(C) MT fibrosis obtained from measurements of H&E and MT labeled myocardial 
sections from cMyBP-C110kDa and NTG hearts (n = 3 NTG hearts, 53 sections 
and 5 cMyBP-C110kDa hearts, 74 sections). (D) Representative SHG imaged 
myocardial sections from cMyBP-C110kDa and NTG hearts (left). Images are 
magnified in the right panels. Green channel is backward SHG (BSHG) depicting 
predominantly collagen fibers, red channel is autofluorescence (AF) and blue 
channel is forward directed SHG (FSHG) showing sarcomere pattern and their 
merge. Quantifications of (E) percent FSHG sarcomere area and (F) percent 
SHG fibrosis obtained from SHG imaged myocardial sections from cMyBP-
C110kDa and NTG hearts (n = 3 NTG hearts, 12 sections and 5 cMyBP-C110kDa 
hearts, 19 sections). *p < 0.01, ****p < 0.0001. 
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around the cardiac vasculature and may be due to the observed increase in 
blood vessel size in the hearts of cMyBP-C110kDa animals. However, fibrosis was 
also detected within the interstitial tissue. Next, SHG imaging of myocardial 
sections from cMyBP-C110kDa and NTG hearts was implemented to detect 
sarcomere area with forward directed SHG (FSHG) and collagen deposition with 
backward directed SHG (BSHG) (Figure 20D). Quantification of FSHG images 
demonstrated a significant increase (p < 0.01) in percent sarcomere area in 
cMyBp-C110kDa myocardial sections (Figure 20E), which corresponded to the 
increase in heart size observed in cMyBP-C110kDa hearts (Figure 18). In line with 
the MT data, quantification of BSHG images demonstrated a significant elevation 
(p < 0.01) in percent fibrosis in cMyBP-C110kDa myocardial sections compared to 
NTG sections (Figure 20F). Together, these data signify that myocardial fibrosis 
accompanies the cardiac remodeling that results from contractile dysfunction in 
cMyBP-C110kDa mice due to the absence of the N’-C0-C1f region of cMyBP-C.     
cMyBP-C110kDa Incorporates Properly into the Cardiac Sarcomere 
cMyBP-C110kDa mice develop contractile dysfunction, myocardial 
hypertrophy, and fibrosis (Figures 17-20). Therefore, I next elucidated whether 
this pathology was specifically due to the absence of the C0-C1f region of 
cMyBP-C in the cMyBP-C110kDa TG protein or whether the dysfunction and 
morphological changes seen in cMyBP-C110kDa hearts was due to aberrant 
mislocalization of the cMyBP-C110kDa protein acting as a poison polypeptide, 
which has been previously demonstrated for the C0-C1f fragment of cMyBP-C 
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(Govindan, Sarkey, et al., 2012; Witayavanitkul et al., 2014). To address this 
question, I isolated single cardiomyocytes from 3-month old NTG and cMyBP-
C110kDa hearts and performed immunofluorescence imaging to detect cMyBP-C, 
the cMyBP-C110kDa TG protein, and α-actinin (Figure 21). I coupled this with SHG 
imaging to simultaneously detect myosin structure. As expected, myosin 
localized within the A-band of the sarcomere between α-actinin at the Z-line with 
no overlap in the I-band (Figure 21). Myocytes from NTG and cMyBP-C110kDa 
hearts were stained with an antibody targeted towards cMyBP-C’s N’ region (C0 
domain), which detected only endogenous FL cMyBP-C (Figure 21A). In both 
NTG and cMyBP-C110kDa myocytes, the classical staining pattern of two cMyBP-C 
bands between the Z-lines of the sarcomere (stained with α-actinin) was 
observed, demonstrating proper localization of endogenous cMyBP-C in both 
groups of animals (Figure 21A). However, the staining of endogenous cMyBP-C 
in cMyBP-C110kDa myocytes was faint and nearly undetectable indicating low 
levels of endogenous FL cMyBP-C within the sarcomeres of cMyBP-C110kDa 
myocytes (Figure 21A). This corresponds to the Western blot data that 
suggested only 19% incorporation of endogenous FL cMyBP-C in cMyBP-C110kDa 
myofilament fractions (Figure 16B). Myocytes were then stained with an 
antibody targeted towards cMyBP-C’s more C-terminal region (C5 domain) to 
identify endogenous FL cMyBP-C in NTG and cMyBP-C110kDa myocytes as well 
as the cMyBP-C110kDa TG protein in cMyBP-C110kDa myocytes (Figure 21B). In 
both NTG and cMyBP-C110kDa myocytes, the classical staining pattern of two 
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Figure 21. cMyBP-C110kDa Incorporates Properly into the Cardiac Sarcomere. 
Single cardiomyocytes were isolated from NTG and cMyBP-C110kDa hearts. (A) 
Myocytes were labeled with antibodies against cMyBP-C’s N’ region (C0 domain) 
(green) and α-actinin (red). SHG imaging was implemented to show myosin 
structure (blue). Also depicted is the merge of all three signals and fluorescence 
line scans. (B) Myocytes were labeled and imaged as in A but using and antibody 
against cMyBP-C’s more C’ region (C5 domain) (green), which depicts 
endogenous cMyBP-C in NTG and cMyBP-C110kDa myocytes as well as the 
cMyBP-C110kDa TG protein in cMyBP-C110kDa myocytes. (C) Myocytes were 
labeled and imaged as in A and B but using an antibody against c-Myc (green), 
which shows only the c-Myc-tagged cMyBP-C110kDa TG protein. (D) Myocytes 
were labeled and imaged as in A-C but using antibodies against c-Myc (green) 
and cMyBP-C’s N’ region (red) with no staining for α-actinin. As in C, the c-Myc 
signal was seen only in myocytes from cMyBP-C110kDa hearts. Endogenous 
cMyBP-C was detected in both NTG and cMyBP-C110kDa myocytes. Scale bar = 
5µm. 
NTG 
cMyBP-C110kDa 
N’-cMyBP-C Myosin α-Actinin Merge 
C’-cMyBP-C Myosin α-Actinin Merge 
NTG 
cMyBP-C110kDa 
c-Myc Myosin α-Actinin Merge 
NTG 
cMyBP-C110kDa 
c-Myc N’-cMyBP-C Myosin Merge 
NTG 
cMyBP-C110kDa 
A 
B 
C 
D 
0 2 4 6 8 100
50
100
150
200
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
N'-cMyBP-C
α-Actinin
Myosin
0 2 4 6 8 100
25
50
75
100
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.) C'-cMyBP-C
α-Actinin
Myosin
0 2 4 6 8 100
25
50
75
100
c-Myc
α-Actinin
Myosin
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
0 2 4 6 8 100
50
100
150
c-Myc
N'-cMyBP-C
Myosin
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
0 2 4 6 8 100
25
50
75
100
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
0 2 4 6 8 100
20
40
60
80
100
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
0 2 4 6 8 100
50
100
150
200
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
0 2 4 6 8 100
25
50
75
100
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
NTG cMyBP-C110kDa 
NTG cMyBP-C110kDa 
NTG cMyBP-C110kDa 
c- yc
α-Actinin
Myosin
i t  ( )
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
0 2 4 6 8 100
50
100
150
Distance (µm)
Fl
uo
re
sc
en
t
si
gn
al
 (a
.u
.)
cMyBP-C110kDa NTG 
136 
 
 
 
 
cMyBP-C bands between the Z-lines of the sarcomere (stained with α-actinin) 
was observed (Figure 21B). As staining with an antibody against cMyBP-C’s N’ 
region showed low levels of endogenous FL cMyBP-C (Figure 21A) and staining 
with an antibody targeted towards cMyBP-C’s C5 domain indicated increased 
expression of cMyBP-C similar to the levels observed in NTG myocytes (Figure 
21B), it was likely that the anti-C5 domain antibody was detecting the cMyBP-
C110kDa TG protein within the sarcomeres of cMyBP-C110kDa myocytes and that the 
TG protein was localizing at the C-zone. Therefore, to test this, myocytes from 
NTG and cMyBP-C110kDa hearts were stained for an antibody directed against c-
Myc, which targeted only the c-Myc-tagged cMyBP-C110kDa TG protein. The signal 
observed by staining for c-Myc depicted a doublet pattern of the c-Myc-tagged-
cMyBP-C110kDa TG protein between the Z-lines in cMyBP-C110kDa myocytes with 
no staining observed in NTG myocytes (Figure 21C). This implied proper 
localization of the cMyBP-C110kDa protein. Importantly, the lack of c-Myc staining 
at the Z-lines suggested the cMyBP-C110kDa transgenic protein does not 
aberrantly localize throughout the sarcomere but localizes specifically within the 
A-band and possibly within the C-zone. To determine definitively that the cMyBP-
C110kDa TG protein localizes within the C-zone of the A-band, myocytes from NTG 
and cMyBP-C110kDa hearts were stained with antibodies against c-Myc and 
cMyBP-C’s N’ region. As in Figure 21C, the c-Myc signal was observed in 
myocytes from cMyBP-C110kDa hearts, but not NTG hearts (Figure 21D). 
Additionally, using the antibody targeted against cMyBP-C’s N’ region, 
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endogenous FL cMyBP-C was detected in both NTG and cMyBP-C110kDa 
myocytes (Figure 21D). Merging of the c-Myc and endogenous FL cMyBP-C 
signals in cMyBP-C110kDa myocytes showed co-localization and complete overlap 
of endogenous cMyBP-C and the cMyBP-C110kDa TG protein in the classical 
doublet pattern, confirming that the cMyBP-C110kDa TG protein localizes within the 
C-zone of the cardiac sarcomere in cMyBP-C110kDa hearts along with endogenous 
cMyBP-C (Figure 21D). Together, these data confirm that the dysfunction and 
morphological changes observed in cMyBP-C110kDa hearts was instigated by the 
absence of the C0-C1f region of cMyBP-C and not aberrant mislocalization of the 
cMyBP-C110kDa TG protein within cMyBP-C110kDa sarcomeres. This further 
supports a critical role for the N’-C0-C1f region of cMyBP-C in regulating cardiac 
function at the level of the sarcomere.    
cMyBP-C Phosphorylation is Elevated in cMyBP-C110kDa Hearts 
To determine whether phosphorylation at serine residues 273, 282, and 
302 within the M domain of cMyBP-C was altered in cMyBP-C110kDa hearts during 
HF compared to NTG hearts, I performed Western blot analysis using 
myofilament fractions from 7-month old NTG and cMyBP-C110kDa hearts (Figure 
22). Antibodies targeted against phosphorylated serine residues 273, 282, and 
302 were used, as have been previously reported (Copeland et al., 2010). 
Intriguingly, phosphorylation at serine residue 273 of the endogenous FL cMyBP- 
C from cMyBP-C110kDa myofilament fractions was significantly higher (p < 0.001) 
than that of the cMyBP-C110kDa TG protein in these fractions and was also  
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Figure 22. cMyBP-C Phosphorylation is Elevated in cMyBP-C110kDa Hearts. 
(A) Western blot analysis presented in Figure 16A and including phosphorylation 
of serine residues 273, 282, and 302 of cMyBP-C and phosphorylation of cTnI 
and serine residues 23/24. Densitometry analysis of the phosphorylation levels of 
endogenous FL cMyBP-C from NTG and cMyBP-C110kDa (TG-FL) myofilament 
fractions and the cMyBP-C110kDa TG protein (TG-110 kDa) from cMyBP-C110kDa 
myofilament fractions at serine residues (B) 273, (C) 282, and (D) 302 as well as 
at serine residues (E) 23/24 of cTnI. n = 3 hearts per group. **p < 0.01, ***p < 
0.001. 
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significantly higher (p < 0.01) than that of the endogenous FL cMyBP-C from 
NTG myofilament fractions (Figure 22 A, B). Importantly, phosphorylation of 
serine residue 273 in the cMyBP-C110kDa TG protein was absent (Figure 22 A, 
B). This was likely due to the disruption of the PKA recognition motif for 
phosphorylation of serine residue 273 in the cMyBP-C110kDa TG protein by the 
removal of the N’-C0-C1f region of cMyBP-C (removal of residues 1-271). 
Phosphorylation of serine residue 282 of the cMyBP-C110kDa TG protein in 
cMyBP-C110kDa myofilament fractions was significantly higher (p < 0.01) than that 
of endogenous FL cMyBP-C in NTG myofilament fractions (Figure 22 A, C). 
Strikingly, phosphorylation at serine residue 282 of both the endogenous FL 
cMyBP-C and cMyBP-C110kDa TG protein from cMyBP-C110kDa was significantly 
elevated (p < 0.01) than that of endogenous FL cMyBP-C in NTG myofilament 
fractions (Figure 22 A, D). No difference in phosphorylation of cTnI at serine 
residues 23/24 between NTG and cMyBP-C110kDa samples was detected (Figure 
22 A, E). Together, these data suggest that both endogenous FL cMyBP-C and 
the cMyBP-C110kDa TG protein are hyperphosphorylated at specific serine 
residues within the M domain in cMyBP-C110kDa sarcomeres, which may play a 
functional role in the contractile dysfunction observed in cMyBP-C110kDa hearts. 
Maximum Force and ktr are Increased in cMyBP-C110kDa Hearts  
The experiments performed as part of my Specific Aim 2 determined how the 
absence of the N’-C0-C1f region of cMyBP-C in cMyBP-C110kDa hearts alters 
myofilament function to elucidate whether this region is necessary for controlling 
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physiological contraction kinetics in the heart. Therefore, I performed a steady-
state fiber force-ATPase experiment using isolated cardiac LV papillary muscle 
fibers from 3-month old cMyBP-C110kDa and NTG mice. I performed these 
experiments using animals at 3-months of age as this was prior to severe global 
cardiac dysfunction and would allow me to determine the mechanism(s) by which 
the absence of the N’-C0-C1f region of cMyBP-C instigates sarcomeric 
contractile dysfunction leading to whole-heart dysfunction and remodeling 
(Figures 17-20). The parameters that I measured included force production, 
Ca2+ sensitivity of force development, tension cost, cross-bridge stiffness, and 
rate of tension redevelopment (ktr). Intriguingly, LV papillary fibers from cMyBP-
C110kDa hearts generated significantly more force (p < 0.01) at maximum Ca2+ 
compared to those from NTG hearts (Figure 23 A, B). However, no difference 
was observed in Ca2+ sensitivity of force development (Figure 24 A, B), tension 
cost (Figure 25 A, B), and cross-bridge stiffness (Figure 26) between cMyBP-
C110kDa and NTG fibers. Remarkably, the rate of tension redevelopment (ktr) was 
significantly higher (p < 0.05) than that of NTG fibers (Figure 27). Together, 
these data demonstrate the underlying contractile abnormalities that occur in 
cMyBP-C110kDa sarcomeres that likely give rise to global heart dysfunction in 
these animals. 
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Figure 23. Maximum Force is Increased in cMyBP-C110kDa Hearts. (A) Force-
pCa curves depicting force production at various pCa values for NTG and 
cMyBP-C110kDa LV papillary muscle fibers at 3-months of age. (B) Maximum force 
produced by NTG and cMyBP-C110kDa fibers derived from force-pCa curves in A. 
Mean values plotted as “+” symbols. n = 5 fibers from 5 NTG hearts and 6 fibers 
from 6 cMyBP-C110kDa hearts. **p < 0.01.  
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Figure 24. Ca2+ Sensitivity of Force Development is Preserved in cMyBP-
C110kDa Hearts. (A) Force-pCa curves depicting normalized force production at 
various pCa values for NTG and cMyBP-C110kDa fibers at 3-months of age. (B) 
pCa50 (Ca2+ sensitivity) values derived from normalized force-pCa curves in A. 
Mean values plotted as “+” symbols. n = 5 fibers from 5 NTG hearts and 6 fibers 
from 6 cMyBP-C110kDa hearts. 
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Figure 25. Tension Cost is Unaltered in cMyBP-C110kDa Hearts. (A) Force-
ATPase curves depicting ATPase activity for NTG and cMyBP-C110kDa fibers at 3-
months of age. (B) Tension cost values derived from force-ATPase values in A. 
Mean values plotted as “+” symbols. n = 5 fibers from 5 NTG hearts and 6 fibers 
from 6 cMyBP-C110kDa hearts. 
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Figure 26. Cross-bridge stiffness is Unchanged in cMyBP-C110kDa Hearts. 
Cross-bridge stiffness normalized to force for NTG and cMyBP-C110kDa fibers at 
3-months of age. Mean values plotted as “+” symbols. n = 4 fibers from 4 NTG 
hearts and 6 fibers from 6 cMyBP-C110kDa hearts. 
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Figure 27. Rate of Tension Redevelopment (ktr) is Increased in cMyBP-
C110kDa Hearts. ktr generated by NTG and cMyBP-C110kDa fibers at 3-months of 
age following a rapid slack-restretch maneuver. Mean values plotted as “+” 
symbols.  n = 6 fibers from 6 NTG hearts and 5 fibers from 5 cMyBP-C110kDa 
hearts. *p < 0.05. 
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CHAPTER SIX 
 
DISCUSSION 
 
The data reported in this work support my central hypothesis that the N’-
C0-C1f region of cMyBP-C is critical for normal cardiac function in vivo. Indeed, 
the results of my experiments demonstrate that the absence of the N’-C0-C1f 
region of cMyBP-C in the cardiac sarcomeres of cMyBP-C110kDa mice leads to a 
significant reduction in percent FS by 3-months of age that is even further 
reduced by 6-months of age (Figure 17). Crucially, the cMyBP-C110kDa protein 
was expressed at high levels in the hearts of cMyBP-C110kDa mice (Figure 16) 
and localized properly within the C-zone of cMyBP-C110kDa sarcomeres (Figure 
21). The dysfunction that developed in cMyBP-C110kDa hearts led to pathological 
cardiac remodeling producing LV and RV chamber enlargement (Figure 18) and 
a significant elevation in both sarcomere area (Figure 20) and in markers of 
pathological myocardial hypertrophy (Figure 19). Additionally, the remodeling 
observed in cMyBP-C110kDa hearts led to a significant elevation in myocardial 
fibrosis (Figure 20), which likely contributed to the dysfunction seen in the hearts 
of these animals. Importantly, the dysfunction and remodeling that developed at 
the whole organ level in cMyBP-C110kDa hearts was likely instigated by the 
contractile deficiencies produced within cMyBP-C110kDa sarcomeres due to the 
absence of the N’-C0-C1f region of cMyBP-C. Specifically, using a steady-state 
force-ATPase assay with isolated, permeabilized papillary muscle fibers from 
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cMyBP-C110kDa hearts and NTG hearts for comparison, I observed a significant 
increase in maximum force and ktr produced by cMyBP-C110kDa fibers (Figures 
23, 27). This indicates contractile abnormalities at the level of the cardiac 
sarcomere (Specific Aim 2) that generates overt cardiac dysfunction (Specific 
Aim 1) within cMyBP-C110kDa animals. Finally, at the molecular level, I detected 
hyperphosphorylation of cMyBP-C in both FL cMyBP-C and the cMyBP-C110kDa 
TG protein from cMyBP-C110kDa cardiac myofilament fractions, which may play a 
role in the dysfunction observed in cMyBP-C110kDa hearts (Figure 22).  
The critical finding of this study was that cMyBP-C110kDa animals 
developed severe cardiac contractile dysfunction and myocardial remodeling. 
The remodeling within cMyBP-C110kDa hearts led to LV and RV chamber 
enlargement with no significant differences in LV and septal wall thicknesses 
between cMyBP-C110kDa and NTG hearts. However, it is important to note that the 
LV and septal wall thicknesses were reduced in cMyBP-C110kDa hearts compared 
to NTG hearts, however, again, this difference was not significant. Although, 
expectedly, if cardiac function continues to worsen beyond 6-months of age in 
cMyBP-C110kDa hearts it is likely that thinning of the LV and septal walls would be 
evident producing a cardiac phenotype consistent with DCM. Intriguingly, the 
DCM phenotype has been previously observed in the homozygous mutant 
cMyBP-C t/t mouse model developed in the Seidman lab, which expresses less 
than 10 percent of a truncated form of cMyBP-C that does not incorporate into 
the cardiac sarcomere and that develops depressed systolic contractility and 
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diastolic dysfunction (McConnell et al., 1999). The t/t mouse is essentially a 
functional knockout of cMyBP-C produced by a knock-in mutation in the 
MYBPC3 gene that was developed on the FVB/N background. In contrast, the 
cMyBP-C110kDa mouse is a TG mouse model produced by the TG expression of a 
N’ truncated cMyBP-C protein that lacks the N’-C0-C1f region of cMyBP-C 
developed on the C57BL/6 background. Interestingly, these two animals develop 
a similar phenotype, but which is more severe in the t/t mouse model (McConnell 
et al., 1999) likely due to the complete absence of cMyBP-C in the cardiac 
sarcomere rather than only the absence of the N’ region. However, the t/t mouse 
is not a true genetic model of MYBPC3 ablation as it still expresses a small 
amount of cMyBP-C. Interestingly, the cMyBP-C genetic knockout mouse model 
developed on the SV/129 background by the Moss lab in the early 2000’s 
develops a phenotype consistent with hypertrophic cardiomyopathy and harbors 
both systolic and diastolic dysfunction (Harris et al., 2002).  
Understanding how and why the heart remodels to produce HFpEF, as in 
HCM, or HFrEF, as in DCM, is truly fascinating. Importantly, there are three 
possible reasons that I speculate may produce the differences observed in 
cardiac remodeling and function (HCM vs. DCM) between cMyBP-C knockout, 
t/t, and cMyBP-C110kDa animals. The first possibility is that all three mouse models 
were developed on different mouse strains. As such, these different mouse 
strains may respond differently to mutations of cMyBP-C. Another possibility is 
the fact that the cMyBP-C knockout mouse is a homozygous MYBPC3 knockout 
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mouse model while the t/t mouse is a homozygous MYBPC3 knock-in mouse 
model and the cMyBP-C110kDa mouse is a TG model due to truncation of the 
MYBPC3 gene. As such, these methods to produce truncation or knockout of 
cMyBP-C could lead to different expression levels of cMyBP-C or responses of 
the heart to these manipulations between the mouse models. Finally, one 
obvious possibility, as stated above, is that the absence of the N’ region of 
cMyBP-C in cMyBP-C110kDa animals produces a different form of contractile 
deficiency at the level of the sarcomere than occurs in cMyBP-C knockout and t/t 
mice, which lack FL cMyBP-C. This would suggest an important role for the C’ 
region of cMyBP-C in regulating cardiac function in addition to the N’ region of 
cMyBP-C.  
Previously, work performed using the t/t mouse model has shown that the 
absence of cMyBP-C in this model leads to a shorter myosin cross-bridge lifetime 
when the myosin isoform is controlled and a compression of the cardiac 
myofilament lattice induced by rigor (Palmer et al., 2011). Additionally, it was 
demonstrated that a constitutively unphosphorylated form of cMyBP-C developed 
on the t/t background (AllP-t/t) had the same effect suggesting that the presence 
and phosphorylation of cMyBP-C at it’s N’ region provides structural support and 
radial rigidity to the myofilament lattice (Palmer et al., 2011). Stated differently, 
this suggests that the cMyBP-C provides radial rigidity to the myofilament lattice 
through its N’ region and that disruption of phosphorylation of cMyBP-C is 
sufficient to abolish this structural role of the N’ region of cMyBP-C and shorten 
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cross-bridge lifetime (Palmer et al., 2011).  Intriguingly, this may explain why an 
elevation in phosphorylation of cMyBP-C from cMyBP-C110kDa hearts was 
observed in this study. During HF, cMyBP-C has been shown to be 
dephosphorylated (Sadayappan et al., 2006a; Tong, Gaffin, Zawieja, & 
Muthuchamy, 2004). However, more recently, cMyBP-C has been shown to be 
hyperphosphorylated following MI as the hearts became decompensated 
(Toepfer et al., 2016). Extrapolating the findings by Palmer et al. that both the 
absence or dephosphorylation of cMyBP-C leads to structural alterations and 
shortened cross-bridge lifetime, it is possible that when cMyBP-C is absent or 
dephosphorylated, the restraint it places on myosin heads from interacting with 
actin is abolished leading to increased cross-bridge cycling rate and decreased 
cross-bridge lifetime. Here, I found that the absence of the N’-C0-C1f region of 
cMyBP-C led to increased rate of tension redevelopment after a rapid slack-
restretch maneuver and an increase in maximal force production at maximum 
levels of Ca2+ suggesting decreased cross-bridge lifetime and increased cross-
bridge cycling rate as was observed on studies with t/t mice. The increase in ktr in 
cMyBP-C110kDa fibers may also indicate that more fibers are binding faster, which 
could lead to the increase in maximal force observed in these fibers. 
Furthermore, it is possible that the hyperphosphorylation of cMyBP-C in cMyBP-
C110kDa sarcomeres may act as a compensatory mechanism that attempts to 
increase cross-bridge lifetime and slow cross-bridge cycling rate. However, while 
this may be effective in FL cMyBP-C, this effort is futile in the N’ truncated 
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cMyBP-C110kDa protein. Yet, the exact mechanism by which this would occur is 
difficult to determine as it is currently thought that the phosphorylation of cMyBP-
C at low Ca2+ relieves cMyBP-C’s constraint on myosin heads and may activate 
the thin filament and accelerate cross-bridge kinetics (Tong, Stelzer, Greaser, 
Powers, & Moss, 2008) while at high Ca2+, cMyBP-C binding to the thin filament 
may slow thin filament sliding within the C-zone. Therefore, in the cMyBP-C110kDa 
mouse model, the hyperphosphorylation of the cMyBP-C110kDa TG protein may 
increase cross-bridge cycling kinetics at low Ca2+ further accounting for the 
increased ktr but may act to slow cross-bridge cycling rate and increase cross-
bridge lifetime at high Ca2+ levels due to more molecules of cMyBP-C binding to 
actin. However, again, this effort at high Ca2+ would be fruitless in an N’ 
truncated form of cMyBP-C such as the cMyBP-C110kDa protein. Additionally, the 
ablation of the PKA phosphorylation motif for phosphorylation of serine 273 in the 
cMyBP-C110kDa TG protein may play a role in the ability (or inability) of this protein 
to regulate contraction.  
Additional work by Palmer et al. using the intact heart, trabeculae, and 
skinned fibers from t/t mice indicated that t/t ventricles display reduced peak 
elastance and an abbreviation of systolic elastance time course (Palmer, 
Georgakopoulos, et al., 2004). This was also observed in the cMyBP-C knockout 
mouse model (Palmer, Georgakopoulos, et al., 2004). Furthermore, t/t mice 
displayed earlier time-to-peak trabecular tension, increased unloaded shortening 
velocity in skinned muscle strips, and reduced myofilament stiffness at diastolic 
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calcium concentrations (Palmer, Georgakopoulos, et al., 2004). Conclusively, t/t 
mice exhibited abnormal sarcomere shortening velocity and abbreviated muscle 
stiffening (Palmer, Georgakopoulos, et al., 2004). Additionally, Palmer et al. 
demonstrated reduced cross-bridge dependent stiffness of skinned myocardium 
from t/t mice (Palmer, McConnell, et al., 2004). In the present study, no 
difference in stiffness normalized to force production was observed between 
cMyBP-C110kDa and NTG skinned fibers, indicating a potential role for the more C’ 
region of cMyBP-C in regulating cross-bridge dependent stiffness within the 
sarcomere. Importantly, much of the current understanding of the role cMyBP-C 
plays in regulating cardiac contractile function comes from studies on the cMyBP-
C knockout mouse. As mentioned previously, isolated cardiac myocytes from 
cMyBP-C knockout hearts develop a reduction in myofilament Ca2+ sensitivity of 
tension (Harris et al., 2002), deficit in diastolic relaxation and increased LA 
myofilament Ca2+ sensitivity (Pohlmann et al., 2007), acceleration of stretch 
activation (Stelzer, Dunning, et al., 2006) and force development (Stelzer, 
Fitzsimons, et al., 2006), and loss of PKA mediated stretch activation (Stelzer, 
Patel, et al., 2006). Furthermore, cMyBP-C knockout mice failed to compensate 
for increased load and demonstrated a significant reduction in systolic and 
diastolic function when challenged with pressure overload (Brickson et al., 2007). 
Finally, ablation of cMyBP-C led to radial displacement of myosin cross-bridges 
in cMyBP-C knockout myofibrils compared to wild-type controls (Colson et al., 
2007). Interestingly, cMyBP-C knockout LV myocytes had a reduction in Ca2+ 
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sensitivity of tension (Harris et al., 2002), while isolated knockout LA had an 
increase in sensitivity to external Ca2+. In contrast, papillary muscle fibers from 
the cMyBP-C110kDa mice used in this study showed no difference in Ca2+ 
sensitivity of force development compared to fibers from NTG controls, indicating 
that regions beyond the N’-C0-C1f region of cMyBP-C may be implicated in 
cMyBP-C’s regulation of myocardial Ca2+ sensitivity of tension. 
As mentioned previously, in this study, isolated, permeabilized papillary 
muscle fibers from cMyBP-C110kDa hearts generated a significant elevation in 
maximal force production and ktr compared to fibers from NTG controls at 3-
months of age. This may be the underlying contractile abnormality within the 
cardiac sarcomeres of these animals that leads to global cardiac remodeling and 
dysfunction. Interestingly, no clear difference in sarcomere organization (data not 
shown; collaboration with Dr. Roger Craig) was observed between cMyBP-
C110kDa and NTG animals, likely due to previous observations that the C’ region is 
the portion of cMyBP-C important for its incorporation into the C-zone of the 
cardiac sarcomere (Freiburg & Gautel, 1996; Gilbert et al., 1999; Miyamoto et al., 
1999; Okagaki et al., 1993; Pfuhl & Gautel, 2012). Recently, our group has 
generated a mouse model that harbors a frameshift mutation within the C’ C10 
domain of cMyBP-C that leads to aberrant mislocalization of cMyBP-C at the Z-
lines of the cardiac sarcomere and contractile dysfunction (unpublished data), 
which we also observed by adenoviral expression of this mutant form of cMyBP-
C in adult rat cardiomyocytes (Kuster et al., 2015). This further suggests the 
154 
 
 
 
importance of the C’ region of cMyBP-C in the localization of cMyBP-C within the 
sarcomere. However, the findings that I present here clearly demonstrate that the 
cMyBP-C110kDa TG protein properly localizes to the C-zone of the cardiac 
sarcomere and, therefore, the cardiac dysfunction observed is likely instigated by 
the absence of the N’-C0-C1f region of cMyBP-C and not aberrant 
mislocalization of this protein, which has its C’ region intact allowing for proper 
incorporation. Intriguingly, the ability of cMyBP-C to slow actin-filament sliding 
within the C-zone of native thick filaments isolated from NTG hearts was lost on 
thick filaments from cMyBP-C110kDa hearts (data not shown; collaboration with Dr. 
David Warshaw and Dr. Michael Previs). Particularly important, the cMyBP-
C110kDa mouse model was developed based upon several of the following 
observations. Initially, our group identified this region as a predominant N’ 
cleavage fragment of cMyBP-C following myocardial ischemic injury (Govindan, 
McElligott, et al., 2012). Furthermore, we discovered that the C0-C1f fragment 
was sufficient to cause contractile dysfunction in isolated rat ventricular myocytes 
(Govindan, Sarkey, et al., 2012) and that it could impair myofilament function in 
human cardiac myofilaments (Witayavanitkul et al., 2014). Later work by 
Razzaque et al. demonstrated that endogenous expression of C0-C1f was 
sufficient to cause HCM and HF in mice (Razzaque et al., 2013). Most 
importantly and referring back to our observation that the cMyBP-C110kDa TG 
protein could not slow actin-filament sliding within the C-zone of native thick 
filaments from cMyBP-C110kDa hearts, it has been reported that the first 17 
155 
 
 
 
residues of the M-domain (the “f” region of C0-C1f) are crucial to the ability of C0-
C1f to inhibit actin filament sliding over myosin (Previs et al., 2012; A. Weith et 
al., 2012). This may implicate a role for the N’-C0-C1f region of cMyBP-C in 
regulating cMyBP-C’s interactions and function at both low and high Ca2+ levels. 
Together, these previous studies and my findings in this study suggest that the 
N’-C0-C1f region of cMyBP-C is necessary for regulating myofilament function. 
Therefore, I conclude that the N’-C0-C1f region of cMyBP-C is essential for 
cMyBP-C’s regulation of both actomyosin interactions and cardiac contractile 
function. 
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CHAPTER SEVEN 
 
 CONCLUSIONS AND FUTURE DIRECTIONS 
 
In conclusion, the data that I have presented here demonstrate that 
cMyBP-C110kDa mice, which lack the N’-C0-C1f region of cMyBP-C, develop 
cardiac dysfunction that progresses to severity by 6-months of age. Indeed, 
cMyBP-C110kDa mice developed a significant deficit in cardiac function at the level 
of the whole heart and at the tissue fiber level. Furthermore, cMyBP-C110kDa mice 
developed cardiac enlargement and an elevation in markers of pathological 
hypertrophy as well as an increase in myocardial fibrosis. Importantly, the 
cMyBP-C110kDa TG protein localized properly within the C-zone of the cardiac 
sarcomere along with endogenous FL-cMyBP-C. Together, these data indicate 
that the N’-C0-C1f region of cMyBP-C is a critical regulator of cardiac function 
and is necessary for maintaining normal cardiac function. Therefore, this study 
has been important for expanding the current body of knowledge on cMyBP-C’s 
mechanistic function in both health and disease and may provide a better 
understanding of which N’ domains of cMyBP-C are important for regulating 
actomyosin function and cardiac contractile function in vivo. Translating this 
clinically, the results of this study could prove important for understanding the 
cellular mechanisms by which individuals with N’ mutations in cMyBP-C develop 
cardiomyopathies.  
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Future efforts by our group will focus on further understanding how 
cMyBP-C regulates cardiac contraction from its N’ to C’ domains and will 
specifically focus on how mutations in cMyBP-C lead to both HCM and DCM. As 
such, we are currently performing genome-wide studies of how cMyBP-C 
mutations lead to HCM, for example. Specific to the cMyBP-C110kDa TG mouse 
model, an important future experiment that we are pursuing is to perform X-ray 
diffraction studies in collaboration with Dr. Thomas Irving at the Illinois Institute of 
Technology and Argon National Laboratories to elucidate myofilament lattice 
spacing between actin and myosin filaments in cMyBP-C110kDa sarcomeres 
compared NTG sarcomeres. We hypothesize that the absence of the N’-C0-C1f 
region of cMyBP-C disables cMyBP-C from complete binding to myosin’s S2 
region and may thereby lead to increased proximity of myosin to actin and a 
decrease in lattice spacing. Furthermore, our group has considered replacing the 
N’ region of cMyBP-C by expressing the N’-C0C2 region of cMyBP-C in cMyBP-
C110kDa hearts with the use of adeno-associated virus to determine if we could 
prevent cardiac dysfunction in these animals.  
While cMyBP-C has been well studied since its initially discovery in the 
early 1970’s, it’s exact mechanistic function, particularly in relation to its function 
at low and high Ca2+ levels, is still being investigated. It is my hope that the work 
that I have performed during my dissertation studies has provided a better 
understanding of cMyBP-C’s function and that the cMyBP-C110kDa TG mouse 
model will be a useful tool to other scientists seeking to answer novel questions 
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in relation to cMyBP-C’s role in regulating cardiac function. Perhaps, together, 
my work and future work by others using this mouse model will prove to be one 
step forward in the journey to find cures for human cardiomyopathy caused by 
cMyBP-C mutations.  
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